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ABSTRACT 
Nitric oxide (NO), produced by the inducible nitric oxide synthase (NOS II), 
is important in host defence against invading pathogens including bacteria, fungi 
and certain viruses. Its induction by LPS and pro-inflammatory cytokines (e.g., 
TN F-a, IFN-y, and IL-1 (3) is well established in murine monocytic cells. However, 
the same can not be said for human monocytic cells. This work explored the 
possibility that the failure of human cells to express NOS II following LPS 
stimulation might be due to a lack of key signalling molecule(s) essential to the 
pathway. 
Since studies with PKC inhibitors have implicated protein kinase C (PKC) in 
NOS II regulation in murine monocytic cells, a complete investigation comparing 
PKC isotype expression between human and murine monocytic cells was needed 
to address whether a lack of one of the isotypes may be responsible for the failure 
of human monocytic cells to express NOS II. We found that human monocytic cells 
lacked PKC-11 (eta), while the murine counterparts lacked PKC-~1 (beta 1 ). 
Subsequently, it was determined that human monocytic cells transfected with PKC-
11 could induce NOS II expression and produced NO production following LPS 
stimulation. This provides direct evidence that PKC-11 may be involved in NOS II 
regulation. We have now established expression correlation between PKC-11 and 
NOS II in monocyte-derived macrophages (MOM) from patients with inflammatory 
diseases (lA) (rheumatoid arthritis [RA] and spondyloarthropathies [SpA]). 
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Severely- affected lA patients (with > 5 swollen joints) showed highly elevated 
plasma NO (237.8 ± 34.41JM, n=10) relative to healthy (131.1 ± 18.9 IJM, n=9), 
osteoarthritis (126.9 ± 40.9 J..IM, n=13), or mildly affected lA individuals (with< 5 
swollen joints) (131.1 ± 18.9 J..IM, n=1 0). Analysis of transcriptional expression of 
NOS II revealed that only in lA patients with elevated plasma NO was NOS II 
present in MDM, and that PKC-11 was always expressed in the NOS It-reactive 
cases. MDM in individuals with normal circulating NO were negative for both PKC-
11 and NOS II. This was true in 15 out of 16 (94%) cases tested implicating for the 
first time a requirement of PKC-11 for the development of a NOS It-positive 
phenotype in human monocytic cells. 
In our study, TN F-a did not seem to be involved in NOS II regulation as lA 
patients (n=7), who responded well clinically to infliximab (anti-TNF-a monoclonal 
antibody), showed elevated NO and expressed both NOS II and PKC-11 in MOM. 
In contrast, lA patients responding well to anakinra (IL-1 receptor antagonist) had 
normal plasma NO, did not express NOS II but were positive for PKC-11 in MDM. 
We propose that in severely affected lA, there may be three stages in the 
development of NOS II positive phenotype in monocytes with IL-1 somehow being 
involved in the regulation of NOS II expression. 
Two synthetic (JPK-101 and JPK-109) and one natural (JPK-113) 
compounds from Trypterigyum plant, whose extract is used as traditional Chinese 
medication for the treatment for RA, were investigated for their effects on the 
Ill 
induction of NOS II as well as production ofTNF-a, NO, and matrixmetalloprotease 
(MMP). We found that the compounds could inhibit production of NO (via 
suppression of NOS II) and TN F-a, but not MMP. These findings support their well 
known, but poorly explained, anti-inflammatory effects. 
IV 
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CHAPTER ONE 
INTRODUCTION 
1.1 THE MACROPHAGE 
1.1.1 Development 
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Monocytes (Mo) and macrophages (Mel>) are mononuclear cells which 
perform diverse functions ranging from accessory cell function to microbe, and even 
tumor cell, killing. Three times bigger than lymphocytes, Mo and Mel> have a single 
large kidney-shaped non-segmented nucleus and a well-defined cytoplasm. On 
average, peripheral blood monocytes constitute 1-5% of the total leukocyte or white 
blood cell, population. 
Ever since the first designation of Mel> introduced in1892, intense discussion 
of the origin, development and differentiation of Mel> has continued. Since then, 
there have been two major theories proposed for the origin and the developmental 
process of the Mel>. Aschoff (1924) put forward the concept that Mel> were a part of 
the reticulo-endothelial system together with the reticulum cells and 
reticuloendothelia. In contrast, Langevoort eta/. (1970) presented the theory ofthe 
"mononuclear phagocyte system" (MPS) which asserted that all Mel>, including those 
produced during inflammation (exudate Mel>) and those residing in tissues during 
normal conditions (resident Mel>), are derived from the same precursor cells in the 
bone marrow. However, there is evidence in the literature (Miyamura eta/., 1998) 
suggesting that exudate and resident Mel> are indeed two distinct populations, thus 
contradicting the MPS notion that exudate Mel> exemplify a transitional or 
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intermediate form of resident Met>. Despite the conflicting data, the core of the MPS 
theory has gained a lot of support over the years. The current consensus is that a 
Mo does undergo sequential developmental changes after beginning its life as a 
hematopoietic stem cell (HSC) in the bone marrow. In the presence of various 
growth factors including interleukin-3 (IL-3), interleukin-6 (IL-6) and granulocyte 
macrophage-colony stimulating factor (GM-CSF), the HSC differentiates into a 
granulocyte-macrophage-colony forming cell (GM-CFC). In an environment rich in 
macrophage-colony stimulating factor (M-CSF), the latter then progresses into a 
macrophage colony-forming cell which sequentially develops into a monoblast, a 
pro-monocyte and then finally a Mo. The Mo then leaves the bone marrow and 
enters the circulation. After approximately two days, it leaves the circulation, takes 
up residence in various tissues and becomes a Mcp. In addition, the bone marrow 
can and does release immature myeloid GM-CFC into peripheral blood. These 
cells then migrate to tissues where, in the presence of in situ GM-CSF and M-CSF, 
they differentiate into long-lived resident Met> or related cells (e.g. Langerhans in the 
skin and Kupffer cells in the liver). In response to inflammatory stimuli, Mo migrate 
to the affected tissue and differentiate into exudate Met> (Beelen et a/., 1978). 
Resident Met> differ from exudate Met> in that the former are long-lived in tissue and 
capable of self-renewal (Takahashi eta/., 1996). As their production is only 
induced as a result of an insult, it is prudent that exudate Met> be short-lived and 
incapable of proliferation. 
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1.1.2 Role of mononuclear phagocytes in immunity 
M<l> are extraordinarily versatile cells. These "cells for all seasons" are found 
in most tissues in the body participating in a wide range of biological processes 
including development, bone remodelling, and wound healing (Morrissette eta/., 
1999). However, it is as sentinels of the immune system that M<l> exploit their full 
functional repertoire. When microorganisms such as bacteria invade the tissue, M<l> 
are chemotactically attracted to the site of insult and begin to phagocytose. 
Activated M<l> are professional phagocytes in that they detect, ingest, and destroy 
infectious agents. This makes M<l> essential components of innate immunity. 
Phagocytosed bacteria are killed, and then degraded by a number of mechanisms, 
all of which are part of the innate response. Moreover, activated M<l> also promote 
the development of an acute inflammatory response through secretion of soluble 
inflammatory mediators including platelet activating factor (PAF), prostaglandin 
(PG}, leukotrienes (L T), reactive oxygen intermediates (ROI) (e.g. hydrogen 
peroxide and superoxide), reactive nitrogen intermediates (RNI) (e.g. nitric oxide 
[NO]) as well as cytokines including IL-6 (IL-6), interleukin-1 (IL-1) and tumor 
necrosis factor (TNF-a). Platelet activating factor is important in the activation of 
platelets, chemotaxis of eosinophils, as well as activation and degranulation of 
neutrophils and eosinophils. Prostaglandin increases vascular permeability and 
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dilation resulting in tissue edema and leukocyte extravasation. Break-down of 
arachidonic acid via the lipoxygenase pathway in Mo, M<l> and mast cells gives rise 
to LT. This lipid inflammatory mediator induces smooth muscle contraction and 
attracts neutrophils. In addition, activation of two oxidative pathways, NADPH 
oxidase and inducible nitric oxide synthase (NOS II), also known as the respiratory 
burst, produces toxic ROI and NO, respectively, exerting injury to the target in a 
number of different ways (Chapter 3). ROI and RNI account for one of the most 
powerful weapons of the M<J> against microbial organisms. Mice with NOS II knock-
out are more susceptible to infection with intracellular bacteria than wild type mice 
(MacMicking eta/., 1997). Also, studies with M<l> deficient in these two enzymes 
reveal their role in helping to orchestrate the profound transcriptional remodelling 
that underlies macrophage activation (Ehrt eta/., 2001 ). The three cytokines IL-1, 
IL-6, and TNF-a produced by activated tissue M<J> induce many of the local and 
systemic changes. Included in this list are an increase in vascular permeability, 
enhanced expression of cell adhesion molecules, induction of chemokines (e.g. 
interleukin-8 [IL-8]), and upregulation of their own production as well as that of 
others (e.g. interleukin 12 [IL-12]) (Picker et a/., 1999; Akira, 2000). These 
cytokines contribute, in many ways, in bringing other immune cells to the site of 
infection/injury, where they participate in clearance of the invading organism and 
healing of the tissue. If the invasion by the microorganism persists, the innate 
inflammatory response will be supplemented by the various elements of acquired 
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immunity, in which Mel> play an important role in the development of both humoral 
and cell-mediated immune response by helping antigen processing and 
presentation. Activated Met> can also further cytokine secretion. For example, IL-1 
and IL-8 are involved in the activation of the endothelium, upregulation of cell 
adhesion molecules and promotion of leukocyte extravasation. IL-6 induces 8 cell 
terminal differentiation into lgG-secreting plasma cells. IL-12 helps activate natural 
killer (NK) cells and promotes differentiation of the Th1 subset. IL-1, -6 and, TN F-a 
are all involved in the production of acute phase proteins and inducing fever 
(Uthaisangsook eta/., 2002). Although not as powerful an antigen presenting cell 
(APC) as dendritic cells (DC), activated Mel> can also present antigen-derived 
peptides in the context of major histocompatibility class (MHC) II molecules to CD4+ 
T cells, thus initiating a T cell response. Activated T cells, in turn, secrete cytokines 
and help activate other immune cells. The overall result is that the host is able to 
mount a specific response against the invading antigen. Therefore, with all ofthese 
capabilities, Met> play an important role in bridging the two arms of innate and 
adaptive immunity. 
In adaptive immunity, activated Met>, along with DC and 8 cells, are 
professional APC which present exogenous foreign peptides to T cells in the 
context of self MHC molecules, thus initiating T cell responses. The peptides may 
be generated after the foreign antigen is phagocytosed and degraded by proteases 
produced in the activated Met>. 
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1.1.3 Activation 
M<l> are remarkably versatile cells in that they are responsive to a diverse 
range of stimuli. Thus, M<l> can be activated in a number of different ways. First, 
pathogen- recognition molecules/receptors (PRR) expressed on the surface of the 
M<l> can bind to pathogen-associated molecular patterns (PAMPs) on micro-
organisms. These PAMPs including lipopolysaccharide (LPS), peptidoglycan 
(PGN), lipoteichoic acid (L TA), lipopeptides, and CpG DNA. The recent discovery 
of the Toll-like receptor (TLR) family in mammalians (reviewed by Underhill and 
Ozinsky, 2002) has greatly enhanced our understanding of PAMP recognition by 
the PRR. Each member of the TLR family (ten have so far been characterized) has 
been shown to recognize specific components of microbes. For example, TLR-4 
is thought to be involved in stabilizing the LPS-CD14 interaction as well as signal 
transduction mediated by LPS (Arbour eta/., 2000), whileTLR-2 has been reported 
to signal the presence of bacterial lipoproteins (Aiiprantis et a/., 1999) and 
lipoteichoic acids (Schwandner et a/., 1999). Bacterial CpG DNA, once bound to 
its ligand TLR-9, becomes a potent inducer of Th1 response and helps induce 
maturation of DC (Takeda and Akira, 2002). Macrophage activation leads to 
induction of various stimulatory products including NO (Chapter3), TN F-a, IL-1 and 
matrix-degrading enzymes like matrix-metalloproteases (MMP) (Chapter 4). 
Second, TN F-a and IL-1 once produced by activated M<l> can bind to their receptors 
on the M<l>, thus initiating autocrine stimulatory loops. In addition to being activated 
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by microbial products and autocrine regulators, as described above, M<l> can also 
be activated by products of T lymphocytes, endocytic stimuli, and many 
physiological hormones. The most studied of the T cell products is inteferon-
gamma (IFN-y). This cytokine helps activate M<l> such that the cells acquire 
increased killing potential against intracellular bacteria and tumor cells (Nathan et 
a/., 1984). IFN-y also helps upregulate the expression of MHC class II molecules 
on M<l> allowing them to become more effective APC. 
1.1.4 Regulation of macrophage function 
As important as M<l> might be in immunity, their activation must be tightly 
regulated to ensure integrity of the host. In most cases, an excessive immune 
response is often accompanied by activation of negative feedback mechanisms. 
In so doing, the host is spared from an overproduction of pro-inflammatory 
cytokines and other products of activated M<l> with tissue-damaging potential. 
However, when and if these controls go awry, M<l> can become the etiological 
agents of a number of inflammatory disease processes. 
Two best characterized cytokines known to be involved in modulating 
macrophage activation and functions are tranforming growth factor-P (TGF-P) and 
interleukin-10 (IL-10) (Assoian eta/., 1987). Although TGF-P is classically known 
as a potent "macrophage-deactivating agent", there is increasing evidence in the 
literature suggesting that TGF-~ can perform dual functions as an activator and 
9 
suppressor (Tsunawaki eta/., 1988). TGF-(31 is the most abundant form in tissues, 
and the predominant isoform present at sites of inflammation/tissue injury. It is the 
major TGF-(3 isoform secreted by circulating Mo and tissue M<l>. At the sites of 
tissue insult, the initial action of platelet degranulation releases TGF-(31, which at 
femtomolar concentrations, can induce the most potent chemoattractant response 
in recruiting monocytes to the sites of inflammation or tissue inury (Pierce et a/., 
1989). Also, femtomolar concentrations ofTGF-(31 trigger activation of resting Mo, 
and subsequent release of cytokines by the activated Mo. TGF-(3 also mediates an 
upregulation of Fe gamma receptor Ill (CD16) on the surface of peripheral blood Mo 
and mature M<J>, thus enhancing phagocytosis and removal of cellular debris (Welch 
eta/., 1990). As the inflammatory process progresses, activation and differentiation 
of Mo (into mature M<l>) leads to a marked down-regulation of the high affinity type 
1/11 TGF-(3 receptors on activated Mo at sites of inflammation, thus decreasing 
sensitivity to TGF-(31 (Brandes eta/., 1991 ). In addition to the receptor modulation 
mechanism, TGF-(3 may exert its effects as an anti-inflammatory mediator by 
inhibiting the release of a number of cytokines/chemokines from activated Mo and 
M<l> which are known to promote development of the inflammatory process (e.g. 
monocyte chemotactic protein-1 [MCP-1 ], monocyte inactivating protein-alpha [MIP-
1a), IL-8, GM-CSF, and TNF-a). Alternatively, TGF-(3 can also influence the 
expression of (1) receptor or receptor antagonists of pro-inflammatory cytokines 
(e.g. IL-1) (Turner eta/., 1991), or (2) anti-inflammatory cytokines (e.g. IL-10) 
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(Ashcroft et a/., 1999). These anti-inflammatory effects of TGF-J3 reflect the 
importance of the cytokine in the resolution phase of the inflammatory response. 
Another cytokine that is often associated with anti-inflammation and immune 
suppression is IL-1 0. The mode of action for this cytokine is similar to that of TGF-
~- IL-1 0 may attenuate the inflammation process by reducing cytokine production 
in activated M<t> through upregulation of suppressor of cytokine signalling-3 (SOCS-
3) and of interleukin-1 receptor antagonist (IL-1 Ra) (Lang eta/., 2002). When 
produced by M<t>, IL-1 0 can bind to its receptor on the M<t>, thus effectively forming 
part of an auto-inhibitory autocrine loop, which controls the production of cytokines 
such as TN F-a (Donnelly eta/., 1995). In addition, stress hormone glucocorticoids, 
can also help modulate the inflammatory response by inhibiting the production of 
pro-inflammatory cytokines by M<t> (Goldstein eta/., 1992). 
Recently, Wang and colleagues (2002) provided novel findings for possible 
regulation by cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) of the 
immune processes associated with Mo or modulation of Mo/M<l> functions. The 
surface marker, which directly competes with CD28 for COSO and CD86 binding, 
plays a role in initiating the formation of inhibitory signalling complexes that 
eventually lead to quiescence or anergy (Sansom eta/., 2000). Functional CTLA-4 
was found to be constitutively expressed in monocytic cells, and its expression 
could be up-regulated by PMA and IFN-y (Wang eta/., 2002). In addition to the 
membrane-bound form, soluble CTLA-4 is also expressed by activated Mo. These 
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investigators have proposed that ligation of CTLA-4 leads to: (1) inhibition of the 
activation of a number of transcription factors including NF-KB, and AP-1 in the 
activated Mo and (2) downregulation of CD86, CD54, HLA -DR and HLA-DQ, which 
are all crucial to the development of immune responses. Taken together, the 
balance between anti-inflammatory and inflammatory mediators is absolutely 
essential to maintaining a healthy host. In fact, this balance is skewed critically, 
one way or another, in a number of infectious, inflammatory, and allergic diseases. 
Thus, better understanding of how biochemical processes involved in the 
production of these molecules may provide critical insights into mechanisms 
underlying a variety of common human diseases including rheumatoid arthritis (RA). 
Only then will there be an opportunity for therapeutic intervention for these 
diseases. 
1.2 NITRIC OXIDE AND NITRIC OXIDE SYNTHASES 
1.2.1 Nitric oxide (NO) 
NO is generated by a five-electron oxidation of one of the terminal guanidine 
nitrogen atoms of L-arginine (Fig. 1.1) and the reaction is catalyzed by members of 
the nitric oxide synthase family. The enzymatic combination of a single nitrogen 
atom and a single oxygen atom forms NO, the smallest synthetic molecule (30 
Dalton) of mammalian cells. To understand why NO was singled out by nature to 
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Figure 1.1: Nitric oxide as catalyzed by nitric oxide synthases 
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Taken from Marietta (1994) Cell:78,927-930 
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perform diverse biological functions, it is necessary to know the physical properties 
of this molecule. It has an unpaired electron, which makes the free radical 
extremely reactive in that it constantly looks for a species that it can either accept 
an unpaired electron or share this odd one. 
1.2.2 Nitric oxide synthases (NOS) 
To date, there are three members constituting the nitric oxide synthase family 
(L-arginine, NADPH: oxidoreductases; EC 1.14.13.39). Two of the three NOS 
members are constitutively expressed: neuronal (nNOS, ncNOS and NOSI) and 
endothelial (eNOS, ecNOS and NOSIII). The third member of the family is the 
inducible NOS (iNOS, NOSII) whose expression typically requires cell activation 
with, among other stimuli, bacterial product lipopolysaccharide (LPS) (Table 1.1 ). 
The three NOS isoforms have been isolated, cloned, characterized and they differ 
in several important aspects including expression characteristics, tissue 
localization, NO output levels, and regulation of activity. All NOS proteins are 
protoporphyrin IX heme enzymes which require three co-substrates (L-arginine, 
NADPH and 0 2) and five co-factors including FAD, FMN, calmodulin, 
tetrahydrobiopterin [BH4], and heme. 
The three NOS isoenzymes are encoded by different genes. The amino 
acid sequences deduced from the respective eDNA show that the three proteins 
share less than 50% sequence homology. However, across species, there is a 
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Table 1.1: Nitric oxide synthase isoforms: designation and 
characteristics 
nNOS (NOS I) iNOS (NOS II) eNOS (NOSIII) 
Human chromosome 12q24.2 17cen-q12 7q35-36 
location 
Size of the gene > 200 kb 37 kb 21 kb 
Number of exons 29 26 26 
SizeofmRNA 8.5-9.5 kb· 4.2-4.5 kb 4.3-4.8 
Number of amino acid I 1433/161 1203/131 1153/133 
Protein size {kDa) 
Subcellular localization Cytosol/ ·Cytosol Membrane 
membrane 
Expression of RNA and Constitutive Inducible Constitutive 
protein 
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higher degree of similarity within each type of NOS suggesting a significant 
phylogenetic conservation. For example, amino acid sequences for NOS I and NOS 
Ill, are more than 90% homologous in human, bovine, and rat. Similarly, more than 
80% of the NOS II sequence is shared by humans and rodents. 
1.2.2.1 Neuronal NOS (nNOS, ncNOS, NOS I) 
1.2.2.1.1 Expression 
NOS I was first named as the neuronal NOS after its discovery in the brain cells 
of various species (Bredt and Snyder, 1990). Since then, it has been identified in 
a number of cell types including skeletal muscle cells, pancreatic islet cells, and 
kidney macula densa cells (Bredt and Snyder, 1994 ). In the brain, its activity is 
associated with synaptic elasticity, but in the peripheral nervous system, NOS I is 
primarily connected to smooth muscle relaxation (Kerwin eta/., 1995). 
Assigned to the 12q24.2 region of chromosome 12, the human NOS I is by far 
the largest of the three NOS enzymes with its gene spanning over 150 kb of DNA 
(Marsden et a/., 1993). The mRNA is encoded by 29 exons with the translation 
initiation and termination sites in exons 2 and 29 respectively, leaving the 
untranslated region in exon 1. The human NOS I eDNA has an open reading frame 
of 4299 nucleotides encoding for a protein of 1433 amino acids with a predicted 
molecular weight of 161 kDa. It is known that NOS I is only capable of producing 
picomolar quantities of NO. 
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1.2.2.1.2 Regulation of activity and NOS I enzyme expression 
The activity of NOS I is primarily regulated by calmodulin in a calcium-dependent 
manner. The enzyme is generally activated by stimuli which cause a transient 
increase in intracellular Ca2+ levels. With regards to the regulation of NOS I 
expression, little information is available to this end. However, the presence of the 
binding sites in the 5'-flanking regions of exon 1 for a number of cis-acting 
transcription factors including AP-2 (activator protein-2), TEF-1/MCBF (transcription 
enhance factor-1/M-CAT binding factor), CREB/ATF (cAMP response element 
binding protein/activating transciption factor), c-fos, NF-1, and NFkB-Iike sequences 
suggests that NOS I is likely to be transcriptionally regulated (Hallet a/., 1994). 
There is also evidence supporting a role of estrogen in upregulating NOS I mRNA 
and activity in various tissues (Weiner eta/., 1994 ). In addition, chronic salt loading 
of rats also resulted in an increase in mRNA accumulation and protein (Zhang et 
a/., 1994). Functional studies of the human NOS I promoter with reporter gene 
constructs demonstrate that phorbol esters can increase transcription by two-fold 
in Hela cells (Young et a/., 1995). These findings, thus, show that NOS I 
expression can be up-regulated in certain instances. However, the molecular 
mechanisms behind the phenomenon have yet to be elucidated. Post-
transcriptional control of the NOS I gene also exists in the form of alternative mRNA 
splicing. For instance, 5% of neuronal NOS I transcripts lacked two exons encoding 
105 amino acids from position 504 to 608 in the NOS I protein (Ogura eta/., 1993). 
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Similar structural diversity due to mRNA alternative splicing was also found in 
human cerebellum and differentiated skeletal muscle, where the NOS I protein is 
a distinct entity from that of the putative neuronal NOS. Together, the variants of 
NOS I support a notion that alternative mRNA splicing functions as a mechanism 
for tissue-specific regulation of NOS I. 
Mice generated by homozygous deletion of exon 2 exhibited inappropriate 
sexual and aggressive male behaviour (Nelson et a/., 1995) and hypertrophic 
pyloric stenosis (Vanderwinden eta/., 1992). It should be noted that in these mice, 
the deletion did not lead to a complete absence of neuronal NOS. Rather, due to 
the alternative mRNA splicing, the lack of exon 2, gives rise to other variants of 
NOS that may likely explain the lack of histopathological abnormalities in the brain 
in these animals. 
1.2.2.2 Inducible NOS (iNOS, NOS II) 
1.2.2.2.1 Expression 
The human NOS II gene is assigned to the 17q11.2-q12 region of chromosome 
17. It consists of 26 exons and 25 introns spanning about 37 kb of human genomic 
DNA. The translation starts at exon 2 and terminates at exon 26, leaving a 5'-
untranslated region of about 22 nucleotides. The full length open reading frame is 
3459 base pairs encoding a protein of about 1153 amino acids. NOS II was named 
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"i NOS" (Xie et a/., 1992) to depict its independence of intracellular Ca2• fluxes. 
Originally identified in macrophages, NOS II, which is localized in the cell cytosol, 
has since been shown to be expressed in various cell types including hepatocytes 
(Shiratori eta/., 1998), chondrocytes (Grabowski eta/., 1996), f3-islet cells (Suarez-
Pinzon et a/., 2001 ), mesangial cells (Wang and Marsden, 1995), murine mature 
bone marrow-derived DC (Lu eta/., 1996), and murine splenic natural killer cells 
(Diefenbach et a/., 1999). Unlike neuronal and endothelial NOS where the 
expression is constitutive, that of the NOS II has to be induced. LPS and pro-
inflammatory cytokines TNF-a, IL-1 and IFN-y were among the first immunologic 
and inflammatory stimuli found to be successful in inducing NOS II. lnterleukin-2 
(IL-12) IL-18, and IFN-a have all been described as stimulators of NOS II 
expression (Kroncke et a/., 1995). However, the type of cytokine and/ or their 
combination which induce superior NOS II expression varies greatly among species 
and between cell types within the same species. In addition to LPS and cytokines, 
other agents were also identified as inducers of NOS II. Included in this list are: 
cAMP-elevating agents, such as forskolin or dibutyryl cAMP (Gilbert and 
Herschman, 1993a; Hortelano eta/., 1993), platelet-derived growth factor, and 
fibroblast growth factor (Gilbert and Herschman, 1993 b). Changes associated with 
certain disease processes such as RA, diabetes, and AIDS-associated dementia 
may also lead to the induction of NOS II (St. Clair et a/., 1996; Adamson et a/., 
1999; Suarez-Pinzon eta/., 2001 ). On the other hand, there are a large number of 
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compounds or molecules thought to be able to prevent the expression of NOS II. 
For instance, IL-4, IL-8, IL-1 0, MCP-1, and TGF-f3 are all thought to be NOS II 
inhibitors in M<l> (Bogdan eta/., 1994; McCall eta/., 1992; Cunha eta/., 1992; Rojas 
eta/., 1993; Ding eta/., 1990). Glucocorticoids, such as dexamethasone, are 
effective in inhibiting NOS II induction in a number of cell types including 
endothelial cells, M<l>, fibroblasts, and smooth muscle cells (DiRosa eta/., 1990; 
Gilbert and Herschman eta/., 1993 b; Kanno eta/., 1993). 
1.2.2.2.2 Regulation of activity and NOS II enzyme expression 
Unlike nNOS and eNOS, NOS II does not depend on Ca 2+ influx for activation. 
The reason for the difference is because binding affinity of calmodulin and NOS II 
is so great that calmodulin can tightly bind to the enzyme even at very low 
intracellular calcium levels. Given that all three NOS isoforms need the same co-
factors, including NADPH, FAD and (6R)-5,6,7,8-tetrahydrobiopterin (BH4), the 
difference in the activation signal may explain the high and continuous levels of NO 
produced by NOS II (Iyengar eta/., 1987). Primer extension analyses with the RNA 
of human hepatocytes activated with LPS and IFN-y mapped the transcription 
initiation site to 30 base pairs downstream of the TAT A box. Functional studies of 
the cloned murine NOS II promoter have identified a number of sequences/binding 
motifs that are likely to be involved in the regulation of NOS II expression. For 
example, there are several consensus sequences for the binding of transcription 
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factors including IFN-y-responsive element (IRE), IFN-a-stimulated responsive 
element, activating protein (AP)-1 site, and a palindromic TNF-a-responsive 
element like site. Binding sites/motifs for NF-KB and nuclearfactor-IL6 (NF-IL6) are 
also present in multiple copies. Analyses of reporter gene constructs of mutants of 
the NOS II 5'-flanking region have revealed two functionally important sequences 
of the 5'- regulatory region. Containing the putative binding sites for NF-IL6 and 
NF-KB, the first region (positions 49 to 209) is thought to regulate LPS-induced 
expression of NOS II, as its removal by deletion leads to absence of NOS II 
induction in LPS-stimulated cells (Lowenstein et a/., 1993). The NF-KB inhibitor 
pyrrolidine dithiocarbamate (PDTC) prevented the activation of proteins binding to 
the NF-KB binding site and the production of NO in LPS-treated murine M<P, 
suggesting that the nuclear factor was essential to NOS II transcription in murine 
(Xie eta/., 1994). The second region spanning residues 913 to 1029 contains a 
cluster of 4 enhancer motifs known to bind to IFN-y responsive transcription factors, 
including an IFN-y regulatory factor binding site (IRF-E). Deletion of residues 
within the IRF-E was shown to abolish upregulation of NOS II transcription, as a 
result of IFN-y stimulation. Findings such as these support a notion that this 
second region of the 5'-regulatory sequence might be responsible for the 
synergistic effect of NOS II induction by IF N-Y and LPS co-stimulation. 
As mentioned earlier, a number of cytokines (especially Th2 type cytokines) and 
other compounds have been identified as inhibitors of NOS II induction. We are 
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beginning to understand the mechanism whereby these molecules exert their 
inhibitory function. The evidence shows that TGF-~ may: (1) reduce NOS II mRNA 
levels via decreasing its stability without affecting the transcription; (2) attenuate 
translation efficiency, and (3) accelerate protein degradation (Vodovotz et a/., 
1993). On the other hand, interleukin- 4 (IL-4), a Th2 type cytokine, does not 
appear to negatively affect NOS II stability. Rather, it has been shown to reduce 
both mRNA expression and protein display 24 to 72 h post stimulation. 
NO production can also be regulated by interfering with availability of the main 
substrate L-arginine. The high output production of NO by NOS II requires 
extracellular arginine in addition to intracellular arginine. Extracellular arginine is 
transported inside the cell by a group of carriers known as cationic amino acid 
transporters (CAT), which themselves are up-regulated after LPS stimulation. 
Studies with M<l> from CAT2-t-mice showed more than 90% suppression of arginine 
uptake and as a result, NO production after LPS or IFN-y stimulations (Nicholson 
et a/., 2001 ). Both IL-4, interleukin-13 (IL-13), dexamethasone, and cyclic 
adenosine mono-phosphate (cAMP) have been found to strongly increase 
expression of arginase I and arginase II (Munder eta/., 1999; Rutschman eta/., 
2001; Gotch and Mori, 1999). The up-regulation of arginase prior to NOS II 
induction by cytokines or LPS prevents NO production by substrate depletion 
(Munder et al., 1999; Rutschman et a/., 2001 ). 
Adding to the complexity of the mechanism regulating NOS II expression is the 
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fact that some molecules may stimulate NOS II induction in one cell type and inhibit 
in another. For example, as previously discussed TGF-J3 has been documented to 
suppress NOS II expression in mouse M<l> (Ding et a/., 1990), but stimulate 
induction in 3T3 fibroblasts (Gilbert and Herschman, 1993 a,b). Similarly, cAMP 
and cAMP-elevating agents have been reported to mediate an upregulation of NOS 
II expression in rat Kupffer cells (Gaillard, 1992) and smooth muscle cells (Koide 
eta/., 1993}, but prevent NOS II induction in rat astrocytes (Feinstein eta/., 1993). 
Findings such as these show that signal transduction pathways leading to NOS II 
induction appear to differ markedly among different cell types of the same species 
or even within the same cell type of different species. 
1.2.2.3 Endothelial NOS (eNOS, ecNOS, NOS Ill) 
1.2.2.3.1 Expression 
NOS Ill was first identified in endothelial cells, and therefore named eNOS. 
Immunohistochemical studies have localized the enzyme to various types of arterial 
and venous endothelial cells in many tissues, including those in human (Pollock et 
a/., 1993). In addition, NOS Ill has also been found in syncytotrophoblasts of human 
placenta (Myatt et a/., 1993) and interstitial cells of the canine colon (Xue et a/., 
1994). This gene is mapped to the 7q35-7q36 region of chromosome 7 (Marsden 
eta/., 1993), and like NOS I, NOS Ill is constitutively expressed. The gene contains 
26 exons spanning about 21 kb of the genomic DNA. The translation initiation and 
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termination sites are located in exon 1 and exon 26 respectively, leaving the 
untranslated region of about 22 nucleotides. Unlike NOS I and NOS II, which 
primarily exist in the cell as cytosolic proteins, NOS Ill is thought to exist in a 
membrane-bound form (plasma and microsomal) through a single myristoylation 
site on the enzyme. Phosphorylation results in detachment of the enzyme from the 
membrane and subsequent translocation to the cytosol. 
1.2.2.3.2 Regulation of activity and NOS Ill expression 
Like NOS I, NOS Ill is controlled by calmodulin/Ca2+, and several mechanisms 
have been proposed for its regulation. For example, sheer stress produced in the 
flowing blood was shown to give rise to an acute increase in NO release 
(Lamontagne et a/., 1992), and an upregulation of endothelial NOS expression 
(Nishida eta/., 1992). A putative sheer stress response element in the promoter 
region of NOS Ill has since been cloned (Marsden et a/., 1993), suggesting 
increased sheer stress may likely give rise to increased NOS Ill gene expression 
and greater capacity for vasodilation. TN F-a has also been shown to down-regulate 
NOS Ill mRNA, protein and activity in cultures of bovine endothelial cells (Nishida 
eta/., 1992), and the effect has been attributed to destabilization of mRNA NOS Ill 
(Yoshizumi eta/., 1993). As in the case of NOS I, there is evidence for stimulatory 
effects of estrogen on NOS Ill activity and/or expression. 
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Figure 1.2: Crucial differences between NOS isoforms 
Nathan and Xie (1994) Cell: 78, 915-918 
25 
1.2.3 Structure of NOS enzymes 
NOS are homodimers whose monomers are two enzymes fused. The COOH-
terminus is the reductase domain while the NH2- terminus is the oxidative domain. 
The central portion of the enzyme contains a binding site for Ca 2+/calmodulin. 
Generally, constitutive transcription of NOS I and Ill gives rise to the formation of 
noninteractive monomers (Fig. 1.2). Upon binding to heme, BH4 and L-ariginine, 
a conformational change is presumed to take place at the N- terminal region to 
allow for dimerization of the monomers, such that the oxidase domain of one 
monomer is approximated with the reductase counterpart of the other monomer 
(Nathan and Xie, 1994). Such head-to-tail orientation allows interdomain contact 
without violating constraints imposed by hydrodynamic values, and this would also 
imply that the homodimer is elongated (Schmidt eta/., 1991). It should be noted 
that dimerization of the two constitutively expressed NOS isoforms does not directly 
lead to activation of the enzymes. Rather, the binding of Ca 2+ ions (whose levels 
increase as a result of agonists) to calmodulin leads to a conformational change in 
the calmodulin structure and subsequent activation of the protein. The active 
calmodulin binds to the NOS homodimer at an exposed, hydrophobic site leading 
to "rotation" of the reductase domain and activation of the (NOS I or NOS Ill) dimer. 
In contrast, the basic, hydrophobic site in NOS II monomers can bind calmodulin 
even at trace levels of Ca 2+ present in the cytosol of resting cells (Cho eta/., 1992). 
Rotation of the reductase imparted by the binding of calmodulin, however, is not 
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sufficient for NOS II to be enzymatically active. L-arginine, heme, and BH4 are all 
required for dimerization of NOS II monomers. Since these positive allosteric 
regulators are replete in cells transcribing NOS II, neither monomers of NOS II nor 
calmodulin deficient NOS II dimers are likely to accumulate under normal 
conditions. The binding affinity of NOS II to calmodulin is sufficiently high that the 
strong NOS 11-calmodulin interaction ensures sustained enzymatic activity, even in 
the absence of calcium influxes. This property ensures that the enzyme is fully 
active in the presence of NAPDH, L-arginine, and oxygen (Abu-Soud and Stuehr, 
1993). Taken together, the main control for activity of NOS I and Ill rests in the 
level of calcium in the cytosol while that for NOS II depends on the level of gene 
transcription. 
1.2.4 Major roles of NO 
Since the discovery that NO can be produced by a mammalian cell (Stuehr and 
Marietta, 1985), a tremendous amount of research has been devoted to studying 
the physiological roles of this molecule. In fact, it was named "Molecule of the 
Year'' by the journal Science in 1992 (Koshland, 1992). Depending on where it is 
synthesized, the amount produced, the targets and most importantly, its levels in 
the local environment, NO can exert remarkably different effects. For example, in 
the endothelium, NO is vital to the regulation of muscle tone (Palmer eta/., 1987). 
In controlling the blood flow, NO is thus indirectly involved in the regulation of 
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oxygen supply to organs. It also prevents platelet adherence and aggregation as 
well as neutrophil aggregation to the vascular endothelium (Billiar, 1995). To 
varying degrees, NO can down-regulate a number of adhesion molecules, namely 
vascular cell adhesion molecule-1 (VCAM-1 ), intercellular adhesion molecule-1 
(ICAM-1 ), E-selectin (CD62E), and P-selectin (CD62P) (Spiecker eta/., 1998). 
Impaired NO synthesis by the endothelium leads to adverse consequences. In both 
spontaneously hypertensive rats and in humans with essential hypertension, NO 
production has been shown to be defective (Panza et a/., 1990; Durante et a/., 
1988). Nitric oxide produced by NOS I plays a role as a neurotransmitter in 
peripheral autonomic neurons referred to as noradrenergic, noncholenergic nerves 
(Gillespie eta/., 1989). Also, it promotes motility of the gastrointestinal tract. In 
contrast, at higher levels, as when produced by the NOS II, NO functions as an 
inflammatory mediator making it essential to the host innate response against 
microbial pathogens especially intracellular bacteria. NO has also been shown to 
be effective in mounting the response against certain viruses (Croen, 1993; 
Karupiah eta/., 1993), protozoa (Liew eta/., 1991), and helminth (Lane eta/., 
1994 ). The contributions of NOS II and NO in the immune system in general, and 
innate immunity, in particular, is discussed in greater details later (Section 1.2.6) 
The ability of NO to inhibit tumor cell growth or promote tumor cell death was the 
first function of NO to be discovered (Nathan, 1992). NO derived from M<l> can 
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1.2.5 Mechanisms for NO actions 
Nitric oxide is a powerful free radical that can exert its functions via a number of 
mechanisms. When "attached" to a carrier to extend its short half life, NO can 
reach target cells by simple diffusion. Being a lipophilic molecule, NO can readily 
traverse the lipid bilayer and travel to various intracellular locations where it can 
perform its duty. One of those places is the nucleus where it may distort the 
structure of DNA by interacting with the amine groups of the nitrogenous bases. 
However, given that the half-life of the authentic NO gas is less than 15 seconds, 
NO could carry out its functions much more effectively if it reacted with other 
radicals to form more stable products. Indeed, it is thought that the chemistry of 
NO mostly involves interrelated redox forms, the most important ones being those 
with transitional metal ions and with free thiols, with oxygen-derived free radicals, 
and with molecular oxygen (Abramson et a/., 2001 ). For example, the binding of 
NO to prosthetic iron groups and thiol groups forming complexes that can lead to 
activation or inactivation of many important enzymes. The physiologically most 
relevant action of NO is the activation of soluble guanylate cyclase by nitrosation 
of its haem moiety (lgnarro, 1990). Subsequent increase in cGMP levels is crucial 
in vasorelaxation in the vasculature and neurotransmission in the central nervous 
system (CNS). In addition to soluble guanylate cyclase, NO is also thought to help 
activate cyclooxygenase (COX). The inducible type of COX, COX-2, appears to be 
activated under stimulation with low concentrations of NO, whereas higher 
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concentrations may inhibit the enzyme. For example, glyceraldehyde-3-phosphate 
dehydrogenase is inhibited by NO via iron nitrosylation of the thiol group at the 
active site of the enzyme (Molina eta/., 1992). Aconitase, NADH: ubiquinone 
oxidoreductase and succinate: ubiquinone oxidoreductase ofthe electron transport 
chain are inactivated by the attacks on the iron of the iron sulfur (Fe-S) clusters 
essential to the function of these enzymes (Drapier et a/., 1986). In addition to 
disrupting iron-sulfur clusters and S-nitrosylating, NO can also inactivate proteins 
by binding to zinc fingers or by peroxidation of membrane lipids (Bogdan eta/., 
2000). Because of the importance of these molecules in cell function and survival, 
their inactivation by NO results in cytostasis and cytolysis of invading micro-
organisms and tumor cells (Hibbs eta/., 1987; Stuehr and Nathan, 1989). Thus, the 
inhibition of these and other enzymes (e.g., ribonucleotide reductase and 
cytochrome P450) is believed to be the mechanism by which NO can inhibit the 
growth of target cells, whether they be invading microorganisms, tumor cells or 
lymphocytes. The highly active free radical can also react with superoxide anion 
to form peroxynitrite, nitrogen dioxide and hydroxy radicals. Peroxynitrite is a highly 
toxic compound which nitrosylates tyrosine residues on proteins leading to 
accumulation of injurious intracellular oxidants (Pryor and Squadrito, 2001 ), or a 
change/disruption of normal protein function (Hausladen eta/., 1996). In addition, 
the ability of peroxynitrite to spontaneously react with other free radicals to 
generate other ROI and RNIIeads to a possibility of DNA mutation. Lastly, in the 
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presence of molecular oxygen, NO is spontaneously converted to nitrite and nitrate, 
inactivating the molecule. Nitrite and nitrate are NO indicators in sera and culture 
media (Stamler eta/., 1992). Originally, it was thought that NO actions were strictly 
limited to the local environment. This is because free radical NO is rapidly 
consumed or inactivated either when released from the cell, within the cell, or in the 
circulation where it binds to the heme group of erythrocyte hemoglobin. However, 
Stamler and colleagues (1992) showed that NO may also form stable adducts with 
albumin or glutathione in the form of S-nitrosothiols (such as S-nitroglutathione ), S-
nitrosylated proteins, and nitrosyl-metal complexes which can circulate and diffuse 
to remote sites, where bioactive NO is spontaneously released (Billar, 1995). 
Alternatively, NO can also be freed from the complexes upon cleavage by 
ectoenzymes found on such cells as T and B lymphocytes (Henson eta/., 1999). 
This process may not be limited to extracellular transport of NO as there is evidence 
for glyceraldehyde-3-phosphate in platelets serving as an intracellular storage and 
transport vehicle for NO (McDonald et a/., 1993). In this light, where NO can be 
stored and travel long distance without losing its activity, it is conceivable to think 
of NO as having hormone-like properties. 
1.2.6 NOS II, NO and their impact on the immune system 
Of the three isotypes of the NOS family, it is NOS II that has captured most of 
the attention within the research community. The special interest is most likely due 
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to its inducibility and the ability to release a sustained high output of NO. Findings 
which show that over-expression of NOS II and over-production of NO may 
contribute to pathogenesis deepen a desire to further our understanding as to how 
this enzyme is regulated. 
Because of its capacity to induce apoptosis, NO might have a place in T cell 
selection and developmental processes. Epithelial cells and DC in the 
corticomedullary junction and medulla of the thymus have been shown to 
constitutively express NOS II whose expression is further enhanced upon contact 
with self antigens, alloantigens, or with thymocytes activated by TCR stimulation 
(Tai eta/., 1997; Aiello eta/. 2000, Moulian eta/., 2001 ). The literature shows that 
double positive thymocytes are highly susceptible to killing by NO whereas single 
positive thymocytes are not, suggesting that NO released by NOS II expressing 
stromal cells is among the mechanisms whereby double positive thymocytes are 
deleted in the thymus (Tai eta/., 1997; Aiello eta/., 2000, Moulian eta/., 2001 ). 
Also, because of its capacity to induce apoptosis, nitric oxide has been proposed 
to confer host protective effects during infectious diseases by inhibiting tissue 
fibrosis (Hesse eta/., 2000). 
In vivo production of NO and superoxide by phagocytes (M<I> and neutrophils) 
in a CD4+ T cell dependent manner is crucial to systemic anti-tumor immunity, as 
deletion of the NOS II gene and tumor-mediated suppression of macrophage NOS 
II expression correlate with reduced tumor rejection (DiNapoli et a/., 1996). 
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Conversely, production of NO in certain NOS 11-transfected or NOS II upregulated 
melanoma or sarcoma cells prevents metastasis and induces in vivo tumor 
regression (Bodgan, 2001 ). 
As alluded to in an earlier section, NOS II is in most instances expressed 
following cell activation by immunologic and inflammatory stimuli. It is the high NO 
output generated by the inducible isoform (approximately a thousand fold that 
released by the other two isoforms) that accounts for its role as an inflammatory 
mediator. Employing the mechanisms discussed above, NO and its intermediates 
provide a first line host defence against invading pathogens. In fact, RNI (NO and 
its derivatives) constitute the most important defence mechanism against 
intracellular bacteria like Mycobacterium tuberculosis, one of the most successful 
pathogens of mankind. The importance of NOS II and NO in innate immunity was 
revealed from studies where NOS II knock-out mice were more susceptible to 
infection with intracellular bacteria than wild type mice (MacMicking eta/., 1996). 
In addition, NO also aids in reducing thrombosis formation and improving blood 
supply to injured tissue. 
In addition to the various direct actions of NO discussed here, the antimicrobial 
activity of NOS II might also be mediated via its indirect functions. Infectious 
pathogens such as African trypanosomas, T. Cruzi, and Giardia Iamblia, are 
dependent on exogenous arginine for production of polyamines and cell 
proliferation. In this light, the induction of NOS II (or arginase) by macrophages and 
33 
other immune cells will lead to consumption of the available arginine and possible 
growth inhibition or cell death of the parasites (Eckmann eta/., 2000; Piacenza et 
a/., 2001 ). 
However, as much as its actions can benefit the host, excessive NO production 
can also cause tissue damage to the host's own cells. Therefore, understanding 
of how NOS II expression can be regulated and hence, how NO production can be 
modulated is crucial to the development of therapeutic approaches where excessive 
NO production and/or NOS II over expression have been shown to play an 
important role in the development and duration of the inflammatory process in a 
number of chronic inflammatory conditions. This aspect will be further discussed 
in chapter 6. 
1. 3. LIPOPOLYSACCHARIDE (LPS) 
It is generally accepted that bacterial products are among the most potent stimuli 
leading to activation of Mo and MQ>. Of all of those bacteria-derived components 
which have been studied in the past six decades, endotoxin LPS is considered to 
be the microbial activator of choice for many studies. The choice is partly because 
only a small amount of the agent is required for Moor M<l> activation (Chen eta/., 
1992). Adding to the high potency is the fact that highly purified LPS can be 
readily obtained commercially, and that the component responsible for the 
biological activity of LPS (see below) has been chemically identified and 
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Figure 1.3: E. coli envelope organization 
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characterized. 
1.3.1. Structure 
LPS constitutes the lipid portion of the outer leaflet of the Gram-negative 
bacterial cell wall, and is essential for bacterial cell growth (Figure 1.3). The 
amphipathic LPS molecule consists of an polysaccharide-0 chain, a core 
oligosaccharide and a lipid A moiety. 
The 0 chain is immunodominant, and confers serological specificity to each 
Gram-negative bacterium. Making up of an inner core and an outer core (Figure 
1.4), the oligosaccharide is more conserved than the 0 chain across the different 
species of bacteria. The covalently linked lipid A moiety contains a 
diphosphorylated glucosamine disaccharide acylated with characteristic 
hydroxylated and non-hydroxylated fatty acid chains. The two phosphate groups 
are in defined positions. Variation in this structural arrangement such as a 
reduction of the number of acyl chains or the change in their distribution or degree 
of saturation results in a dramatic reduction in biological activity (Rietschel et al., 
1996). This third region of the LPS molecule is highly conserved in that the moiety 
is shared by all Gram-negative bacteria (Westphal eta/., 1975). The lipid moiety 
is considered to be the functional essence of the LPS molecule, and not surprisingly 
the region associated with highest cytotoxicity. Functional significance of lipid A 
has been documented in a number of studies using different approaches. For 
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Figure 1.4: The lipopolysaccharide structure 
O~antigen :outer 
i Core 
I 
I 
Inner. 
!Core! 
I I 
I I 
' ' I I 
' 
' 
' 
' 
'I 
'' I I 
I I 
I I 
'' I I 
I I 
Monosaccharide 0 
Phosphate • 
Ethanolamine <1 
Fatty acid chain 
Adapted from Morrison and Ryan (1992) 
Lipid A 
In Molecular Biochemistry and Cellular Biology, volume 1 
37 
example, Doe and colleagues (1978) have shown that isolated, highly purified lipid 
A, under appropriate moiety, will inhibit essentially important LPS-mediated 
macrophage functions including: (1) production and secretion of cytokines (Chia et 
a/., 1989); (2) generation of procoagulant activity (Niemetz and Morrison, 1977), 
and (3) macrophage dependent tumor cell cytotoxicity (Doe eta/., 1978). Work with 
synthetic lipid A and other related structures have shown that these components 
are able to mediate the release of inflammatory cytokines (e.g. IL-1) from M<l>, 
further strengthening the importance of lipid A in cell activation (Kotani eta/., 1985; 
Lopponow eta/., 1989). 
Studies of the chemical requisites for LPS endotoxic activity have shown that the 
activation of Mo and M<l> by LPS depends on a novel, peculiar structure of the lipid 
A moiety present on the invading bacterium (Mueller-Loennies eta/., 1998). Recent 
work has now suggested that biological activities of LPS are determined by the 
shape of their lipid A portion (Schramm eta/., 2000). Only (hexaacyl) lipid A that 
adopts a conical/concave shape, with the cross-section of the hydrophobic region 
being larger than that of the hydrophilic region, could induce cytokine production 
in M<l>. On the other hand, LPS molecules with cylindrical shape do not exert 
endotoxic activity on cells, and interestingly these structures have been shown to 
possess antagonistic activity (e.g. they prevent initiation of cell signalling mediated 
by biologically active LPS). Thus, synthetic compounds whose structures resemble 
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that of the cylindrically shaped LPS may provide novel insights for the development 
of therapeutic approaches for conditions like sepsis. 
1.3.2 Biological activity 
During the course of infection by Gram-negative bacteria, LPS is shed from the 
outer membranes of the invading pathogen, and released into the circulation, where 
it subsequently plays a crucial role in initiating the immune response against the 
micro-organism. There is substantial evidence from both in vitro and in vivo studies 
to support a crucial role of LPS in eliciting, in macrophages, most of the cellular 
responses usually attributable to multifunctional inflammatory cells. For instance, 
it has been established that in macrophages LPS can induce production of a 
number of important cytokines (both pro-inflammatory and immunosuppressive), 
such as IL-1, type I interferons (IFN-a/(3), and TNF-a (Aggarwal eta/., 1985). 
Evidence for LPS mediating release of leukotrienes and arachidonic acid has also 
been documented (Schade et a/., 1987). In addition, LPS isolated from 
Helicobacter pylori has also been shown to induce mitogenic activity, spleen growth, 
and TNF-a production from mononuclear 
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initiating factor is bacterial sepsis. It is believed that the ability of LPS to initiate 
activation of multiple inflammatory pathways, and thus production of various 
inflammatory mediators, is central to the development of sepsis. Sepsis or 
endotoxic shock is manifested by the overproduction of pro-inflammatory cytokines 
such as IL-1, TNF-a, and IL-6 by M<l>. The condition is characterized by fever, 
hypotension, leukopenia, hypoxia, acidosis and disseminated intravascular 
coagulation. If left untreated, multisystem organ failure or even death is not 
uncommon (Tracey et a/., 1986). What started out as a beneficial immune 
response against the bacterial infection turns into a perpetuating cycle of cell 
activation and production of inflammatory mediators. In addition to sepsis, bacterial 
LPS has also been detected in plasma of patients with inflammatory bowel diseases 
(Caradonna eta/., 2000). In these patients, there is an increased production of pro-
inflammatory cytokines and chemokines in mucosal tissue and in the circulation. 
1.4 PROTEIN KINASE C (PKC) 
1.4.1 Structure 
First described by Nishizuka (1984) as a histone protein kinase activated by 
phospholipids, 1,2-diacylglycerol (DAG) and Ca2+, subsequent molecular 
biochemical studies in the past fifteen years have revealed the presence of multiple 
isoforms of PKC differing in structure, cofactor requirements and substrate 
specificity. The PKC superfamily is a group of serine/threonine kinases which play 
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an integral part in many different signalling systems including those that regulate 
the activities of ion channels, cytoskeletal proteins, and other molecules involved 
in cell growth and cell function (Casabona, 1997; Taker, 1998). To date, there are 
about twelve known members discovered in mammalian cells, and several in non-
mammalian cells (Mellor and Parker, 1998). The mammalian PKC are subdivided 
into three smaller subgroups of conventional (or classical), novel and atypical PKC 
(Fig. 1.5). The conventional PKCs (cPKC), which include -a (alpha), -131 (beta 1 ), 
-132 (beta 2), and -V (gamma), can be activated by phorbol esters, DAG, and Ca2+ 
(Table 1.2). Lacking the Ca2+ binding motif seen in the conventional group, the 
novel PKC (nPKC) group, which is made up of-~ (delta), -e (epsilon), -8 (theta), 
and -r, (eta) (L), does not depend on elevated calcium levels for activation. Rather, 
they are activated by DAG, phorbol esters and certain fatty acids. The atypical 
PKCs ( aPKC) include -~(zeta) and -~ (lamda)/1 (iota) (Ono eta/., 1989; Gomperts, 
2002) that are neither responsive to phorbol esters nor to Ca2+. PKC of the atypical 
sub-family may have some constitutive activity but are also activated by 
phosphoserine (PS), phosphatidylinositides or unsaturated fatty acids. It is thought 
that the lamda isoform is a mouse homologue of the human iota isoform (Nishizuka, 
1995). Exactly how these two isotypes are activated has not been fully elucidated, 
but it has been suggested to involve the Ras protein (Diaz-Meco eta/., 1994). In 
addition to the three subgroups above, there is also a group of PKC-related kinases 
(PRK), of which there are PKC-~ and its mouse homologue termed PKD, PKCv, or 
Table 1.2: Characteristics of protein kinase C isoforms 
lsoform Protein size (kDa) Known activators Predominant expression 
Conventional PKC (cPKC) 
Alpha (-a) 74 Ca2+, DAG, cis-FA, PS Universial cells 
Beta 1 H~1) 81 Ca2+, DAG, cis-FA, PS Fibroblasts 
Beta 2 (-132) 80 Ca2+, DAG, cis-FA, PS Spleen, kidney 
Gamma (-y) 80 Ca2+, DAG, cis-FA, PS Rat brain 
Novel PKC (nPKC) 
Epsilon (-£) 97 cis-FA, PIP3 Murine brain 
Delta (-0) 82 DAG, PIP3 Lung, brain, kidney 
Mu (-IJ)/PKD 104 PMA, PKC-~ Thymus, lung 
Theta (-9) 79 ? Skeletal muscle, T lymphocytes 
Eta (-11) 68 PIP3 Lung, skin 
Atypical PKC (aPKC) 
Iota (-1)/Lamda (-A) 67 ? Ovary, testis 
Zeta H) 67 PS, FA, PIP2, PIP3 Lung, fibroblasts,epidermis 
cis-FA, cis-unsaturated fatty acid; DAG, diacyglyceride; PS, phosphoserine; PIP3, phosphotidyl-
inositol 3 phosphate. 
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PKD2. Originally categorized in the novel PKC or even considered as an aPKC by 
some workers, PKC-1..1/PKD has now been placed in the PRK group owing to subtle 
differences in its structure compared to that of the others (see below). 
As depicted in Figure 1.5, the structure of PKC isoforms consists of conserved 
domains (C1-C4) flanked by variable domains (V1-V5), whose function is not clear. 
The V1-V3 section of the N-terminus makes up the regulatory domain in all PKC 
isoenzymes, while the V3-V5 portion constitutes the catalytic domain. Separating 
the regulatory half and the catalytic half of the PKC molecule is the hinge region, 
located within the third variable region. The hinge is susceptible to calpain (Ca2+ 
dependent neutral protease) digestion. The C1 region contains two cysteine rich 
zinc finger like sequences, necessary for the binding of DAG and phorbol ester. 
The crystal structure of the isolated C1 domain of PKC-<5 has shown a globular 
species comprising two-beta sheets, which form the ligand binding cavity (Zhang 
eta/., 1995). The binding of PKC-<5 to DAG alters the hydrophobicity of the surface 
of the C1 domain, thus allowing hydrophobic interactions and membrane targeting 
(Hurley eta/., 1997). Also located in C 1 is a pseudosubstrate binding motif, which 
has an autoregulatory function of blocking the catalytic site located in the C-
terminus of the enzyme. Analyses of the crystal structure of the purified C1 domain 
have shown that the aPKC isoforms have only one of these finger motifs, and thus 
lack the residues necessary to form the hydrophobic surface at the ligand-binding 
site (Hurley eta/., 1997). These isoforms 
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Figure 1.5: The structure of the PKC superfamily 
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structure of PKC is organized as such that each constant region is flanked by two 
variable regions, whose function is not really known. Each PKC starts with V1 and 
ends with VS. 
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are, therefore, unable to respond to stimulation by either DAG or phorbol ester. 
Structural analyses of the C2 domain from synaptogamin known to share homology 
with that of PKC have shown that this region is rich in beta-sheet. Interactions 
between these anti-parallel sheets forms a novel Ca2+ binding pocket, which can 
coordinate two metal ions (Sutton eta/., 1995). As with the C1 domain, PKC 
isoforms which do not respond to calcium lack the necessary residues to 
accommodate metal ions. Of the three PKC subgroups, only the conventional PKC 
isotypes have such required residues to form the cavity. Subsequently, they are the 
only ones which are responsive to calcium activation. The C2 region also houses 
part ofthe receptor for the activated C-kinase 1 (RACK-1) binding domain (Mochly-
Rosen et a/., 1995). 
PKC-1..1 is structurally different from the others in this group in that the zinc finger 
like domains are separated by an unusually long stretch of 7 4 amino acids. The 
extension forms a putative transmembrane domain and a pleckstrin (platelet and 
leukocyte C- kinase substrate protein) homology domain (PH domain) (Fig. 1.5). 
This isoenzyme also does not have the typical pseudosubstrate region and has 
shown poor binding of phorbol esters. For these reason, PKC-1..1 is referred to by 
some researchers as a member of the aPKC subgroup. 
The C-terminal regions spanning from C3 to V5, have been established in all 
PKC isoenzymes as the catalytic domain. C3 contains a consensus ATP-binding 
sequence, similar to that seen in other kinases. The C4 region constitutes a 
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Table 1.3: Phosphorylation sites that render PKC isoforms 
catalytically competent 
lsoform In activation loop In (-terminus site I In C-terminus site 2 
hPKCu. GVTTRTFCGTPDYIAPE T497 RGQPVLTPPDQLVI T638 Q5DFEFGSYVNPQ 5657 
HPKC~l GVTTKTFCGTPDYIAPE TSOO RQPVELTPTDKLFI T642 QNEFAGFSYTNPE 5661 
HPKC~2 GVTTKTPCGTPDYIAPE TSOO RHPPVLTPPDQEVI T641 Q5EFEGFSFVN5E 5660 
hPKCy GTTTRTFCGTPDYIAPE T514 RAAPAVTPPDRLVL T655 QADFQGFTYVNPD T674 
hPKC& E5RASTFCGTPDYIAPE T507 NEKARL5Y5DKNLI 5645 QSAFAGFSFVNPK 5664 
hPKCt GVTTTTFCGTPDYIAPE T566 REEPVLTLVDEAIV T710 QEEFKGFSYFGED 5729 
hPKCt] GVTTATFCGTPDYIAPE T510 KEEPVLTPIDEGHL T650 QDEFRNFSYV5PE 5672 
hPKCO DAKTNTFCGTPDYIAPE T538 NEKPRL5PADRALI 5676 QNMFRNFSFMNPG 5695 
hPKCI; GDTT5TFCGTPNYIAPE T410 5EPVQLTPDDEDAI T552 Q5EFEGFl:YINPL E579 
hPKCA GDTT5TFCGTPNYIAPE T411 NEPVQLTPDDDDIV T563 Q5EFEGF:'YINPL E582 
hPKC~t KSFRR5VVGTPAYLAPE 5742 Absent Absent 
Adapted from Gomperts, 2002; P- 203 
Phosphorylation targets are indicated in red. The site 2 serines are 
substituted by a glutamate (E, yellow) in PKC-( and PKC-A. 
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1.4.2 Activation of PKC 
PKC is synthesized as an inactive catalytically incompetent protein residing 
primarily in the cytoplasm (Dutil and Newton, 2000). In order for the kinase to be 
functional, three phosphorylation processes have to take place sequentially 
followed by removal of the pseudosubstrate from the catalytic site. Phosphorylation 
of a threonine (Table 1.3) by a protein kinase (e.g. Phospholipid dependent kinase 
-1 [PDK-1]) in the activation loop within the catalytic domain leads to auto-
phosphorylation of the two C-terminus sites. The enzyme is now still inactive but 
catalytically competent because of the presence of the pseudosubstrate in the 
catalytic site. When only C1 or C2 ligand is present, the substrate-binding site is 
assumed to maintain contact with the pseudosubstrate region, keeping the enzyme 
catalytically competent but inactive. The calcium-binding site is thought to interact 
with phospholipid molecules like PS, increasing the affinity of the enzyme for the 
phospholipid. Subsequent binding of co-factors DAG, Ca2+ and phospholipids 
(Table 1.2) typically induces a conformational change to the catalytic domain 
allowing for the removal of the pseudosubstrate, and thus making the once-
occupied site now accessible to the real substrate. 
Studies using synthetic peptides have revealed a basic consensus 
phosphorylation motif of RXXS/TXRX, where X represents any amino acid, and the 
importance of basic residues (e.g., Arg [R]) N- and C-terminal to the 
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phosphoacceptor residue (Taker eta/., 1998). Although there are some subtle· 
differences between the three subgroups, all PKC isoforms preferring basic 
residues at positions -6, -4 and -2 to the Ser/Thr with cPKC also prefering basic 
amino acids at positions +2, +3 and +4. As discussed previously, the N-terminal 
extension of PKC-I.J (Fig. 1.5) is thought to be possibly responsible for its strikingly 
distinct optimal phosphorylation motif from all other PKC. This particular isoform 
has a strong selectivity for Leu at the -5 position (Nishikawa eta/., 1997). Taken 
together, despite the subtle difference, it appears that members of the PKC family 
tend to phosphorylate very similar substrates. This suggests that there must exist 
other mechanism(s) which can dictate which PKC isoforms participate in what 
signalling pathways. Several switch points can come into play here, and these can 
include different cofactors as discussed above, and cellular localization. It is now 
known that individual PKCs are brought to appropriate subcellular sites (e.g., 
plasma membrane, nuclear membrane) where their substrates are located by PKC 
binding proteins including receptors for activated C kinase (RACKs) (Schechtman 
and Mochly-Rosen, 2001) and proteins interacting with C kinase (PICKs) 
(Gomperts, 2002). The anchors, which have shown some selectivity/specificity 
among various PKC isotypes (e.g. RACK1 is specific for the beta-2 isoform while 
RACK2 is the PKC-e chaperone protein), also help appropriately position PKC to 
respond to specific receptor mediated activating signals. The activated PKC is then 
translocated to other subcellular locations where substrates of the activated PKC 
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are within the vicinity. 
1.4.3 Expression and functions of the Individual PKC isotypes 
The importance of PKC in pathophysiology and signalling mechanisms is not a 
novel concept. However, what it is less clear is the exact mechanisms used by 
these enzymes to exert their effects. Adding to the complexity of the picture is the 
fact that not only may the same PKC isoenzymes be expressed in different cells but 
that several PKC isoforms may be present within the same cell type. It is, therefore, 
difficult to fully understand what each of these PKC isoforms does at a particular 
moment in a given cell. The story becomes even more complicated when one has 
to reconcile the fact that a given PKC isoform may be activated by different PKC(s) 
in different cell types in response to different stimuli. For example, in epithelial 
cells, PKC-mu/PKD is activated by the upstream PKC-eta (Brandlin eta/., 2002), 
but in aortic smooth muscle cells PKC-mu needs PKC-delta for its activation (Tan 
eta/., 2002). 
Below is a brief review of their expression characteristics and some of their 
known functions. It should be kept in mind that the summary is by no means a 
complete list of functions for the various PKC isotypes. Whenever possible, the 
review will be focussed on regulation of individual PKC isoenzymes in Mo and M<l> 
functions. 
1.4.3.1 Conventional PKC 
1.4.3.1.1 PKC-alpha (PKC-a) 
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PKC-a appears to be a ubiquitous enzyme which can be found in most or all 
tissues. In human monocytic cell lines, this isoform is thought to be required for 
superoxide production by activated cells (Li eta/., 1999), and for the inhibition of 
Fe-y receptor mediated intracellular killing of Staphylococcus aureus by human Mo 
(Zheng et a/., 1995). In line with its role as a positive regulator of production of 
ROis, PKC-a is also believed to play a role upregulating transcription of pro-
inflammatory mediators such as IL-12, G-CSF, and NOS II (St-Denis eta/., 1998). 
1.4.3.1.2 PKC-beta (PKC-(3) 
This isoenzyme consists of two related forms, PKC-(31 and PKC-(32. They are 
a product of alternative mRNA splicing. Like PKC-a, PKC-(3 is typically expressed 
in most tissues. However, unlike the alpha isoform, PKC-(3 is responsible for the 
stimulation of the Fe-y receptor mediated killing of S. aureus (Zheng eta/., 1995). 
In addition, there is also evidence to support a role of both PKC-(3 and PKC-t5 in the 
differentiation of myeloid leukaemia cells into M<P (Kaneki eta/., 1999). 
1.4.3.1.3 PKC-gamma (PKC-y) 
Compared to the other members of the PKC family, PKC-y has the most 
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restricted tissue expression profile. The enzyme is only found in the CNS 
(Nishizuka, 1988). Although not expressed during early embryonic and fetal 
development of the nervous system, PKC-y is present in great abundance in adult 
CNS (Sposi eta/., 1989). Its preferential expression in the nervous system is 
thought to play a role in cellular mechanisms through which pathological brain 
activity impairs certain aspects of spatial memory (Beldhuis eta/., 1992). 
1.4.3.2 Novel PKC 
1.4.3.2.1 PKC-delta (PKC-~) 
Both delta and epsilon isoforms have a rather broad expression profile across 
the tissues. In addition to its role in monocyte differentiation, the delta and epsilon 
isoforms have been associated with the signalling pathways leading to apoptosis 
(Sawai et a/., 1997). Work with rottlerin, a PKC-~ specific inhibitor, by Kontny et 
a/. (2000) has shown that suppression of PKC-~ activity resulted in inhibition of 
DNA binding of such transcription factors as AP-1 and NF-KB leading subsequently 
to attenuation of IL-1 and TNF-a production by human monocytic cells previously 
exposed to LPS or PMA. 
1.4.3.2.2 PKC-theta (PKC-8) 
Unlike other members of the PKC superfamily, PKC-8 has a limited tissue 
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distribution. The kinase is predominantly expressed in hemapoietic cells (particular 
T cells) and, skeletal muscle. To a lower extent, this particular isoform may also be 
found in lung, skin, and brain (Osada eta/., 1 992). Sun and colleagues (2000) 
have recently shown that PKC-8 is rapidly recruited to the site of TCR clustering 
and that the kinase is required for TCR-induced NF-KB activation in mature T cells, 
but not in developing thymocytes. In a number ofT cell clones and in primary lymph 
node T cells from TCR transgenic mice, ten minutes is all that required to observe 
the translocation of PKC-8 to the plasma membrane following T cell recognition of 
the antigen. 
1.4.3.2.3 PKC-epsilon (PKC-e) 
The epsilon isoform is found in great abundance in brain and other (neuronal) 
tissues (Tokar, 1998). As with other isoforms in the novel PKC subfamily, PKC-e 
is responsive to both DAG and PS in vivo. There is also evidence for its activation 
by the phosphotidylinositol-3-kinase (PI-3K) lipids (Ptdlns-3,4,5-P3) in vitro (Tokar 
et a/., 1994), as well as mitogenic stimuli in vivo (Ohno et a/., 1994). When 
overexpressed in fibroblasts, PKC-e can function as an oncogene. Increased 
activity of the epsilon isoform has also been associated with characteristics of 
neoplastic transformation (e.g. increased growth in soft agar and tumor formation 
in nude mice) (Cacace eta/., 1993). In addition, this PKC isoform has been linked 
to the activation of a number of transcription factors, namely c-fos and c-jun, NF -AT, 
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AP-1, and NF-KB. 
1.4.3.2.4 PKC-eta (PKC-rl) 
In normal conditions, PKC-11 is thought to be most abundantly expressed in the 
skin and lung, but only slightly in the thymus and the brain (Bacher eta/., 1991 ). 
Both the alpha and eta isoforms are potent activators of Raf-1. Using transfection 
and antisense approaches in glioblastoma cell lines, Hussaini et a/. (2002) have 
demonstrated that PKC-11 can help confer cell resistance to UV-and gamma 
radiation-induced apoptosis by preventing activation of caspase-9. 
Confocal analyses of mammary epithelial cells MCF7 and HEK293b has 
revealed that PKC-11 co-localizes with PKC-mu/PKD in perinuclear compartments, 
and the former directly phosphorylates the latter (Brandlin eta/., 2002). The 
observation suggests that PKC-11 is crucial for PKC-1..1 dependent cellular 
processes. Interestingly, when eta and mu isoforms are co-expressed, PKC-1..1 
mediated effects are enhanced while, at the same time, those triggered by PKC-11 
will be reduced. Specifically, activation of PKC-1..1 by PKC-11 leads to an increase 
in the PKC-1..1 dependent p42/p45 MAPK cascade and a simultaneous decrease in 
the PKC-11 triggered JNK signalling pathway (Brandl in eta/., 2002). Findings such 
as these suggest a mutual regulation for these two members of the PKC family 
affecting different arms of the p38/ERKIJNK MAPK pathways. 
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1.4.3.3 Atypical PKC (aPKC) 
1.4.3.3.1 PKC-iota (PKC-1)/PKC-Iambda (PKC-A) 
PKC-1 has been shown to protect cells against drug-induced apoptosis. Par-4, 
a gene which is induced during apoptosis, specifically interacts with and potently 
inhibits the kinase activity of members of the aPKC subgroup. This suggests a role 
for PKC-1 and the other aPKC in the regulation of cell growth (Diaz-Meco eta/., 
1996). 
1.4.3.3.2 PKC-zeta (PKC-~) 
PKC-~ is another member of the PKC superfamily that is ubiquitously expressed 
in most tissues. In the past decade, evidence has been put forward to support a 
role for PKC-~ and its close relative, PKC-~ as crucial mediators of mitogenic signal 
transduction. The zeta isoform is thought to be required for maturation of Xenopus 
oocytes, and for synthesis of DNA in fibroblasts as a consequence of Ras activation 
(Berra eta/., 1993). A number of studies have shown that activation of the mitogen 
activated protein kinase (MAPK) pathway is downstream of the zeta isoform. For 
example, co-transfection experiments with PKC-~ and MAPK have revealed that the 
serine/threonine kinase stimulated the activation of both MAPK-kinase and MAPK 
(Berra eta/., 1995). However, it should be noted that the activation of MAPK is not 
restricted to PKC-~. but that other PKC family members, including conventional 
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PKC, are also capable of activating MAPK in vivo, demonstrating redundancy 
among the PKC isoenzymes. Furthermore, PKC-~ is also implicated as an 
important mediator of some of the physiological actions of insulin. Stimulation of 
adipocytes with insulin leads to activation of the kinase in a PI-3K dependent 
manner (Bandyopadhyay eta/., 1997; Mendez eta/., 1997). The process of insulin-
stimulated glucose uptake is mediated by GLUT 4, a major transporter, which acts 
downstream of PKC- ~ (Standaert eta/., 1997). Thus, the zeta isoform might 
regulate glucose homeostasis in part by mediating translocation of GLUT 4. There 
is also evidence for a requirement of PKC-~ for M<l> differentiation in insulin-like 
growth factor I stimulated cells. 
As for a role of PKC-~ in neoplastic transformation, the picture is less clear in 
that this PKC form appears to have both growth-promoting and growth-inhibitory 
properties (Toker, 1998). It is difficult to reconcile such idea for a molecule but 
recent evidence suggested a rationale for the observation. Kamper et a/. ( 1998) 
proposed the idea of a hierarchical signalling cascade, which involves 
consecutively the lambda, epsilon, and zeta isoforms in transcriptional activation 
of the c-fos promoter in cells expressing oncogenic Ha-ras (Kampfer eta/., 1998). 
Thus, depending on the expression profile of PKC in the cell of interest, PKC-~ may 
function as a growth promoter or growth inhibitor. 
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1.4.3.3.3 PKC-mu (PKC-f.J)/PKD 
PKC-tJ is the human analogue of PKD, and has been found to selectively 
associate with PKC-Il PKC-tJ is ubiquitously expressed, and its expression is 
abundant in the thymus and lung (Rennecke et a/., 1996). The mu isoform is 
potently and rapidly activated by a number of agonists including bradykinin, 
bryostatin and phorbol esters. These stimuli can also activate other members of the 
PKC family in vivo. Although direct phosphorylation of PKC-~ by the epsilon and 
eta isoforms has not been clearly established, Abedi eta/. (1998) demonstrated that 
activation of PKC-tJ in cells occurs via a PKC-dependent pathway, such that PKC-e 
and PKC-11 act upstream of PKC-tJ. Obviously, more work needs to be done before 
one can decipher exactly how this enzyme regulates in vivo, and whether there is 
also a hierarchical signalling cascade like that observed in PKC-~. As mentioned 
previously, PKC-tJ does not have a pseudosubstrate region per se, however, 
mutagenesis studies revealed that deletion or mutation of the PH domain (Fig. 1.5) 
results in constitutive activation of the enzyme (Iglesias and Rozengurt, 1998). 
However, it is still unclear as to what co-factors, lipids or proteins or both, bind to 
the PH domain in vivo to result in such activation. Lastly, there is also evidence for 
a role of PKC-tJ in B cell receptor signalling, and its activation following cross-
linking of the B cell receptor (Sidorenko eta/., 1996). 
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1.5 RATIONALE AND OBJECTIVES OF PRESENT INVESTIGATIONS 
Through its action on monocytic cells, bacterial LPS or endotoxin can trigger 
responses that can be both protective and injurious to the host. As discussed 
previously (Section 1.1.3), many PAMPs including LPS, peptidoglycan, lipoteichoic 
acid, lipopeptides, and CpG DNA are all able to activate Me!> to produce cytokines. 
Among these, however, only LPS has so far been shown to trigger NOS II 
expression in macrophages. Although the induction of NOS II by LPS has been 
fairly well studied and established in murine monocytic cells, much less work is 
done for the human cells. The main reason is due to the difficulty in inducing in 
vitro expression of NOS II in human monocytic cells using LPS. Over the years, 
several concepts have been put forward as possible explanations for the peculiar 
behaviour (Chapter 3) but the fundamental question remains: "what is it about 
human monocytic cells that is so different from their murine counterparts which 
causes such different response to LPS" ?. The herein thesis work was, therefore, 
aimed at trying to answer this question. Understanding of how human NOS II 
expression in Mo/Mc!> may be regulated would offer important insights, and perhaps 
potential therapeutic application for inflammatory diseases known to be associated 
with the over-expression of NOS II and/or over-production of NO, including 
rheumatoid arthritis (RA) and insulin-dependent diabetes mellitus (IDDM). To help 
answer the previously posed question, the following investigations were 
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sequentially conducted. First, we evaluated the ability of human and murine 
monocytic cells from various cell lines to respond to LPS or phorbol myristate 
acetate (PMA) (Chapter 3), and produce NO. The assessment was also to confirm 
the inability of the human cells to make NO following these stimulation. Second, in 
light of earlier evidence from our laboratory (Mouland, 1998) as well as that from 
others (Paul et a/., 1995; Sodhi and Kumar, 1994) demonstrating that PKC 
inhibitors could down-regulate LPS-induced NO production in murine monocytic 
cells, we performed for the first time a complete comparative analysis of PKC 
isotype expression in human and murine monocytic cells (Chapter 5). Third, the 
data obtained from such analysis subsequently enabled us to propose, and test a 
hypothesis that a missing member of the PKC family in human monocytic cells may 
be responsible for their inability to express NOS II and make NO following LPS 
stimulation. Fourth, the findings obtained from the third investigation in the cell 
lines allowed us to test the applicability of the in vitro data to in vivo situations. To 
this end, we have tested the hypothesis in monocyte-derived macrophages (MOM) 
and corresponding plasma samples of patients with rheumatic diseases including 
rheumatoid arthritis (RA) and spondyloarthropathies. In addition, as aside mini-
project but also highly relevant to the main objectives of this thesis, we were 
interested in investigating the effects of one natural and two synthetic derivatives 
of Trypterygium wilfordii Hookf (TwHf), a Chinese traditional medicine used in the 
treatment of a number of inflammatory diseases including RA, on the expression of 
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NOS II, as well as production of NO, TNF-a, and MMP in monocytic cells. 
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CHAPTER TWO 
MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 CHEMICALS 
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1 ) Most chemicals for preparation of buffers used in electrophoresis (DNA and 
protein) and Western blotting were obtained from Sigma Aldrich (Ontario, Canada). 
2) LPS (from E. Coli, 026:B6, Cat# L2654) was purchased from Sigma Aldrich. 
2.1.2 CELL CULTURE REAGENTS 
All cell culture materials were purchased from Invitrogen Life Technologies 
(Burlington, ON, Canada). Reagents for bacterial cell cultures were obtained from 
Invitrogen Life Technologies and Sigma. Cultures were routinely grown in 75-cm2 
flasks from Falcon (distributed by Becton, Dickinson, ON, Canada). Depending on 
the type of experiment being carried out, cells may have been plated on 6-well, 24-
well or 96-well microliter plates (Falcon). In experiments where RNA or proteins 
were to be extracted, the cells were plated on 35-mm or 60-mm petri dishes. 
2.1.2.1 Cell lines 
J774A.1, THP-1 and U937 were obtained from American Tissue Culture 
Collection (ATCC) (Rockville, MD, USA). Raw 264.7 (ATCC TIB 71) was a 
generous gift from Dr. Ratnam (Department of Public Health, Newfoundland, 
Canada) and Mono Mac 6 (MM6) was purchased from DSM (German Collection of 
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Microorganisms and Cell Cultures, Germany). 
J77 4A.1 (ATCC TIB 67) was adapted to culture from a tumor which arose in 
a female BALB/c mouse in 1968. This cell line was established from the ascites of 
a tumor induced in a male mouse by intraperitoneal injection of Abelson leukemia 
virus. Like J77 4A.1, the Raw 264.7 cell line was established from a tumor induced 
by Abelson murine leukemia virus in a male BALB/c mouse. The THP-1 cell line 
(ATCC TIB 202) was adapted from peripheral blood mononuclear cells (PBMC) 
isolated from a one-year old boy with acute monocytic leukemia. The MM6 cell line 
was prepared from monocytic cells of an adult with monocytic leukaemia. The U937 
cell line, derived from the pleural effusion of a patient with diffuse histiocytic 
lymphoma, consists of fairly mature monocytoid cells. These cells have many 
macrophage markers including complement receptor-3 (CR3), Fe receptor-1 (FcR1 ), 
non-specific esterase, lysozyme, and peroxidase (Zembala and Asherson, 1989). 
Murine macrophage-like cell lines Raw 264.7 and J77 4A.1 were maintained 
in RPMI-1640 medium supplemented with 10% foetal bovine serum (FBS),1 00 U/ml 
penicillin, 100 J,Jg/ml streptomycin, 2 mM glutamine, and 7.5% (w/v) NaHC03. 
Human monocytic cell lines MM6 and U937 were cultured in the above media plus 
9 J,Jg/ml bovine insulin (1-1882, Sigma), 1 mM sodium pyruvate, and 1 mM MEM 
amino acids. Medium for the THP-1 cells was the same as that for the other two 
human cell lines (MM6 and U937) except that it also had 2 x 1 o-e M P-
mercaptoethanol (2-ME). 
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Murine fibroblast cell line L929 was also obtained from ATCC (Cat#: CCL-1 }. 
L929 cells were propagated in RPMI-1640 (5% FBS, 2 mM L-glutamine, 100 U/mL 
penicillin and 100 J.Jg/mL streptomycin, 25 mM N-2-Hydroxyl piperazine-N-2-ethane 
sulphonic acid (HEPES). 
2.1.2.2 Cytoklnes 
Human recombinant IFN-y (IF002} was purchased from Chemicon 
(Temecula, CA, USA). Mouse recombinant IFN-y was kindly provided by Dr. 
Mookerjea (Memorial University, Newfoundland, Canada) and human recombinant 
TNF-a was a generous gift from Dr. Grant (Memorial University). 
2.1.3 MOLECULAR BIOLOGY REAGENTS 
2.1.3.1 For DNA and RNA purification 
All reagents for plasmid preparations including CONCERT high purity 
plasmid purification system (Cat# 11451-010) and TRizol were purchased from 
Invitrogen Life Technologies. Chloroform and other miscellaneous chemicals 
(molecular miology grade} were obtained from Sigma Aldrich. 
2.1.3.2 For cell transfection 
LipofectAMINE (0.747 mM} and Opti-MEM Reduced Serum Media were 
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purchased from Invitrogen Life Technologies. 
2.1.4 ANTIBODIES 
2.1.4.1 Primary antibodies 
1) Rabbit polyclonal (-~1, -~2, -y, -Z), -e, -11, -8, -1) and mouse monoclonal (-a) anti-
PKC antibodies were kindly provided by Dr. Nigel Groome (Oxford, UK). The 
concentrations used varied among the different antibodies, but they were typically 
in the range of 1:1000-1:5000. 
2) Rabbit polyclonal PKC antibodies specific to ~ and 1J isoforms were from Santa 
Cruz (Santa Cruz, CA, USA). 
3) Rabbit polyclonal anti-NOS II antibody (sc-651) and blocking peptides (sc-651 
P) to PKC-11 and NOS II were also purchased from Santa Cruz. The antibody was 
used at 1 :800 dilutions, while the peptide at five times higher concentration. 
4) Mouse monoclonallgG2a anti-human TLR4 antibody (0.51Jg/IJL, Cat# 14.9917) 
was purchased from eBioscience (San Diego, CA, USA), and used at 1 :50 dilution. 
5) Mouse APC-conjugated anti-human TLR-4 antibody was a generous gift from 
Chemicon, and used at 1:100 dilution. 
2.1.4.2 Secondary antibodies 
1 ) Sheep anti-rabbit and anti-mouse horse radish peroxidase-labelled antibodies 
were from Amersham International (Arlington Heights, IL, USA). The working 
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concentration was 1:3000. 
2.2 METHODS 
2.2.1 DESIGN OF HUMAN (AND MURINE) NOS II-SPECIFIC PRIMERS 
In both murine and human, the NOS II sequence is different from that of the 
NOS I and NOS Ill in that it only shares 73% and 77% homology, respectively 
(values obtained from gene alignment using BLAST 2). Also, human hepatocyte 
and murine monocytic NOS II sequences share 80% homology (Gellar eta/., 1993). 
Taken together, it was necessary to design a primer set that would only allow 
amplification of the NOS II gene in both human and murine monocytic cells. As the 
first step then, alignments of sequences retrieved from the National Institute of 
Health genetic sequence database, GenBank, were performed. Sequence 
alignments were done using the Basic Local Alignment Search Tool (BLAST)/ 
BLAST2, while primer design was done with the help of Primer 3 and Omega 
softwares. In this instance, the design fulfilled the six standard PCR primer criteria. 
First, primers must not be homologous to other portions of the DNA or to the primer 
partner, as this would result in primer-dimers formation. Second, the primer must 
not be self complementary thus eliminating the possibility of a stem loop structure 
formation. Third, the GC content must be at least 50-60%. Fourth, the primers 
should have similar melting temperatures, ideally within 5 °C of each other. Fifth, 
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each primer must have at least one G or C clamp at the end of the primer. Sixth, 
the primer length should not be less than 19 or more than 27 bases. 
The designed primers were custom made by Invitrogen Life Technologies. 
Working solutions of 10 IJM were prepared, and stored along with the stock 
solutions at -20°C until used. 
2.2.2 CELL CULTURE 
All cell cultures were done at 37 °C in a humidified atmosphere with 5% C02. 
Mono layers of J77 4A.1 and Raw 264.7 were washed twice with phosphate buffered 
saline (PBS), and the adherent cells were gently scraped off the surface using a 
sterile rubber policeman. Cell suspensions of THP-1, U937 and MM6 were also 
washed with PBS. Cell pellets collected after centrifugation were resuspended in 
medium appropriate for the cell line, and either used for the experiment or re-
seeded. Cells were passaged (1 :4 splitting) every three days. Only those with 
viability above 85%, as determined by Trypan Blue exclusion, were used in our 
studies. 
2.2.3 PREPARATION OF MONOCYTE-DERIVED MACROPHAGES (MOM) 
FROM PERIPHERAL BLOOD 
Fresh venous blood collected in ACD vacutainers (yellow top) was typically 
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processed within 2-3 h of collection. The sample was centrifuged for 1 0 min at room 
temperature (RT) at 400 x g (Sorvall RT6000: DuPont, New Hampshire, USA). 
Plasma was transferred to 1.5-ml centrifuge tubes and stored at -70 °C for 
measurements for NO. The cells were diluted 1:1 with PBS, and slowly layered on 
top of a Ficoii-Paque Plus (Pharmacia, AL, USA) in a 2:1 ratio, and care was taken 
to avoid mixing of the two solutions. The cells were centrifuged for 40 min at RT at 
400 x g. The upper top Ficoll layer was discarded, and the interphase containing 
PBMC, was transferred to a 50-ml centrifuge tube. The cells were washed with at 
least 30 ml PBS, and centrifuged for 10 min at 100 x gat RT. The supernatant was 
removed, the cells washed with 10 ml PBS supplemented with 1% FBS, and then 
again centrifuged at RT for 10 min at 250 x g. Any red blood cell (RBC) 
contamination was eliminated by incubating the cell pellet with 5 ml of 0.4 M NH4CI 
for 10 min at RT. PBS (1 0 ml) was added, and the cell suspension spun down for 
10 min at 400 x g. The cell pellet was then resuspended in 10 ml of RPMI-1640 
media (1 0% FBS, 2 mM glutamine, 1 mM sodium pyruvate, 1 mM MEM amino acids, 
100 U/ml penicillin, 100 IJg/mL streptomycin, 25 mM HE PES, and 3 x 1 o-s M 2-ME), 
counted, and cultured for 4 h. Non-adherent cells were subsequently washed twice 
with PBS. Adherent monocytes were allowed to differentiate into MOM in culture 
for 5 days prior to further experimentation. 
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2.2.4 CELL VIABILITY ASSESSMENT 
2.2.4.1 Trypan Blue Exclusion 
The Trypan Blue dye is actively excreted by viable cells, which thus will 
appear colourless when observed under the microscope. Dead cells will appear 
blue due to dye up-take. Cell counting was done using a Neubauer improved 
haemacytometer. Cell viability was determined by the ratio of the number of viable 
cells counted and the total number of cells (dead plus viable cells). 
2.2.4.2 MTT Assay 
This assay, also known as succinate dehydrogenase inhibition (SOl) test, 
was used to measure cell cytotoxicity after being exposed to a drug compound. The 
principle of the assay is based on the reduction of the (3-[4,5-dimethylthiazol-2yl)-
2,5-diphenyltetrazolium bromide tetrazolium) (MIT, Sigma) salt by the succinate-
tetrazolium reductase of the mitochodrial respiratory chain in metabolically active 
cells. Therefore, this bioassay detects only viable cells. MTT is cleaved to form a 
purple coloured water-insoluble formazan salt, which absorbs maximally at 540 nm 
(Bradshaw eta/., 1998). Fallowing the 24-h recovery period after drug exposure, the 
media was removed from the cells from each well, including blanks, and 100 J,JL of 
media containing 0.5 mg/ml MIT was added. The plate was then incubated at 37 
°C for 4 h. After which time, cell media was removed and the insoluble formazan salt 
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was dissolved in 100 J,JL of DMSO (Sigma) with gentle agitation for 20 min. The 
absorbance was then read at 490 nm on a microplate reader (Model 3550: BioRad, 
San Diego, CA, USA). 
2.2.5 TRANSFORMATION AND BACTERIAL CELL CULTURE 
20 J,JL DH5a E. Coli competent cells (kindly provided by Mr. Suresh 
Belkhode, Memorial University) was added to a chilled 0.6-ml microfuge tube 
followed by 0.3 J,JL of appropriate plasmid DNA. The control tube contained only 
DH5a cells. The samples were mixed gently and kept on ice for 30 min. After 
which time, .the tubes were transferred to a 42 °C water bath for exactly 2 min and 
then immediately transferred to ice for another 2 min. Luria LB broth (400 J,JL, [25 
g/L, Invitrogen Life Technologies]) was then added, and the tubes placed in a 
controlled environment incubator shaker (New Brunswick Scientific Co. Inc, New 
Jersey, USA) at 37 °C for 2 h. Subsequently, 10-100 J,JL of the LB broth was 
removed from the tubes and the cells streaked on a solid agar plate (previously 
equilibrated to 37 °C) containing 50 J,Jg/ml ampicillin (Novopharm, Toronto, 
Canada). Ampicillin was used because the desired plasmids (pBABE and 
pks1.PKC-rl) contained the ampicillin resistance gene AmpR. The plate was placed 
in a humidified 37 °C incubator (Fisher) for overnight. Colonies were developed 
after 14-16 h incubation. A single colony was removed, and placed in 3 ml LB 
broth containing 20 J,Jg/ml ampicillin. The cells were next cultured for 13 h. The 
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next day, 1.5 ml of this LB broth was used to prepare a DNA mini-preparation. 
2.2.6 PLASMID PURIFICATION 
2.2.6.1 Miniprep 
A miniprep was prepared as follows. The broth described above (1.5 ml) 
was transferred to an eppendorf tube and spun at 4 °C for 2 min in a microfuge 
(Eppendorf, Centrifuge 5415 C, Brinkmann, USA). The supernatant was removed 
and 100 IJL of freshly made suspension buffer (25 mM Tris, 50 mM glucose, 10 mM 
EDTA, pH 8.0) was added to the cell pellet. The sample was pipetted up and down 
several times to ensure complete dispersion of the cells. The tube was then placed 
on ice, to which 200 IJL of freshly made lysis solution (0.1 M NaOH, 1% sodium 
dodecyl sulphate [SDS]) was added. The sample was gently mixed and incubated 
on ice for 5 min. Next, 150 IJL of a neutralizing solution (3 M potassium acetate, 
11.5% [v/v] glacial acetic acid) was added, and the sample was incubated for 
another 7 min. It was next centrifuged at 10000 x g for 2 min in a microfuge. To the 
supernatant, 3 IJL of 10 mg/ml bovine pancreatic DNAse-free RNAse A (Sigma) 
was added, and the sample further incubated for 25 min at 37 °C. Subsequently, it 
was extracted with 1 ml phenol: chloroform: isoamyl alcohol (25:24: 1, Sigma), and 
then re-extracted with 1 ml chloroform: isoamyl alcohol (Sigma). The sample was 
spun at 1 0000 x g for 2 min and DNA, present mostly in the aqueous phase, was 
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precipitated with 2 volumes of absolute ethanol and one-tenth volume of 3 M 
potassium acetate (pH 8.0). The sample was centrifuged for 20 min at 4 °C, the 
supernatant decanted, and the pellet washed with 70% ethanol. The air-dried pellet 
was resuspended in water, and stored at -20 °C until used. 
2.2.6.2 Midiprep 
After identity of the plasmid DNA obtained from the mini prep was confirmed 
by digestions with restriction enzymes, 10 IJL of the original bacterial culture was 
added to a sterile conical flask containing 20 ml of LB broth supplemented with 20 
IJg/mL ampicillin. The cells were cultured for 10 to 13 h or when the cell density 
was approximately 109 cells/ml ( 1-1.5 Asoo units/ml). Plasmid DNA used in 
transfection studies was purified using CONCERT high purity plasmid purification 
system. All buffers used in the midi prep were provided with the purification system 
by the manufacturer. Centrifugation was done at 15,000 x g in a Beckman 
centrifuge (model J-21 ), unless otherwise stated. Overnight culture (15-20 ml) was 
centrifuged for 10 min (1 0,000 x g) at RT. Supernatant was removed carefully but 
as thoroughly as possible, and the cell pellet resuspended in the RNAse -containing 
cell suspension buffer (4 ml) until homogeneous. Subsequently, the cell lysis 
buffer (4 ml) was added, the tube inverted five times to mix, and the sample 
incubated for 5 min at RT. The lysis was stopped with neutralization buffer (4 ml), 
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and the mixture left undisturbed for 1 0 min at RT. The supernatant was loaded 
onto the provided purification column that had been previously equilibrated with 10 
ml of the equilibration buffer in the kit. The solution in the column was allowed to 
drain by gravity flow. The flow-through was discarded, and the column washed 
twice with 1 0 ml each of the wash buffer. The DNA was next eluted from the 
column with 5 ml of the elution buffer. The solution was again drained by gravity 
flow. Isopropanol (3.5 ml) was added to the eluate, the sample mixed and 
centrifuged for 30 min at 4 °C at 15,000 x g. The plasmid DNA pellet obtained was 
washed with 3 ml of 70% ethanol, and centrifuged for another 5 min at 4 °C. The 
ethanol wash was carefully and fully pi petted off, and the pellet air-dried for 10-15 
min. The DNA was dissolved in 200 IJL Tris-EDTA (TE) buffer (10 mM Tris, 1 mM 
EDTA, pH 8.0), and stored at -20 °C until used in transfection experiments. 
2.2. 7 TOTAL RNA EXTRACTION FROM MONOCYTIC CELLS 
Human and murine cells were plated at a density of 1 x 1 06 per 60-mm dish 
for overnight at 37 °C (5% C02), and then exposed to 1 IJg/mL LPS for 8 h. Cells 
were then spun down for 5 min at 400 x g (Sorvall RT6000) and total RNA isolated 
using Trizol. Briefly, Trizol (1 ml) was added to the cell pellet, and the cells were 
incubated for 5 min at RT. 200 IJL of chloroform (Sigma) was added and the sample 
shaken vigorously by hand for 15 sec. After a 3-min incubation, the sample was 
clarified by centrifugation for 15 min at 12,000 x g at 4 °C. The RNA was 
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subsequently precipitated with 0.5 ml of isopropanol for 10 min at RT, and then 
centrifuged for 10 min at 12,000 x gat 4 °C. The RNA pellet was next washed twice 
with 75% ethanol, and centrifuged again for 5 min at 7,500 x gat 4 °C after each 
wash. It was then air dried for 7-10 min, dissolved in TE and quantified spectre-
photometrically at 260 nm. Integrity and purity of RNA were assessed by both 
~601280 ratio and formaldehyde gel electrophoresis. RNA used in RT -PCR 
experiments generally had A 2601280 ratio of greater than 1.8. RNA samples were 
immediately used for reverse transcription reactions. Remaining RNA was stored 
at -70°C. 
2.2.8 RT -PCR 
1.5 - 2 I.Jg of total RNA was used to prepare eDNA in a 20 IJL reaction 
volume. Briefly, to the RNA sample 251Jg/ml Oligo (dT)12_18 and 0.5 mM dNTP (all 
reagents for reverse transcription reactions were from Invitrogen Life Technologies) 
were added. The mixture was heated for 5 min at 65 °C and chilled on ice for a few 
minutes. After a quick spin (15 sec), a mixture containing 1 x first strand buffer (50 
mM Tris-HCI, pH 8.3, 75 mM KCI, and 5 mM MgCI2), 10 mM dithiotreitol (OTT), and 
40 U RNaseOut Recombinant Ribonuclease Inhibitor was added to the sample, 
which was incubated for 2 min at 37 °C. 200 U of Moloney Murine Leukemia Virus 
Reverse Transcriptase was then added to the mixture, and the sample further 
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incubated for 50 min at 37 °C. The reaction was then heat inactivated for 15 min at 
70 °C. The resulting eDNA was used as a template for amplification by PCR. In 
some experiments, reverse transcription with 32P incorporation was done to ensure 
validity of the reverse transcription. 
For amplification of NOS II and housekeeping GAPDH genes, 2 IJL of the 
eDNA was resuspended in a PCR mixture containing 20 mM Tris-HCI, pH 8.4, 50 
mM KCI, 1.5 mM MgCI2, 200 IJM dNTP, 2.5 U Taq DNA Polymerase (Invitrogen Life 
Technologies), and 0.51-JM of gene-specific primers. The final PCR reaction volume 
was 50 IJL. 
The primers for PKC-11 were AACGAGGAGTTTTGCGCTAA (sense) and 
TGG TAAAATGTTTGAAGATCCG (antisense) (Oshevskie eta/., 1999). The NOS 
II primers were CGGTTCTACTCCATCAGCTC (sense) and TGCCAGAAACTG 
CGGAAGGG (antisense). The nucleotide sequence of GAPDH is identical in both 
human and mouse (National Center for Biotechnology Information). The GAPDH 
primers used were TCACCAGGGCTGCTTTTAAC (sense) and GGAGGC 
ATTGCTGATGATCT (antisense). For both NOS II and GAPDH, the eDNA was 
subject to 30 cycles of 1 min denaturation at 94 °C, 1 min annealing at 60 °C and 
30 sec elongation at 72 °C. Cycling parameters for PKC-11 were 1-min denaturation 
at 94 °C, 2 min annealing at 58 °C and 1 min elongation at 72 °C for 35 cycles. The 
first 5-min denaturation at 95 °C and the final 1O-m in extension at 72 °C were 
applied in all three cases. Amplification produced a 264-base pair (bp) fragment for 
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the NOS II gene, a 400-bp fragment for GAPDH, and a 259-bp product for PKC-I"J. 
A mock reaction, which contained all the PCR reagents but no template, was 
prepared in parallel to eliminate false positive amplification. Samples which had all 
reagents minus the reverse transcriptase served as another negative control. Nine 
IJL of PCR products was gently mixed with 2 IJL of 6 x loading buffer (0.25% 
bromophenol blue [BPB], 4% sucrose, 0.25% xylene glycol FF). The sample was 
then loaded on a 1.0-1.5% agarose gel containing 0.5 IJg/mL ethidium bromide 
(EtBr), and electrophoresed in a mini-sub cell GT electrophoresis cell (Bio-Rad) at 
constant voltage (1 00 V) for 35 min. DNA was visualized under a UV light. 
2.2.9 SOUTHERN BLOT HYBRIDIZATION 
The following procedure was performed at RT, unless stated otherwise. 
Following electrophoresis, the gel was incubated in denaturing buffer (0.5 M NaOH, 
1.5 M NaCI, pH 8.3) for 30 min, followed by two 45-min incubation periods in 
neutralizing buffer (1.5 M NaCI, 1 M Tris-HCI, pH 7.4). A gel sandwich was 
assembled, and DNA transferred by gravity capillary transfer to a nylon membrane 
(HyBond-N, Pharmacia) for overnight. The blot was then baked for 2 hat 80 °C, 
prehybridized for 1 h at 65 °C in a 6 ml solution containing 6 X sse (500 mM NaCI, 
50 mM sodium citrate, pH7.0), 1% SDS, 5 x Denhart's solution, and 100 IJg/mL 
denatured salmon sperm DNA, and probed for overnight at 65 °C with a 32P-Iabelled 
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recombinant NOS II fragment (106 cpm). The blot was then washed twice in 10 ml 
(each time) of 2 x SSC/0.1 %SOS at RT, followed by two additional washes of 0.1 
x SSC/0.05%SOS at 65 °C. The blot was then briefly dried, sealed with one layer 
of Saran wrap, and exposed by radiography for 24 h at -80 °C. 
2.2.10 PREPARATION OF CELL EXTRACTS 
2.2.1 0.1 For assessment of PKC protein expression 
Monolayers or cell suspension were washed twice with ice-cold PBS, 
scraped (with a rubber policeman for monolayers), and centrifuged for 5 min at 200 
x g (Sorvall RT6000). The cell pellet was resuspended in 100 IJL (per 4 x 1 06 cells) 
of a cold lysis buffer containing 20 mM Tris-HCI, pH 7.5, 2 mM ethylenediamine-
tetraacetic acid (EOTA), 0.5 mM ethylene glycol-bis-(fl-aminoethyl ether)-N, N, N', 
N'-tetraacetic acid (EGTA), 86 IJg/mL phenylmethyl-sulfonyl fluoride (PMSF) and 
10 IJg/ml aprotinin, and left on ice for 30 min with two 1 O-see vortexing periods. 
The extract was next passed repeatedly through a 26.5 G syringe, and left on ice 
for another 30 min with two 1 O-see vortexing periods. The homogenate was then 
clarified by centrifugation for 12 min at 11,000 x g (Eppendorf) and the supernatant 
collected. Protein levels were quantified using a protein assay kit (P 5656) 
purchased from Sigma. Samples were subsequently stored at -70 °C until used. 
76 
2.2.1 0.2 For assessment of NOS II protein expression 
After J77 4A.1 cells were treated either with LPS alone or LPS in the 
presence of TwHf compounds, 220 IJL of boiling lysis buffer (125 mM Tris, 5% 
glycerol, 4% SDS, pH 6.8) was added to each well of a 6-well plate. The cells were 
gently scraped with a disposable cell scraper. Viscosity was reduced by pi petting 
the sample through a pipette tip several times. The cell homogenate was 
transferred to a 1. 7 -ml Eppendorf tube, and boiled for 5 min. Subsequently the 
sample was clarified after 5 min centrifugation at 13, 000 x g at 4 °C in a microfuge. 
Protein levels were measured as described, and samples stored at -70 °C until used 
(no later than 2 days). 
2.2.11 WESTERN BLOTTING 
Celllysates (11 0 IJg) were mixed with an equal volume of Laemmli sample 
buffer (200 mM Tris -HCI, pH 6.8, 20% glycerol, 4% SDS, 1 mM OTT), boiled for 5 
min, and resolved on a 1 0% polyacrylamide gel by electrophoresis for 1 h at 
constant voltage (1 00 V) in SDS running buffer (25 mM Tris, 250 mM Glycine, 1% 
SDS). Molecular weight of samples was determined from the bench-mark protein 
ladder (Invitrogen Life Technologies). At completion, the gel was washed in cold 
Towbin transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol, pH 8.3) three 
times (5 min each time) to remove the SDS, and transferred to a nitrocellulose 
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membrane (Gelman Sciences, Ml, USA) for 5 h at RT (with cooling to reduce heat 
generation). Efficiency of the transfer was checked by subsequently staining the 
gel for 30 min at RT in 0.05% Coomassie Brilliant Blue (CBB) solution (1 0% acetic 
acid, 25% isopropanol). After blotting, the membrane was successively blocked 
with 5% non-fat dried milk in Tris-buffer saline (TBS; 20 mM Tris, 137 mM NaCI, pH 
7.6) overnight at 4 °C, probed with rabbit polyclonal (or mouse monoclonal) anti-
PKC or anti-NOS II antibodies for 4 h at RT, and re-incubated for 1 h at RT with 
appropriate (anti-rabbit or anti-mouse) horseradish peroxidase-conjugated 
secondary antibodies. Antibody solutions were prepared in low salt TTBS (TBS 
plus 0.2% Tween-20) containing 0.05% non-fat dried milk. The membrane was 
washed three times (15 min each wash) with high salt Tween-Tris buffer saline 
(TTBS; 20 mM Tris, 0.5 M NaCI, 0.2% Tween-20, pH 7.6) between the two antibody 
incubation periods. In some experiments, specificity of the primary antibody binding 
was assured by pre-incubating, as per protocol, the primary antibody with excessive 
amounts (5 times by weight) of an appropriate competing peptide overnight at 4 °C 
before use. 
The peroxidase activity was detected with Amersham's ECL detecting kit (Cat 
#: RPN 21 08) and Hyperfilm TM -ECL high performance chemiluminescence film from 
Amersham. Briefly, a developing solution prepared from addition of 800 IJL each 
of the provided reagents 1 and 2 was overlayered over the whole surface area of 
the blot, which was then left undisturbed for 1 min in the dark. Radiographs were 
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Figure 2.1: Reaction mechanism underlying nitrite determination by 
the Griess assay 
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Taken from Feelisch et al., 1996, p. 494 
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photographed, digitized, and analyzed by densitometry using a Chemi Imager ( 4000 
Imaging system: Alpha lnnotech Corp., San Leandro, CA, USA). 
2.2.12 DETERMINATION OF NITRIC OXIDE LEVELS 
2.2.12.1 Detection in cell culture media 
NO is an extremely active free radical with the half-life of about 10-15 sec. 
In the presence of molecular oxygen, the free radical is spontaneously converted 
to nitrite, a much more stable derivative, in a 1:1 ratio. In cell culture most, if not all, 
NO is present in the nitrite form. For this reason, we assessed NO production by 
indirectly measuring the levels of nitrite by the Griess assay (Fig. 2.1 ). Unless 
otherwise stated, all reagents were obtained from Sigma. In brief, 100 IJL of cell-
free supernatants was well mixed with 100 IJL of the Griess reagent (50 IJL of 1% 
(w/v) sulfanilamide in 5% H3P04 plus 50 IJL of 0.1% (w/v) N-(1-naphthyl) ethylene 
diamine in water), incubated in the dark for 15 min, and measured for optical density 
at 590 nm using a microplate reader (Bio-Rad) It should be noted that although not 
highly sensitive, the measurement of nitrites by the Griess method provides an 
adequate assessment of NOS II expression because the continuous production of 
NO by the enzyme, combined with the demonstrated stability of nitrites results in 
sufficiently high nitrite concentrations. 
For measurements of nitrite levels which were below the limits of detection 
of the Griess assay (2 IJM), nitrite measurements were done using a fluorometric 
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assay which is 50-100 times more sensitive than the Griess assay (Misko, 1993). 
The fluorometric method basically makes use of the fact that non-fluorescent 2,3-
diaminonaphthalene (2,3-DAN) reacts with nitrite in acidic conditions and generates 
a fluorescent product 1 (H)-napthotriazole in a 1:1 ratio. As a result, the 
fluorescence intensity directly correlates with the amounts of nitrite present. Briefly, 
10 t.JL offreshly prepared (0.05 mg/mL in 0.62 M HCI) was added to 100 t.JL of cell-
free supernatants, and mixed immediately. After 10 min-incubation in the dark at 
RT, the reaction was terminated with 5 t.JL of 2.8 N NaOH. The intensity of the 
fluorescence signal was determined using a double beam fluorescence 
spectrophotometer (Perkin-Elmer 512) with excitation at 365 nm and emission at 
450 nm. A series of solutions with known concentrations of purified sodium nitrite 
(Sigma) prepared in the same media was used to construct a standard curve, from 
which the unknowns were to be extrapolated. Samples which lacked either 
sulfanilamide or N-( 1-naphthyl)ethylenediamine of the Griess reagent were used as 
negative controls. 
2.2.12.2 Detection in biological fluids 
Unlike in cell culture where NO is mostly present in the nitrite form, nitrate is 
the more predominant derivative of NO in plasma. Therefore, in order to quantify 
NO levels in the circulation, it is necessary to convert nitrate to nitrite first, and then 
measure nitrite by the Griess assay, as described in Section 2.2.12.1. Briefly, 
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plasma samples (50 JJL) from patients or healthy individuals were diluted four fold 
with sterile distilled water. 90 U/L E. coli nitrate reductase and 44 JJM NADPH/FAD 
(Boehringer, Mannheim, USA) were added to the diluted plasma and the samples 
incubated for 24 h at RT. Excess NADPH in the samples was eliminated with a 
mixture containing 480 U/L of L-glutamic dehydrogenase, 4 mM a-ketoglutaric acid, 
and 84 mM (NH4hS04 (Sigma). The samples were further incubated for 20 min at 
RT, deproteinated with 15 g/L ZnS04, vortexed and clarified by centrifugation for 5 
min at 10,000 x g. Total levels of nitrite and nitrate were determined by the Griess 
assay, as described above (Section 2.2.12.1 ). 
2.2.13 ASSESSMENT OF TNF-a PRODUCTION BY L929 FIBROBLAST 
CYTOTOXICITY BIOASSAY 
This bioassay is based on the principle that fibroblast L929 cells are 
sensitive to TNF-a in the presence of actinomycin D (1 J.Jg/ml, [Merck Sharpe & 
Dohme International, Rahway, NJ, USA] ). Cells were normally seeded in a 75-cm2 
flask at 5 x 1 04/ml, and cultured for 3-4 days (with media changed, if necessary) 
until they reached confluency. Confluent cells were successively trypsinized with 
25 ml EDTA-Tris solution for 15 min at 37 °C, washed twice with PBS, and once 
with medium. The cells were next plated in a 96-well plate at a density of 3 x 
1 05/ml (75 JJL each well) for overnight. Equal confluency was ensured to allow for 
assay reproducibility. 75 J,JL (per well) of samples, containing cell-free supernatants 
82 
from test samples or dilutions of purified TNF -a, were added. The latter were used 
for enumeration of TN F-a levels in the unknowns. After the overnight incubation, 
the medium was removed and the cells were fixed in 5% paraformaldehyde 
(PFA)/PBS for 15 min at RT. The plate was washed gently under running tap water 
until PFA was completely removed. Subsequently, the cells were stained with 1% 
of aqueous crystal violet dye (prepared in distilled water) for 15 min at RT. Excess 
dye was removed with running tap water. The plate was left air-dried for 15 min at 
RT. 100 IJL of 33% of aqueous glacial acetic acid was added to each well, and 
optical density was read at 405 nm on microplate reader (Bio-Rad). 
2.2.14 ZYMOGRAPHY 
This technique was employed to investigate the induction of MMPs. 
Zymography involves the electrophoretic separation of proteins under denaturing 
(with SDS) but non-reducing (no OTT or 2-ME) conditions through a polyacrylamide 
gel containing gelatin, which serves as an in situ substrate for MMPs (Hawkes et 
a/., 2001 ). In brief, cell-free cultures were mixed with equal volume of 2 x sample 
buffer (125 mM Tris, 50% glycerol, 8% SDS, 2% BPB, pH 6.8), heated for 3-5 min 
at 55 °C, cooled for 2 min, and resolved on a 10% gelatin gel (Bio-Rad, Cat#: 161-
1185) by electrophoresis for 2 h (with cooling) at constant voltage (30 V) in SDS 
running buffer (247 mM Tris, 1.91 M glycine, pH 8.3). Purified trypsin was run along 
side as a positive control. Upon completion, the gel was treated as follows, on a 
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shaker at 37 °C, unless otherwise stated. The resolved proteins were renaturated 
twice for 15 min each time in 100 ml of 2.5% Triton X-1 00 (Sigma). Subsequently, 
the gel was incubated in 1 00 ml of a development buffer (50 mM Tris, 200 mM 
NaCI, 5 mM anhydrous CaCI2, 0.02%, Brij-35, pH 7.5) for overnight, and then 
stained in a solution containing 0.5% CBB, 10% acetic acid, and 40% methanol for 
1 hat RT. The gel was de-stained with 10% acetic acid until clear bands were 
observed (representing proteolytic activity of the studied MMPs) against a blue 
background of the undigested gelatin. Band density was quantified by densitometry 
using a Chemi Imager (Alpha lnnotech Corp.). 
2.2.15 DATA AND STATISTICAL ANALYSIS 
Data were analyzed by software Graph Pad Prism (San Diego, CA, USA) and 
the results were expressed as mean ± SEM, unless otherwise stated. Where 
appropriate, statistical analyses (unpaired two-tailed Student's t-tests) were carried 
out using the INSTAT software (San Diego, CA, USA). Probability values of less 
than 0.05 were considered statistically significant. 
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CHAPTER THREE 
INVESTIGATION OF NITRIC OXIDE PRODUCTION AND 
INDUCIBLE NITRIC OXIDE SYNTHASE EXPRESSION IN 
MONOCYTIC CELLS FOLLOWING CYTOKINE AND LPS 
STIMULATION 
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3.1 INTRODUCTION 
It has been shown that murine monocytic cells exposed to LPS expressed 
NOS II leading to the production of high amounts of NO (Dimmeler eta/., 1997; 
Chang eta/., 1992). For many years, similar experiments have been attempted in 
human monocytic cells, but the results have been essentially conflicting. However, 
most agree that LPS- treated human cells do not appear able to release NO in vitro 
at levels comparable to their murine counterparts (Weinberg, 1998; Zemabala et 
a/., 1994). When infected with microorganisms like Leishmania infantum (Panaro 
eta/., 1999) and Mycobacterium tuberculosis (Chang eta/., 1992), or exposed to 
HIV protein gp120 (Pietraforte et a/., 1994), or stimulated with tumor cells 
(Zemabala et a/., 1994), human monocytic cells were able to make NO at 
measurable levels, albeit at remarkably lower quantities than those observed in 
their murine counterparts. Human macrophages collected from the lungs of 
patients with tuberculosis have also been shown to express NOS II (Nicholson et 
a/., 1996). 
To this date, the underlying biochemical explanation for the difference is still 
not known. However, several theories have been proposed to explain the 
phenomenon. For instance, it was suggested by Tzeng and colleagues (1995) that 
deficiency of biopterin, one of the co-factors required by NOS II could result in a 
non-functional NOS II. It was also proposed that the failure of human monocytic 
cells to produce NO could be due to the absence of the NOS II enzyme, as 
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introducing the gene into cells, which do not express otherwise, resulted in 
expression of the NOS II mRNA/protein following LPS stimulation (Bertholet and 
Manuel, 2000). Yet, some believed that human monocytic cells do not synthesize 
NO simply because the evolution is such that NO may not be as important to the 
human immune system, as it is to that of less advanced species (Denis, 1994). 
However, it would be prudent to re-examine this line of thought as there is 
increasing evidence for a link between the over-expression of NOS II and 
pathogenesis of various chronic inflammatory conditions including RA, multiple 
sclerosis (MS), IDDM, and AIDS/HIV-associated dementia (Chapter 7 for 
references). A closer look at a role that NOS II and NO may play in inflammatory 
disease processes is found in Chapter 7. 
3.1.1 Rationale and aims 
The main objectives of the investigation presented in this chapter were to re-
assess the induction of NO by both human and murine monocytic cells in response 
to diverse stimuli including LPS, PMA, and inflammatory cytokines. This was to be 
done using several murine and human monocytic cell lines, as well as MOM 
generated from healthy human volunteers. 
Partial data reported in this chapter has been published in the journal Nitric 
oxide: Biology and Chemistry (Pham eta/., 2003a). 
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3.2 MATERIALS AND METHOD 
3.2.1 Materials 
Stock concentrations of LPS were prepared in PBS to a final concentration 
of 1 mg/mL, and stored at -20°C until used. PMA was dissolved in reagent grade 
absolute ethanol and dispensed in 20 I.Jg/mL aliquots, which were then evaporated 
to dryness. The PMA samples were stored desiccated at -20°C, and resuspended 
in PBS as needed. 
3.2.2 Cell stimulation with LPS and cytokines 
Cells were grown to sub-confluence. Murine Raw 264.7 and J77 4A.1 were 
plated at 1.5 x 105 cells per well in 96-well plates. After 3 h in culture, cells were 
spun down and fresh media containing appropriate concentrations of LPS was 
added to the cells. For stimulation experiments with the human cell lines (MM6, 
THP-1, and U937), trial studies were performed with different numbers of cells (1.5 
x 105 - 8 x 1 05 per well) and at different time points (24, 48, 96, 120, and 144 h). 
In the end, we found that after 48 h of stimulation, cell viability began to drop 
significantly, and that there was virtually no change in the cell number up to that 
point. Therefore, in subsequent studies, murine monocytic cells were treated with 
LPS for 24 hand human cells were exposed to the bacterial endotoxin for 48 h. 
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The human monocytic cells were plated at 8.0 x 105 cells/well in a 24-well petri dish 
and cultured for 3 h. LPS (or PMA) solutions were subsequently added, and the 
cells were treated for indicated length of time. Cell-free supernatant was then 
analyzed for nitrite, as described (Section 2.2.16.1 ). 
In certain experiments where synergistic effects of IFN-y and TNF-a on 
LPS-induced NO production by monocytic cells were investigated, the following 
protocol was adopted. Cells were treated with IFN-y (50 IJg/ml) and TNF-a (0.5 
pg/ml), individually or in combination, for 24 h, and then with LPS (0.25 IJg/mL) for 
another 24 h (murine) or 48 h (human). No such co-stimulation was done for PMA 
and the cytokines. Cell-free supernatants were then analyzed for nitrite, as above. 
A sample containing only medium, treated in parallel, was also measured for nitrite. 
This served as a baseline value which would be taken into consideration in data 
analysis. 
3.2.3 Analysis for display of NOS II protein and expression of mRNA following 
LPS stimulation 
Murine or human monocytic cell lines (4 x 106 cells/100-mm petri dish) were 
stimulated with 1 IJg/mL LPS for 13 h. Total cell extracts were prepared, as 
described (Section 2.2.1 0.2) and the samples were screened for NOS II protein by 
western blotting (Section 2.2.11 ). 
To evaluate the effect of LPS on transcription activity of NOS II in monocytic 
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cells, the following experiment was conducted. MM6 and J774A.1 cells (106 per 
dish) were treated with 1 I..Jg/ml LPS for 8 h. Total RNA were extracted (Section 
2.2. 7), and subjected to RT -PCR analysis (Section 2.2.8) with NOS 11-specific 
primers. Specificity of positive signals on the agarose gel was confirmed by 
Southern hybridization (Section 2.2.9) using a 32P-Iabelled recombinant NOS II 
fragment. 
3.3 RESULTS 
3.3.1 NO production following LPS, cytokine and PMA activation 
Monocytic cells from murine Raw 264.7 and J774A.1 and human U937, 
MM6, and THP-1 cell lines were stimulated with increasing concentrations of LPS 
(10 ng/ml-10 I..Jg/ml) for 24 h (murine) and 48 h (human). Cell-free supernatants 
were subsequently analyzed for nitrite. To obtain a more accurate measurement 
of low NO levels (less than 2 IJM), we chose the fluorometric DAN assay, which is 
50-100 times more sensitive than the popular colorimetric Griess assay. 
Precautions were made to ensure that there were no significant inherent variations 
between the two assays. It was clear from the data (Fig 3.1) that there was a 
marked dose dependent increase in NO production (p < 0.001) by LPS-stimulated 
monocytic cells from the two murine cell lines Raw 264.7 and J7 44A.1. In contrast, 
cells from the three human cell lines tested MM6, U937, and THP-1 failed to 
Figure 3.1: LPS-induced nitric oxide production in human and murine 
monocytic cells 
Murine Raw 264.7 and J774A.1 (1.5 x 1 as per well) or human THP-1, MM6, and 
U937 (8 x 1 as per well) monocytic cells were stimulated with various concentrations 
of LPS for 24 h (murine) or 48 h (human). Cell-free supernatant was measured for 
nitrite colorimetrically by the Griess assay or fluorometrically with 2,3-DAN, as 
detailed in Chapter 2 (Section 2.2.12.1 ). Sodium nitrite was used as a standard to 
construct a standard curve from which the unknowns were extrapolated. Results 
are expressed as mean(± SO, n=3, quadruplicate experiments) NO induction by 
1a6 cells in 24 h after subtraction of blank (sample contained only media). 
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produce any detectable amounts of NO. Different experimental conditions including 
higher cell number and longer incubation periods were also tested in an effort to 
induce a response in these human cells. Still, the results remained unchanged. 
When murine J77 4A.1 monocytic cells were primed with a cocktail of IFN-y and 
TNF-a for 24 h prior to LPS stimulation, the response was further enhanced 
(p<0.001 ), as shown by augmentation of two-fold in NO production relative to that 
of LPS alone (Fig. 3.2). Co-stimulation of either IFN-y or TN F-a with LPS did not 
lead to any upregulation in nitrite levels suggesting that the two cytokines 
complement each other in delivering a "signalling boost". In contrast, human 
monocytic cells from the MM6 cell line remained essentially unresponsive 
regardless of the type of treatment. 
Murine cells J77 4A.1 stimulated with PMA showed a notable increase in NO 
released by the murine cells into the cell culture, albeit the response was 
significantly weaker than that induced by LPS (Fig. 3.3). Similar investigation with 
human cells MM6 yielded no induction of NO following their activation with PMA. 
3.3.2 Effects of LPS on the induction of NOS II protein in human and 
murine monocytic cells 
Our data reported here, as well as those of others, have provided 
strong and consistent evidence for the lack of LPS and/or cytokine-mediated 
Figure 3.2: LPS and cytokine co-stimulation further enhances NO 
production by murine monocytic cells. 
Murine J774A.1 (1.5 x 105 per well) and human MM6 (8 x 105 per well) cells were 
primed with IFN-y (50 J.Jg/ml) and TN F-a (0.5 pg/ml), individually or in combination 
for 24 h. The cells were next exposed to 0.25 J.Jg/ml LPS for 24 h. Cell-free 
supernatants were measured for nitrite, as described (Section 2.2.12.1 ). The results 
were expressed as the mean value (of NO produced by 106 cells in 24 h) ± SO of 
three quadruplet experiments. Statistical significance of the data was evaluated by 
unpaired Student's t-tests. 
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Figure 3.3: Effects of PMA on NO production by murine monocytic 
cells 
Murine J77 4A.1 cells (1.5 x 105 per well) was plated in each well of a 96-well plate, 
and cultured for 7 h. After which time, old media was removed and fresh one 
containing appropriate doses of PMA. The cells were incubated for another 24 h, 
and cell-free supernatants were harvested for nitrite measurements, as described. 
The results were expressed as mean (of NO produced by 106 cells in 24 h)± SO of 
two quadruplicate experiments, after the background (if any, released by untreated 
cells) had been subtracted. 
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NO synthesis in human monocytic cells, at least at the levels to be accurately 
measured in culture, when compared to their murine counterparts (Weinberg eta/., 
1995; Zemabala et a/.,1994; St-Denis eta/., 1998). This raises an interesting 
question as to whether the differences in NO-generating potential might be 
attributed to either the absence of the NOS II enzyme itself or insufficient, or lack 
thereof of, de novo quantities of the co-factors. In an attempt to answer the 
question, we investigated the induction of NOS II by monocytes in response to LPS 
using western immunoblotting. As evident in Figure 3.4 A, there was evident 
induction of NOS II (arrow, 130 kDa) in both LPS-stimulated Raw 264.7 and 
J77 4A.1 cells, but not in any of three human cell lines tested. Binding specificity 
of the antibody was later confirmed by preincubation with a NOS II blocking peptide 
(a 20-amino acid fragment mapped to the N-terminus of the protein), which was 
originally used to raise the antibody in the rabbit (Fig. 3.4 B). As shown, incubation 
of the antibody with the NOS II peptide prior to testing of the samples resulted in a 
complete block of the specific band. It should be noted that the presence of the 
upper band of approximately 178 kDa in the samples is most likely to be due to non-
specific binding, as it was not blocked by the competing peptide. Taken together, 
we conclude that LPS indeed mediates the induction of the functional NOS II 
protein in murine, but not in human monocytic cells. 
Figure 3.4: Investigation of NOS II Induction by endotoxin In human 
and murine monocytic cells 
Murine (J774A.1 and Raw 264.7) and human (THP-1, U937, and MM6) monocytic 
cells (2 x 106 cells per 35 mm dish) were stimulated (T) with1 IJg/mL LPS for 13 
h, and extracted, as described (Section 2.2.1 0.2). 110 IJg of the total cell lysate 
was tested for NOS II by western blotting (Section 2.2.11) using a rabbit polyclonal 
anti-NOS II antibody, which recognized the same epitope in human and murine. 
(A), For each cell line, a sample of untreated (UT) cells was prepared in parallel 
and analyzed under the same conditions as the LPS-treated sample. (B), To 
confirm binding specificity, murine LPS-treated cells were probed with the anti-NOS 
II antibody, which had been pre-incubated overnight with excess blocking peptide. 
The positive signal showed the expected size of NOS II (130 kDa), which is not 
present after pretreatment of the antibody with the blocking peptide. 
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3.3.3 Effect of LPS on NOS II transcription in human monocytic cells 
Our findings from Western Blotting have shown convincingly that stimulating 
human monocytic cells with LPS does not give rise to expression of the NOS II 
gene at the protein level. Since NOS II expression is mainly regulated at the 
transcriptional level, we assessed whether LPS could signal gene transcription by 
RT-PCR. For this experiment, LPS stimulation of monocytic cells was carried out 
for 8 h for maximal detection of NOS II mRNA (Reiling eta/., 1994). As depicted in 
Figure 3.5, no mRNA was evident for the two human cell samples stimulated with 
LPS (MOM and MM6) either before or after LPS stimulation. This is in sharp 
contrast with what was seen in murine J774A.1 where transcription of NOS II was 
clearly detected. Validity of the RT -PCR results was later confirmed by Southern 
hybridization of the PCR products to a 32P-Iabelled NOS II recombinant fragment 
(Fig. 3.5 B). 
3.4 SUMMARY AND DISCUSSION 
In this chapter, we examined the ability of human and murine monocytic cells 
from a series of cell lines as well as MOM (from a healthy volunteer) to produce NO 
in response to the monocyte-activating agent of choice LPS. We have shown that 
unlike human monocytic cells, their murine counterparts were able to produce high 
amounts of NO in response to LPS (Fig. 3.1 ). While priming the murine cells with 
Figure 3.5: Effects of LPS on the Induction of NOS II mRNA In 
human monocytic cells 
Human (MM6) and murine (J774A.1) monocytic cells (106 cells per dish) were 
treated (T) with 1 j.Jg/mL LPS for 8 h. After which time, total RNA was isolated, 
reverse-transcribed and amplified by PCR using NOS 11-specific primers. A sample 
from untreated (UT) cells was also prepared in parallel and analyzed in the same 
way as the test sample. A mock (M) contained only water in place of eDNA and a 
sample contained synthetic NOS II (PS) were used as a negative and a positive 
control, respectively. (A), Nine IJL of PCR products was resolved on a 1.5% 
agarose gel, which was then digitally photographed and scanned. (B), Detection 
specificity was confirmed by Southern hybridization of the PCR products from (A) 
with a recombinant NOS II fragment, as described (Section 2.2.9). 
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a cocktail of pro-inflammatory cytokines (IFN-y and TN F-a) prior to LPS stimulation 
further augmented nitric oxide synthesis by nearly two-fold, the same treatment did 
not give rise to any detectable NO that could be measured accurately in cell 
cultures of human monocytic cells (Fig. 3.2). In the case of murine, further 
upregulation of NO suggests that these cytokines and LPS act on distinct but 
related signalling pathways to synergistically induce the transcription of the NOS 
II gene (Mautino eta/., 1994). In addition, the data from Figure 3.2 also showed 
that the co-stimulation of the murine cells with LPS and individual cytokines did not 
effect any noticeable changes in the levels of NO produced. 
The findings from our western blotting have shown that human monocytic 
cells treated with LPS did not result in the induction of NOS II protein, suggesting 
that the inability of these human cells to make NO may be associated with the lack 
of protein expression. It is not likely that the observations were due to the fact that 
the NOS II antibody used in our studies did not recognize the human antigen on the 
basis that the peptide against which the purchased antibody was raised was 
derived from the highly conserved region shared by both human and murine cells. 
Thus, our data at this point do not appear to support a hypothesis that the failure 
of human monocytic cells to release NO following activation by endotoxin and 
cytokines was due to non-functionality of the NOS II enzymes brought about by the 
lack or insufficient quantities of the cofactors (e.g. BH4, NADPH, to name a couple), 
as suggested previously (Berthelet eta/., 1999). At the same time, however, we 
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could not exclude the possibility that the level of NOS II expression in these cells 
was too weak to be detected by immunoblotting. Thus, we proceeded with 
examining the presence of mRNA in LPS-activated cells by RT -PCR. At this end, 
such analyses have shown no evidence of mRNA for NOS II in human monocytic 
cells stimulated with LPS. In short, our findings as obtained from western blotting 
and RT -PCR have demonstrated unequivocally that LPS did not trigger transcription 
of the human NOS II gene supporting the notion that the failure of human monocytic 
cells to synthesize NO appears to be attributed to gene expression and not its 
functionality, as suggested previously. In fact, our findings reported up to this point 
are consistent with studies which showed that once transfected with the NOS II 
gene, human U937 cells acquire the potential to produce NO in response to LPS, 
and thereby exhibit leishmanicidal activity (Van eta/., 1997; Berthelet and Manuel, 
2000). 
As previously discussed in Chapter 1 (Section 1.2.2.2.2), NOS II expression 
is primarily regulated at the transcriptional level. Our data presented here appears 
to point towards the direction that there may be some blockage in the signal 
transduction pathway leading to NOS II induction, and the defect is likely to occur 
before the transcription. For example, transcription factors involved in the signalling 
pathway leading to NOS II induction may not be expressed or if they are, may not 
be functional. There exists also a possibility that the absence of the NOS II gene 
following activation by LPS could be a result of inherent unresponsiveness of the 
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cells to the stimulus. This phenomenon could be brought about by a lack of 
receptor(s) such as CD14 or TLR-4, which are thought to be required for LPS 
recognition by monocytic cells or due to the lack of key signalling elements in the 
pathway leading to NOS II induction. 
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CHAPTER FOUR 
LPS RECEPTOR EXPRESSION AND LPS-TRIGGERED 
SIGNALLING PATHWAY IN MONOCYTIC CELLS 
102 
4.1 INTRODUCTION 
4.1.1 The role of CD14 and LBP in LPS binding 
The cellular signalling events leading to inflammatory responses in 
monocytic cells activated by LPS have been well studied. Although the complete 
pathway is yet-to-be fully elucidated, major signalling events have been 
established. 
As previously discussed (Section 1.4), LPS is the main ingredient of the 
outer component of the Gram-negative bacterial cell walls. It is widely accepted 
that in order for LPS to signal through CD14, the lipid A portion of LPS has to first 
bind to a 60-kDa serum factor known as LBP. The complex is needed for optimal 
binding of LPS to the membrane-bound CD14 (Hailman eta/., 1994). It is thought 
that the LBP and lipid A interaction enhances the biological activity of LPS by 100-
to 1 000-fold. Alternatively, soluble CD14, formed by surface shedding, may also 
facilitate stabilization of the LPS-LBP interaction. The importance of LBP in LPS 
recognition has been again demonstrated in a recent study by Fierer et a/. (2002) 
where they showed that LBP-knockout mice were more susceptible to Salmonella 
peritonitis than wild type animals. In this model, these investigators illustrated that 
the absence of LBP would lead to a defect in chemotaxis of polymorphonuclear 
phagocytes. The binding of LPS to CD14 on the cell surface is followed by a 
subsequent cascade of intracellular events leading to phosphorylation and 
activation of many key signals giving rise to production of inflammatory mediators 
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including cytokines, RNI, and lipid-derived products (Chow eta/., 1995). Over the 
years, the importance of CD14 in cell responsiveness to LPS has been 
demonstrated in several studies, including that employing site-directed mutagenesis 
(Stelter eta/., 1997), anti-CD14 antibodies (von Asmuth eta/., 1993; Wright eta/., 
1990), and soluble CD14 (Schutt eta/., 1992). 
4.1.2 The role of TLR-4 In LPS signalling 
The fact that CD14 is a glycosylphosphatidyl inositol anchored membrane 
glycoprotein with no cytoplasmic domain confused scientists for years with respect 
to the mechanism by which the glycoprotein transduces the signal across the 
membrane into the cell. As a result, there came forth a hypothesis that there must 
be other receptor(s) or adapter(s) which could actually transmit the signal. This 
theory was strengthened by studies which had shown that anti-CD14 antibodies 
weakened, but did not completely abrogate, LPS signalling, suggesting the 
existence of other molecules (Blondin eta/., 1997; Triantafilou eta/., 2000). In 
addition, it has been observed that C57BU1 OScCr and C3H/HeJ mouse strains, 
which carry a null allele and a missense mutation at residue 712 (Proline replaced 
by Histidine) of the Lps gene, respectively, do not respond to LPS. After much 
anticipated work, the Lps gene identified by positional cloning was the murine TLR-
4, which belongs to the family of PAMPs (Poltorak eta/., 1998; Hoshino eta/., 
1999). Incidentally, the missense P712H mutation was found to be located in the 
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Figure 4.1: Proposed LPS-triggered signalling pathway in monocytic 
cells mediated by CD14 and TLR-4 
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signalling domain of the TLR. TLR4 is the most well characterized isoform of the 
mammalian homologues of the Drosophila Toll receptor first identified as a multi-
functional molecule with antifungal properties (Lemaitre eta/., 1996). TLR4 is a 
single-spanning transmembrane protein with a leucine rich ectodomain and a 
cystoplasmic domain with a Toii/IL-1 like sequence. The importance of TLR4 in 
LPS signalling has been demonstrated in gene-specific mutations and knock out 
mice (Triantafilou and Triantafilou, 2002; Hoshino et a/., 1999). Specifically, 
animals that lacked TLR-4 exhibited hyporesponsiveness to LPS and their 
monocytic cells were not capable of producing inflammatory cytokines, such as 
TNF-a and IL-1 following LPS activation (Hoshino eta/., 1999). 
4.1.3 LPS-triggered signalling in monocytic cells 
By analogy to the immunological synapse, LPS-induced activation of 
mononuclear phagocytes has been proposed to likely consist of two micro-domains 
or zones of activation: a periphery and a core region (Triantafilou and Triantafilou, 
2002). In this scenario, LPS binds to CD14 via LBP triggering recruitment of other 
signalling molecules including heat shock proteins (hsp) 70 and 90, CXCR4 and 
GDFS (growth differentiation factor 5), and CDSS to the site of LPS/LBP-CD14 
ligation. LPS released from CD14 in the lipid bilayer initiates clustering of other 
signal transducing molecules including the TLR4-MD2 complex interacts with MD2, 
CD11 and CD18. MD-2 is a secreted protein but found to be associated at the cell 
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surface with TLR-4 (MD-2 physically interacts with TLR-4 in a similar manner to 
MD-1 binding to RP-1 05, a 8-cell specific receptor; Miyake eta/., 1995). The model 
proposed by Triantafilou and Triantafilou (2002), CD14 having released LPS may 
stay in the periphery while other signalling molecules cluster in the core region (Fig. 
4.1 ). The involvement of the receptor cluster in the recognition of LPS explains the 
multiple signalling cascades triggered by the microbial product. In addition to the 
extracellular molecules discussed here, the LPS signalling pathway also requires 
a number of intracellular signalling factors including MyD88, IL-1 receptor 
associated kinases (IRAK), and TN F-a receptor-associated factor 6 (TRAF-6), to 
name a few. 
LPS has been shown to activate multiple signalling pathways leading to 
alterations in cell functions. For example, the phospholipase C (PLC)/Calcium/PKC 
axis is perhaps the most widely studied signal transduction mechanism. The 
pathway is crucial for the break down of phospholipids by PLC, mobilization of 
intracellular Ca2+ stores, activation of Ca2+ channels and PKC. In addition, LPS 
signalling leads to activation of NF-KB, and mitogen activated protein kinase 
(MAPK) families, including p38 MAPK, extracellular signal regulated kinase 1 and 
2 (ERK1/2), and c-Jun-terminal kinase/stress-activated protein kinases (JNKISAPK) 
(Rao, 2001 ). NF-KB is a very important transcription factor involved in the 
regulation of many different genes including those coding for pro-inflammatory 
mediators. The activation of NF-KB first requires phosphorylation and activation of 
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IKB kinases, namely IKK-a and IKK3 (May and Ghosh, 1999) by upstream kinases 
(e.g., NF-KB inducing kinase [NIK] and mitogen-activated protein kinase ERK 
kinase kinase 1 [MEKK-1]). The activated IKK then phosphorylates its substrate, 
the inhibitory kappa B (IKB) leading to dissociation of IKB from NF-KB, and 
activation of the latter. Activation of all three MAPK pathways in monocytes by LPS 
is thought to be mediated by the src tyrosine kinase family including p53/561vn and 
p58/p64c-tgr (Sweet and Humme, 1996; Shapira eta/., 1994). With regards to the 
ERK1/2 pathway, it is thought that in monocytic cells, binding of LPS to its receptor 
complex at the cell surface leads to rapid phosphorylation and then activation of 
tyrosine kinases (see above). These activated kinases subsequently mediate 
activation of the MEK-ERK1/2 pathway in a Raf-1-dependent manner (Reimann et 
a/., 1994 ). This pathway is required for the production of several inflammatory 
mediators including IL-1, IL-8,TNF-a, and prostaglandin E2 (PGE2). The JNKand 
p38 pathways are also activated in LPS-activated monocytes and are crucial to the 
production of several inflammatory mediators including cytokines. Although there 
may be some degree of functional redundancy between these pathways in terms 
of the genes they help induce, the different and shared signalling events may 
contribute to their synergistic effects in regulating cell functions. 
In addition to activating PLC, LPS is also involved in the activation of other 
lipases including the phospholipase A family and phospholipase D (Chow eta/., 
1995). This group of enzymes is important to the production of lipid-derived second 
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messengers, such as arachidonic acid. 
4.1.4 Inflammatory mediators produced by monocytic cells in response 
to LPS 
As mentioned earlier, several transcription factors including NF-KB, c-Jun, 
STAT, and interferon-responsive factor 1 (IRF-1) are activated by LPS in monocytic 
cells (Nau et a/., 2002). These, in turn, are essential to the activation of various 
genes involved in the defence against microbial pathogens as well as those 
involved in initiation of adaptive immune response. Some of the inflammatory 
cytokines known to be activated by LPS are: TN F-a, IL-1 J3, and IL-6. In addition, 
the microbial product has also been shown to induce the expression of MMP and 
of NOS II in monocytic cells. The latter, of course, leads to the production of NO 
(Chapter 3). 
MMPs (matrixins) form a family of highly homozygous zinc proteinases 
( endopeptidases) divided into four subgroups according to their substrate specificity 
and structural homology, and degrade at least one component of the extracellular 
matrix (Bode and Maskos, 2001 ). Thus, the enzymes allow leukocytes to 
extravasate across the endothelium into the tissue stroma. In physiological 
conditions, integrity of the underlying matrix is preserved by the presence of 
specific tissue inhibitors of metalloproteases (TIMP) (Brew eta/., 2000). However, 
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the balance of MMPs and TIMPs is shifted in certain infections and disease 
processes such that MMP production is greater while that of TIMP is decreased. 
A consequence of this, of course, would be structural damage to the underlying 
tissue. 
4.1.5 Rationale and aims 
The findings described in Chapter 3 indicate that human monocytic cells, 
both from cell lines and primary cultures, failed to release NO following exposure 
to LPS. The data also revealed that this is due to the absence of NOS II gene 
activity on both protein and mRNA levels in the LPS-stimulated cells. In light of the 
above, it was of interest to determine if the unexpected observation could be 
attributed to inherent hyporesponsiveness of these human cell lines to LPS. To test 
this hypothesis, we investigated the expression of TLR4 on MM6 cells, which had 
not been previously examined. We also wanted to assess the ability of the cells to 
produce TNF-a, MMP-2, and MMP-9 following LPS treatment to assess whether 
these cells were responsive to LPS in a known TLR4 signalling-like manner. 
4.2 METHODS 
4.2.1 Cell stimulation with LPS for evaluation of TN F-a 
Human MM6 cells were seeded in a 24-well plate at 0.6 x 106 cells per well. 
After cultured for 3 h, the cells were treated with varying concentrations of LPS for 
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24 h. Cell-free supernatants were evaluated for TNF-a levels by the cytotoxicity 
bioassay with L929 (Section 2.2.13). 
4.2.2 Cell treatment for zymography analysis 
MM6 cells were washed three times with serum-free (SF) medium (same 
medium as that used for MM6 and U937 but without FBS, Section 2.1.2.1 ), plated 
in a 24-well plate at density 106 cells/mL/well, and cultured for 1 h. In a 1.5-mL 
centrifuge tube, 50 J.JL of 10 J.Jg/mL LPS was mixed with 50 J.JL FBS, and incubated 
for 30 min at RT to allow for the formation of LPS and serum LPS-binding protein 
(LBP) complex (Section 4.1.1 ). The mixture was subsequently serially diluted with 
the SF medium such that the final LPS concentration in the well was 1 00 ng/mL. 
The cells were stimulated for 24 h, and cell-free cultures were assessed for MMP 
activity by zymography (Section 2.2.14). A sample containing unstimulated cells 
treated in the same way served as a negative control. 
MMP activity was semi-quantified by a Chemi Imager (Alpha lnnotech Corp.). 
Densitometry reading, if any, obtained from a sample containing only medium was 
used as a background. Values for test samples were recorded after the background 
had been subtracted. 
4.2.3 Immunofluorescence staining 
MM6 cells were harvested, washed once with PBS, and resuspended at 106 
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cells/mL. The following procedure was done on ice. In a 1.5-ml centrifuge tube, 
100 IJL of the cell suspension was incubated with 100 IJL of 10% of human AB 
serum (Rh negative) to block Fe receptors. After 1 h, the cells were washed twice 
with 0. 7 ml of a wash/staining buffer (PBS containing 0.05% sodium azide and 1% 
FBS) for 5 min at 250 x gat RT. The cells were subsequently labelled with 100 IJL 
of mouse APC-conjugated anti-TLR-4 antibody (or an isotype control antibody for 
a control sample) for 1 h in the dark. The cells were next washed twice (5 min each 
time) with 1.5 ml wash buffer and spun down for 10 min at 250 x g at RT. 
Subsequently, they were fixed in 0.5% PFA /PBS for 30 min. After removal of the 
fixative, the cells were resuspended in 50 1J L of the media and mounted on 1 0% 
glycerol/PBS. The slide was covered with a size 22 cover-slip. The cells were 
examined under an Olympus BXSOWI (Diagnostics Instruments, Inc.) microscope 
fitted to a digital camera system controlled by a the SPOT RT software (Version 
3.1) operated by a View Sonic Compaq Computer with Windows 95/98/NT. 
4.3 RESULTS 
4.3.1 Cell surface expression of TLR4 on human monocytic cells 
Cell surface expression of TLR4 was examined by both fluorescence 
microscopy and FACS. As shown in Figure 4.2, MM6 cells expressed a significant 
amount of TLR4 molecules. Cells incubated with the secondary antibody in the 
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absence of the primary antibody showed no evident staining, confirming detection 
specificity. 
4.3.2 Production of TN F-a and MMP by human monocytic cells in response 
to endotoxin stimulation 
In light of our findings which showed that human monocytic cells were 
unable to make NO following LPS stimulation, it was of interest to see if the human 
cells were able to produce other inflammatory mediators, such as TN F-a and MMP 
in response to LPS. As shown in Figure 4.3, TNF-a was produced by MM6 upon 
exposure to LPS, and the response was sharply increased with increasing 
concentrations, maximized at 1 IJg/mL LPS and levelling off quickly at higher 
concentrations. It was also noted that TN F-a was produced even at levels of LPS 
as low as 5 ng/mL suggesting the presence of CD14 in MM6, enhancing the effects 
of the signalling complex. 
In addition, we also examined by zymography the expression of two 
gelatinases MMP-2 and MMP-9 produced byMM6 cells. The principle ofthis assay 
is based on the observation that when the gelatinases produced by activated 
macrophages are resolved by electrophoresis on a gelatin-embedded gel, the 
enzymes will cleave the gelatin substrate leaving clear areas at the site where 
gelatin is digested. The band is visible after the gel has been developed and 
stained with Coomassie blue (Fig. 4.4 A). Figure 4.4 B shows the level of 
Figure 4.2: Cell surface expression of TLR-4 on human MM6 
MM6 (105 cells in100 ~L) cells were incubated with 5% normal human AB serum to 
block Fe receptors. Subsequently, the cells were stained with APC-conjugated 
mouse anti-human TLR4 antibody (MM6-TLR4). In a control sample, MM6 cells 
were stained with an APC-conjugated isotype control antibody (MM6-IgG) instead 
of the TLR-4 antibody. After fixation, TLR-4 expression was assessed by 
immunofluorescence. 
MM6-IgG MM6-TLR4 
Figure 4.3: LPS-induced TNF-a production by human monocytic cells 
Human MM6 cells (600 IJL of 1 x 106 cells/mL) were exposed to varying 
concentrations of LPS for 24 h. Cell-free supernatants were collected for the 
bioassay with L929, as detailed in Section 2.2.13. (A), A standard curve was 
prepared for each bioassay with purified TN F-a to permit translation of cytotoxicity 
into linear units of TN F-a concentrations. (B), Evaluation of TN F-a production of 
the MM6 cells in response to the stated doses of LPS was determined from the 
standard curve in (A). All measurements were performed in triplicate, and the 
results were expressed as mean ± SEM. 
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Figure 4.4: LPS-mediated MMP expression by human monocytic cells 
Human MM6 cells ( 1 06 per well) were stimulated with 1 00 ng/mL LPS for 24 h. Cell-
free media (91JL) was mixed with 91JL of the sample buffer and heat treated for 5 
min. Soluble gelatinases released into the media were resolved by SDS-PAGE on 
a 1 0% gelatin gel. (A), Shown is a typical zymogram gel stained with Coomassie 
Blue, as detailed in Section 2.2.18. Lane 1, untreated MM6 cells; lane 2, LPS-
treated MM6. (B), Level of expression of gelatinases MMP-2 and MMP-9 seen in 
A was quantified by densitometry. The histograms show expression intensity 24 
h after stimulation with LPS. 
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expression, as quantified by densitometry. As evident, LPS caused a 5-6 fold 
upregulation in the constitutive MMP-2, and dramatic induction of MMP-9 following 
24 h of stimulation. The response was also time dependent in that the induction of 
MMP was even stronger at 48 h. 
4.4 SUMMARY AND DISCUSSION 
In this chapter we have presented evidence for a strong TLR4 expression 
on human MM6 cells, suggesting that the lack of NOS II induction and NO 
production by human monocytic cells following LPS activation is not likely to be due 
to the absence of TLR-4. Although not investigated here, CD14 (both membrane-
bound and soluble) has been found on these cells, as reported (La beta eta/., 1993). 
Thus, it appears that from considering the receptor presence, the cells would be 
able to recognize the bacterial product. Subsequent studies presented here have 
shown that upon activation with LPS, MM6 cells were able to release large amounts 
of TN F-a (several fold higher than that by resting cells). In addition, exposure to 
LPS also triggered a significant 
induction of MMP-9, as well as a substantial up-regulation (approximately five-fold 
higher than the constitutive expression) of MMP-2 in these human monocytic cells, 
as detected by zymography. The induction of the two gelatinases also appeared 
to be time dependent in that 48 h stimulation resulted in an even stronger 
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expression of the two MMP by MM6 cells than that seen after 24 h activation. 
As the endotoxin used in these studies was derived from the same strain of 
E. coli as that used earlier for the NO investigation, the lack of detection of NO 
production by the human monocytic cell lines tested (MM6, U937, and THP-1) 
(Chapter 3) could not have been due to inherent unresponsiveness of the human 
cells to this particular strain of the bacteria. Therefore, the lack of NO production 
in human LPS- stimulated cells would likely be due to some blockage along the 
signalling pathway leading to gene activation. 
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CHAPTER FIVE 
PKC-ETA IS REQUIRED FOR LPS-INDUCED EXPRESSION OF 
THE INDUCIBLE NITRIC OXIDE SYNTHASE IN HUMAN 
MONOCYTIC CELLS 
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5.1 INTRODUCTION 
Our data from Chapter 3 have shown convincingly that human monocytic 
cells stimulated with endotoxin do not produce NO. The biochemical mechanisms 
underlying this phenomenon were not clear. However, several lines of evidence 
have supported a role of PKC in the LPS-triggered signalling pathway leading to 
production of NO in murine monocytic cells. For example, Severn and colleagues 
(1992) have shown that the PKC inhibitor Ro31-8220 significantly suppressed NO 
produced by murine J77 4A.1 following their activation with IFN-y. Ro31-8220 was 
also shown to effect suppression of NOS II and PKC activity in murine monocytic 
cells from Raw 264.7 treated with LPS, suggesting that PKC might have an 
obligatory role in the regulation of NOS II by LPS (Paul et a/., 1995). In addition, 
Sodhi and Kumar ( 1994) provided evidence for involvement of other PKC inhibitors 
in the NOS II induction by LPS in murine peritoneal macrophages. H7 and 
chelerythrine chloride were found to significantly inhibit NO synthesis by peritoneal 
LPS-treated macrophages. Studies with PKC isozyme-specific antisense-
oligonucleotides (Fujihara eta/., 1994; Chen eta/., 1998 A) and PKC activator PMA 
(Severn eta/., 1994) demonstrated an important role of PKC in the transcription of 
NOS II in murine monocytic cells. 
5.1 Rationale and aims 
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Findings such as the ones discussed above prompted us to explore further 
what appeared to be a connection between PKC and NO production. Specifically, 
we wanted to determine if the absence of one or more PKC isotypes might be 
responsible for the inability of human monocytic cells to make NO following in vitro 
stimulation with LPS. Given that PKC has a large family, the first step would be to 
conduct a complete comparative expression of such PKC isotypes in both human 
and murine monocytic cells. Such analysis was important as there had been little 
information available regarding PKC isotype expression in monocytic cells. In a few 
studies where the expression was looked at, the investigations were often limited 
to one or two selective isoenzymes in murine (St. Denis eta/., 1998; Chen eta/., 
1998; Diaz-Guerra eta/., 1996) or human (Monick eta/., 1998). Therefore, we first 
compared and contrasted PKC expression in monocytic cells from various human 
and murine cell lines, as well as those of human primary cultures. The findings 
from this investigation, as revealed later, form a basis for the work constituting the 
latter part of this chapter. Specifically, it deals with the effect of PKC transfection 
in a human cell line, studies on NOS II induction, and NO production by these 
monocytic cells following the transfection. 
Majority of the data presented in this chapter has been published in the 
journal of Nitric Oxide: Biology and Chemistry (Pham eta/., 2003a). 
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5.2 METHODS 
5.2.1 Assessment of PKC protein by western blotting and mRNA expression 
by RT-PCR 
Monocytic cells grown in suspension or by adherence to plastic were 
extracted for total homogenates, as described (Section 2.2.1 0.1 ). Resulting cell 
lysates (11 0 IJg) were subjected to acrylamide gel electrophoresis followed by 
western blotting (Section 2.2.11) with isotype-specific anti-PKC antibodies. Equal 
amounts of lysate prepared from fresh rat brain tissue were analyzed in parallel as 
a positive control. 
Expression levels of various PKC isotypes were semi-quantified by a Chemi 
Imager (Alpha lnnotech Corp.). Since they were all differentially expressed, the 
most abundant isotype was given a score of 1 00 and chosen to be a reference. 
Expression levels of all others were then standardized against this isotype. 
In certain experiments where mRNA levels of a particular PKC isotype were 
desired, total RNA (Section 2.2. 7) was prepared and subjected to RT -PCR with 
isotype-specific PKC primers (Section 2.2.8) 
5.2.2 Cell transfection 
MM6 cells were transfeeted with expression plasmid pks1.PKC-r), which 
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contains the full length PKC-11 eDNA placed under the control of CMV/T2 promoter 
by LipofectAMINE. This promoter is useful as it is active in almost all mammalian 
cells. Briefly, cells were harvested and washed once with Opti-MEM I Reduced 
Serum Medium. The cells (3 x 106 cells suspended in 0.8 ml of OPTI-MEM media) 
were plated in each well of the six-well plate and placed in a 37 °C incubator. 
Meanwhile, DNA and LipofectAMINE solutions were prepared as follows. For each 
transfection, 2 iJg DNA and 3 iJL LipofectAMINE were added to separate tubes, 
each of which was made up to 100 iJL with OPTI-MEM media. The two solutions 
were gently mixed, combined, and incubated at RT for 45 min to allow for the 
formation of DNA-Iiposome complexes. Subsequently, the complexes were 
carefully added to the cell suspensions, and the plate swirled gently to ensure 
uniform distribution. After 4 h incubation at 37 °C, the cells were supplemented with 
complete growth media and cultured for another 48 h. Total RNA or cell extracts 
were recovered for RT -PCR and western blotting, respectively. 
5.2.3 Assessment of NO production in PKC-11 transfected MM& cells following 
LPS and cytokine stimulation 
Following transfection, 3 x 106 cells (per well) were seeded in a 6-well plate, 
cultured for 3 h, and treated with various doses of LPS and IFN-y for 48 h. Total 
cell extracts were prepared for evaluation of NOS II protein by western blotting. 
Cell-free supernatants were accordingly analyzed for nitrite. 
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On some occasions, PKC-11 transfected MM6 were treated with TNF-a 
and/or IFN-y in the presence of LPS. Cell cultures were then measured for NO 
levels. 
5.3 RESULTS 
5.3.1 Expression of PKC isoenzymes in human and murine monocytic 
cells evaluated by western blotting 
Using PKC isoform-specific antibodies as a research tool, we assessed 
expression of the isotypes in the three human and two murine cell lines, as well as 
in human MOM generated from PBMC of healthy individuals (Fig. 5.1 ). As shown, 
some isotypes were expressed more abundantly than others, and this was true for 
all cases tested: rat brain (positive control), human and murine monocytic cells. For 
example, as depicted in Table 5.1, PKC-8 was the most weakly expressed isotype 
overall. This was observed across the cell lines, human MOM, and the rat brain. 
On the other hand, PKC-e was the most predominantly expressed, but this was only 
in the case of the rat brain. Taking advantage of its strongest expression, we used 
PKC-e in the brain as a reference (100%) against which expression levels of all 
other isoforms were to be normalized. The results were then expressed as a 
percentage of this reference. As evident, all but one isoform (PKC-11) were present 
in larger quantities in the brain than in the monocytic cells, of either human or 
Figure 5.1: Protein expression of PKC isoenzymes In human and 
murine monocytic cells 
Total cell homogenate ( 11 0 IJg) prepared from murine ( J77 4A.1 and Raw264. 7) and 
human (U937, THP-1, and MM6) monocytic cell lines were subjected to a western 
blotting analysis (Section 2.2.11) for evaluation of PKC isotype expression. Equal 
amounts of a rat brain sample were analyzed in parallel and used as a positive 
control. Shown is a representative western blot image from such analysis. Positive 
signals showed bands of the expected sizes for PKC-IJ (mu) and PKC-~ (zeta). 
Rat Murine Human 
Brain J774 Raw264 MM6 U937 THP-1 
PKC-1-1 ... 104 kDa 
· .. · .. · Figure:5.2: Differential PKC-11 expression in human and murine 
monocytic cells 
.. ~ . -
(A), Tdt~ldell extracts (110 J.Jg) isolated from human (U937, THP-1 and MM6), 
murine (Raw264. 7 and J77 4A.1) monocytic cells and rat brain were subjected to 
western blotting with a rabbit polyclonal anti-PKC 11 antibody (Section 2.2.15.1 ). 
(B), · Binding specificity was ensured by incubating the antibody with excess 
blocking peptide prior to probing of the samples. The expected size of putative 
PKC-11 is 68 kDa. The 82 kDa band present in THP-1 in B is an unknown species. 
A 
U937 THP-1 MM6 Raw264.7 J774 Rat brain 
:;;r~;;.;~.-~~. 
-._~ ... 68kDa 
B 
Raw264.7 J774 THP-1 Rat brain 
... 82kDa 
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murine origin. In addition, PKC-y was not expressed in any of the five cell lines; 
this was consistent with the notion that this particular subtype is exclusively 
expressed in the brain (Nishizuka, 1984). Quantitatively, PKC-a, -P2, -~. -8, -1, -e, 
and -IJ essentially showed similar expression levels in human and murine monocytic 
cells. There was some degree of variations in the levels of PKC-~ expression 
among those tested. The differences, however, were not along the species line in 
that this isoform was present at a slightly higher level in human MM6 and U937 than 
MOM, THP-1 or their murine counterparts. The most intriguing finding of our 
screening lies with PKC-11 and PKC-P1. PKC-11 was abundantly expressed in 
murine cells, but completely deficient in the human cells. In contrast, PKC-P1 was 
barely detected in human monocytes and not found in murine cells. 
In the case of PKC-11, the antibody failed to recognize the cognitive antigen 
in U937 and MM6 cells, while it barely reacted to THP-1 to show a weaker band of 
approximately 68 kDa, which is within the expected size of PKC-11 (Fig. 5.2 A). In 
marked contrast, murine monocytic cells Raw 264.7 and J77 4A.1, as well as the 
positive control rat brain, each showed two very strong bands of 68 and 82 kDa 
when probed with the same antibody, with the 68-kDa entity being the more 
abundant species (Fig. 5.2 A). To confirm binding specificity, identical samples 
were probed with the PKC-11 antibody in the presence of an antibody specific 
peptide. As shown in Figure 5.2 B, the presence of the competing peptide resulted 
in complete blocking of antibody binding to its cognate antigen in the rat brain and 
Table 5.1: Quantitative PKC isotype expression In human and murine 
monocytic cells as detected by western blotting 
8 lsotype expression was quantified by densitometry with PKC from positive control 
rat brain. PKC-e in the rat brain was most abundantly expressed, and thus given 
the highest score of 1 00. Expression levels of the other isotypes were then 
standardized against that of PKC-e. The results are expressed as mean expression 
%of the epsilon isotype (e)± SD (number of experiments). 
cNot done. Expression in both murine and human monocytic cells have been 
reported elsewhere (Ono eta/., 1989; Diaz-Meco eta/., 1994). 
dAbsence of PKC-11 in human monocytic cells was not due to species specificity of 
the antibody as it was able to recognize the antigen in the human brain (Fig. 5.3). 
Table 5.1: Quantitative PKC isotype expression in human and murine 
monocytic cells as detected by western blotting• 
lsoform Murine Human Rat 
Raw264.7 J774 THP-1 MM6 U937 MOM Brain b 
Alpha nld 0 nld 54.9±5 45±9 49.2 ± 10 45.3±5 45.1 ± 2 
(a) (2) (4) (4) (3) (3) 
Beta 1 0 0 14.1:t2 14.3:1:4 20.6:1:2 16.1:1:3 42.0:1:1 
CP1l (4) (4) (2) (4) (4) (3) (3) 
Beta2 35.8± 9 31.7± 8 54.2 ± 13 44.3 ± 14 44.0±11 43.2±7.6 92.6 ± 14 
CP2) (4) (2) (3) (4) (4) (3) (3) 
Gamma 0 0 0 0 0 0 88.7± 2 
(V) (2) (2) (2) (2) (2) (2) (2) 
Epsilon 8.3±7 10.2± 4 10.6± 3 36.3±22 24.9± 4 26.3 ± 12 100 ± 11 
(e) (3) (3) (2) (4) (4) (3) (3) 
Delta 23.1 ± 5 26.1 ± 7 23.1 ±5 27.1 ± 6 23.2±6 22.3± 5.0 91.4± 6 
(li) (2) (2) (2) (3) (3) (3) (3) 
Mu 15± 18 18.1 ± 7 23.0 ±2 11.1±6 18.8± 4 16.0 :t 4 21.4 ±12 
(1..1) (2) (2) (2) (2) (2) (2) (2) 
Theta 11.1±1 9.6± 1 5.6±2 9.0± 1 7.9±2 6.9 :t 2 13.1 ± 1 
(6) (3) (3) (2) (3) (3) (3) (3) 
Etad 142:1:6 146.5:1:2 0 0 0 0 83.7:1:4 
(11) (4) (2) (2) (3) (3) (3) (3) 
Iota 18.4± 2 13.7±2 22.3±2 26.4:1:6 22.9± 6 24.4 :t 3 38.8±3 
(I) (4) (2) (2) (4) (4) (3) (3) 
Zeta 49.6± 8 43.0:1:7 54.5:1:10 93.1:1: 19 71.9:1:22 56.3:1:5 60.9:1: 11 
co (2) (2) (2) (2) (2) (2) (2) 
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murine monocytic cells (Raw 264.7 and J77 4A.1) evident by the disappearance of 
the two bands. However, the peptide failed to block binding of the antibody to the 
single THP-1 band seen in Figure 5.2 A. To address the possible concern that the 
absence of PKC-11 seen in the human cells were likely to be a consequence of 
inherent species specificity of this antibody and subsequent differences in epitope 
recognition, PKC-11 expression was tested against fresh human brain tissue (kindly 
provided by Dr. Simon Avis, Memorial University) by western blotting using the 
same antibody. As shown in Figure 5.3, the antibody recognized the putative 
antigen in the human brain, as it did with murine monocyte J77 4A.1 and rat brain. 
This suggests that the absence of PKC-11 in human monocytic cells was not due to 
the failure of the antibodies, which were used in our studies, to recognize the 
antigen. 
5.3.2 Evaluation of PKC-r, isoenzyme transcription In human and murine 
monocytic cells by RT -PCR 
To explain whether the absence of PKC-11 observed was due to the lack of 
expression of the protein or the inability of the antibody to recognize the antigen, 
we examined the levels of PKC-11 gene transcription by RT -PCR. As shown in 
Figure 5.4, no PKC-11 mRNA was found to be present in human monocytic cells, 
either MM6 or MOM cells. The plasmid pks1. PKC-11 encoding the full length human 
Figure 5.3: Expression of PKC-r) in human brain tissue 
Total cell extracts ( 11 0 IJQ) from human brain, murine monocyte J77 4A.1, and rat 
brain were subjected to western blot analysis with a rabbit polyclonal anti-PKC-r, 
antibody, as described (Section 2.2.15.1 ). Shown is the result from a representative 
experiment. 
Human brain J774 Rat brain kDa 
82 
68 
Figure 5.4: Absence of PKC-11 mRNA In human monocytic cells 
Total RNA (2-41Jg) harvested from human (MM6 and MOM) or murine monocytic 
cells (J774) as well as that from rat brain were analyzed by RT-PCR for PKC-r) 
expression using gene specific primers. Samples containing water (W) in place of 
test eDNA and empty plasmid (pks1) were prepared in parallel as negative controls. 
The plasmid pks1.PKC-r) encoding full length PKC-r) was used as a positive 
control. PCR products (9 IJL) were fractionated on a 1% EtBr-containing agarose 
gel. Positive signals showed the band of expected size of 259 bp. 
pks1.PKC·Tt MM6 MOM Rat brain J774 pks1 
259bp ... 
W Ladder (bp) 
400 
300 
200 
100 
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eDNA was used as a positive control. 
5.3.3 Transfection of MM6 cells with PKC-11 
In light of the findings in Figure 5.4, which showed that PKC-11 mRNA was 
not present in MM6, we proceeded with the transfection of these cells with plasmid 
pks1.PKC-11. This plasmid is a CMV (cytomegalovirus)-driven expression vector 
encoding the full length PKC-11 eDNA MM6 was transfected with the vector using 
lipoFECTAMINE. After 48 h, the cells were assessed for PKC-11 protein expression 
by western blotting. Figure 5.5 shows a typical result from a representative 
experiment. It demonstrates the presence of PKC-11 isoenzyme (68 kDa) in MM6 
cells transfected with the plasmid encoding PKC-11 and in both the murine J77 4A.1 
and rat brain (positive controls), but not in untransfected MM6 cells cells or those 
transfected with the empty vector. 
5.3.4 Effect of PKC-r) on NOS II expression and NO production by human 
monocytic cells 
As illustrated in Figure 5.6 A, NOS II enzyme was not expressed at the 
lowest LPS dosage tested, 0.1 tJg/mL by MM6 cells transfected with PKC-11 
(psk1.PKCfl). Marked upregulation of NOS II was seen at 1 tJg/mL LPS with no 
further augmentation of the enzyme at higher LPS concentrations (up to 10 IJg/mL). 
Figure 5.5: Expression of PKC-r] in human monocytic cells following 
transfection 
(A), MM6 cells (2.5 x 106) were transfected with 31Jg of pks1.PKC-r] (MM6-T) or an 
empty vector (pks1) in the presence of 4 IJg LipoFECTAMINE, as described 
(Section 2.2.16). MM6 cells that were not transfected (MM6-UT) served as a 
negative control while murine J77 4 cells and rat brain served as positive controls. 
After 48 h, total cell extracts were prepared, and the samples (11 0 IJg) probed for 
PKC-r) by Western blotting using the PKC-r)-specific antibody (Section 2.2. 15.1 ). 
(B), To demonstrate binding specificity, an identical western blot was prepared and 
probed with the same PKC-r] antibody previously incubated with the PKC-r] 
competing peptide. Three independent experiments gave identical results. 
MM6-T pks1 MM6-UT J774-UT Rat brain 
68 kDa 
68 kDa 
Figure 5.6: Effect of PKC-r, on NOS II expression and NO production 
in human monocytic cells following stimulation with LPS and 
cytokines 
Human MM6 cells were transfected with either the empty vector (pks1) or plasmid 
encoding PKC-fl (pks1.PKC-fl), as described (Section 2.2.10). The mock 
transfected cells treated in the same way as the PKC-fl expressing cells served as 
a negative controls. After the transfection, 2 ml (per well) of 1.5 x 106 cells/ml was 
seeded in a 6-well plate, and incubated for 3 h. Subsequently, the cells were 
stimulated with varying concentrations of LPS for 48 h and harvested for the 
preparation of total cell homogenate. (A), Total cell lysate (11 0 IJg) was analyzed 
for NOS II by Western blotting. (B), Cell-free supernatant (100 IJL) was collected 
for nitrite measurements by Griess assay. (C), In some experiments, PKC-r, 
expressing MM6 cells were also treated with TNF-a and/or IFN-y, in addition to 
LPS, and cell culture media analyzed for NO contents. NO, if any, released by the 
untreated cells was used as a background. NO values were expressed as mean ± 
SD of three triplicate experiments after the background had been subtracted. On 
the western blot images, the positive signals showed a 130-kDa band, the expected 
size of NOS II. 
A 
0 0.1 
pks1.PKC·11 
pks1 
1 10 LPS (J.lg/ml) 
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In contrast but as expected, NOS II was not found to be expressed at any of the 
LPS doses tested in MM6 cells transfected with the empty plasmid (pks1 ). The 
enzyme induced by the human MM6 cells expressing PKC-r, was functional, as 
shown by the production of NO (Fig. 5.6 B). However, unlike the synergistic effects 
of cytokines and LPS observed earlier in murine monocytic cells (Section 3.2.1 ), 
similar co-stimulation with LPS and cytokines (TN F-a or IFN-y) did not induce any 
increase in the levels in LPS-mediated NO production by these transfected human 
cells (Fig. 5.6 C). It was only when the PKC-r, expressing MM6 cells were co-
treated with LPS and a cytokine combination of TNF-a/IFN-y, did we observe slight 
augmentation of NO released. However, the enhancement was 10-15% of that seen 
in the murine cells (Section 3.2.1 ). 
It is not possible that the NOS II expression and NO induction observed in 
our experiments was due to PKC-rt expression in a few isolated transfected cells 
as the same number of J77 4A.1 cells and the transfected MM6 cells were used to 
prepare total cell extracts, of which the same amounts (11 0 IJg) were analyzed, and 
similar staining of bands observed. 
5.4 SUMMARY AND DISCUSSION 
It is clear from our study that of eleven isoforms known to exist in the PKC 
superfamily, only two make human and murine monocytes differ. First, PKC-r, was 
135 
grossly expressed in the two murine monocytic cell lines J77 4A.1 and Raw 264.7, 
but completely absent from the three human cell lines tested (U937, MM6, and 
THP-1 ). Second, PKC-(31 was minimally expressed in the human monocytic cells 
but was completely absent in their murine counterparts. Because there exists a 
possibility of some unknown factors being spontaneously present in transformed 
cell lines that could alter expression of different genes including PKC, our 
observations regarding the unique distribution of PKC-11 and PKC-(31 may not 
necessarily reflect the in vivo situation. To address the concern, we screened for 
different isotypes of PKC from MOM isolated from healthy human subjects, and 
found that the expression in this instance was identical to that of the cell lines, both 
qualitatively and quantitatively (Table 5.1 ). 
A I iterature search on a link of these isoforms with NO capability in monocytic 
cells was not very fruitful. The work by Chen and colleagues (1998, A and B) with 
antisense oligonucleotides has revealed that PKC-11 was involved in the expression 
of NOS II in murine astrocytes, but that the same isoform had no role in the 
regulation of NOS II gene in murine monocytic cells from the Raw 264.7 cell line 
following 12-0-tetradecanoylphorbol13-acetate (TPA) stimulation. Clearly, these 
findings needed to be further assessed, and more work needed to be carried out 
if one were to achieve better understanding of this very complex pathway. With 
Chen using the approach of "deleting" out the PKC-11 isoform in murine monocytic 
cells by employing the antisense oligonucleotides, it was of interest to us to tackle 
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the issue directly from the human model, as observations made in the murine 
system may not necessarily be applicable in human situation. In addition, we 
wanted to ascertain if Chen's findings were specific to TPA stimulation or they were 
also true with other stimuli such as LPS. With this aim, we proceeded with 
transfection of the gene to the human monocytic cell line MM6. Our findings from 
the transfection studies (Fig. 5.6) have shown for the first time that human 
monocytic cells transfected with PKC-r, are capable of expressing NOS II leading 
to production of NO at levels that could be readily detected in cell culture media. 
This was in marked contrast to what was previously thought (Denis, 1994). The 
evidence here suggests that PKC-r, may play an important role in regulating NOS 
II gene expression in human monocytic cells. However, as alluded to earlier, these 
findings are in contrast with Chen's work (1998 B) which suggested that long-term 
treatment of TPA did not seem to effect down-regulation of PKC-r, like it did with 
other PKC isoforms they tested. The assumption underlying the work was that 
PKC-r, would respond to the TPA treatment, and this raises a question of whether 
or not this is indeed true in all instances. Secondly, in this study the NF-KB 
translocation after LPS stimulation was not measured at various time points. 
Therefore, it is equally possible that the chosen time point might not have been long 
enough to allow for the activation and/or translocation of PKC-r, to the membrane, 
albeit this seems unlikely. 
In murine monocytic cells, expression ofthe NOS II gene is transcriptionally 
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regulated by a basal promoter known as Region I, and by an enhancer element 
known as Region II. Region I is responsive to LPS while Region II is essentially 
IFN-y responsive (Lowenstein eta/., 1993). The work done by Zhang eta/. (1996) 
has shown that the human counterpart Region II shares an approximate 76% 
similarity with that of the murine, and that the nucleotide substitutions within this 
region may be the reason for hyporesponsiveness of human monocytic cells to 
LPS. Their work with chimeric human/murine promoter constructs revealed that the 
response to LPS was qualitatively the same as that of the murine construct. 
Quantitatively, however, the response of the chimeric construct was only half of the 
wild-type construct supporting their hypothesis that Regions I and II of the human 
promoter are not the only regions involved in regulating the expression of NOS II, 
and that there may be other signals needed to fully induce NOS II gene expression. 
Our current work supports this aspect of the hypothesis as at a given concentration 
of LPS, NO production by the human cells was approximately 60% of that seen in 
murine cells. 
Novel findings presented here warrant further research to delineate cross-
talk between PKC-11 and other signalling molecules which are involved in the LPS-
mediated NOS II signalling pathway in human monocytic cells. If a positive 
correlation between NOS II and PKC-11 were to be established in certain disease 
processes, it would be plausible to envision that inhibitors to PKC-11 would offer 
potential therapeutic benefits of inflammatory conditions where inappropriate 
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release of NO is known to contribute to their pathologies. 
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CHAPTER SIX 
EFFECTS OF TRIPTERYGIUM (TwHf) DERIVATIVES ON THE 
IN VITRO PRODUCTION OF INFLAMMATORY MEDIATORS BY 
MONOCYTIC CELLS 
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6.1 INTRODUCTION 
6.1.1 Current management approaches for rheumatoid arthritis 
Currently, there are a number of conventional therapeutic approaches for 
the treatment of RA. The initial drug treatment for RA after the onset of disease 
involves the use of salicylates, nonsteroidal anti-inflammatory drugs and selective 
cyclooxygenase 2 (COX-2) inhibitors (rofecoxib) to reduce pain and improve motion 
(Geba eta/., 2002). Low dose glucocorticoids (e.g., prednisone) are effective in 
relieving inflammation in patients with active RA by interfering with leukocyte 
trafficking, proliferation, and function (De eta/., 2002). These drugs, however, do 
not have a role in preventing the progression of disease, and require additional help 
from a group of compounds known as disease-modifying anti-rheumatic drugs 
· (DMARD). Four of the most widely used DMARDs are Methotrexate (MTX), 
antimalarial, sulfasalazine, and hydroxy-chloroquine which can all reduce disease 
progression owing to their anti-inflammatory and anti-proliferative effects. Although 
less used in the last decade, various gold salt compounds, including sodium 
aurothiomalate and auranofin, have also been ultilized for the treatment of RA 
(Hashimoto et a/., 1994). These gold salts are thought to interfere with the 
formation of synovial blood vessels (neovascularization), thus significantly 
minimizing infiltration of immune cells and impeding growth of the sinovial pannus 
(Saura eta/., 1994). With respect to the involvement of cytokines in RA, it has now 
been shown that TN F-a and IL-1 ~ are arthritogenic, and both are critical in 
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initiating and perpetuating the inflammatory process leading to joint destruction 
(Dayer, 2002; Bingham, 2002). Studies from arthritic patient samples obtained ex 
vivo have lead to the development of monoclonal antibodies against TNF-a (e.g., 
infliximab and cA2) as possible therapeutic interventions for RA. lnfliximab has now 
been approved for yet another type of medication for RA treatment. However, as 
powerful as some of these compounds might be, they all have different side effects, 
with some being more severe than others. Included in this list are neural (Sicotte 
and Voskuhl, 2001 ), gastrointestinal (Thomas eta/., 2002), renal (Fukuchi eta/., 
1998), and respiratory complications (Biancas eta/., 1998). It is also expected that 
RA therapies which target soluble inflammatory mediators such as TN F-a and NOS 
II may not prove efficacious for all patients. Clinical data, as supported by basic 
science studies, have revealed that in basically every approach, there are many 
patients who are unresponsive to the above mentioned treatments (Kalden, 2002). 
For those who do respond, adverse effects arising from these long term therapies 
are poorly documented. Thus, other therapeutic alternatives are needed for the 
disease. 
6.1.2 Tripterygium wilfordii Hook f. (TwHf): a Chinese traditional 
medication with immunological activity 
TwHf is a perennial vine that belongs to the Celastracae family. The plant 
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grows naturally in the mountainous southeastern regions of China, where it is also 
referred to as Lei Gong Teng Pian or Thunder god vine. For 2000 years, crude 
preparations of the plant root, thought to contain all the therapeutic components of 
the plant, have been used in traditional Chinese medication for the treatment of a 
number of conditions including fever, oedema, and joint pain. The exact 
mechanisms by which the herb works, however, are not clearly defined. This is 
partly because of the large number of natural compounds (more than 70) present 
in the root including diterpenes, triterpenes, glycosides and alkaloids although there 
is a great deal of similarity in the structures of many of these (Zhang eta/., 1990). 
To this date, the plant root is still used as a traditional medication for the treatment 
of a number of diseases including RA, systemic lupus erthyematosus (SLE), 
psoriasis, and more recently leukaemia. The medication is usually administered 
orally as either a ground power or a glycosidic extract. 
In the past thirty years, much work has been devoted to refining the crude 
extracts of TwHf and purifying the components. Several different extracts including 
an aqueous concoction, an alcohol extract known as T1, a chloroform/methanol 
extract T2, and an alcohol/ethyl acetate (EA) fraction have been prepared, and 
explored for their anti-inflammatory and immunosuppressive effects in vivo. The 
chloroform preparation T2 was revealed to: 1) ameliorate type 2 collagen-induced 
arthritis in mice (Asano eta/., 1998), and 2) inhibit histamine-induced increase of 
vascular permeability in rats and delayed type hypersensitivity in guinea pigs 
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(Zheng et a/., 1983), while the EA extract was shown to suppress carrageenan-
induced inflammation in rats (Tao eta/., 1999). The mechanism of action of these 
extracts have been studied in vitro with cell cultures either from cell lines or from 
samples obtained from RA patients ex vivo. These investigations have 
demonstrated various anti-inflammatory and immunosuppressive properties of 
these extracts. For example, the numerous glycosides of the T2 extract have been 
shown to dramatically inhibit proliferation ofT lymphocytes as well as IL-2 and IL-4 
production from activated T cells (Dong, 1997). As well, the glycosides have been 
documented to suppress production of IL-1, IL-6, IL-8, TNF-a, and prostaglandin 
E2 (PGE2) by monocytes/macrophages (Chang eta/., 1997) and secretion of lgG 
by B cells (Chang eta/., 1997). In addition to inhibiting IL-2 synthesis, the T2 
extract has also been shown to abrogate the synthesis of PGE2 by mononuclear 
phagocytes (Chou eta/., 1998). Work by Mackawa and colleagues (1999) has 
revealed that the suppression of PGE2 by the glycosides of T2 was due to 
inhibition of COX-2 transcription via NF-kB. Similarly, Tao and colleagues (1998) 
observed the same phenomenon with the EA extract and purified triptolide, a 
diterpenoid triepoxide and a major constituent of the TwHf root. Both types of 
extracts and triptolide had no effects on either the activity or expression of the 
constitutively expressed COX-1, again reflecting the anti-inflammatory properties 
of the herbal medicine. In addition to suppressing the production of PGE2 by 
monocytic cells, triptolide has also been shown to suppress several cytokines 
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including IL-1 (a and J3), IL-6 and TNF-a in the LPS-treated murine mononuclear 
phagocytes. In line with these inflammatory mediators, triptolide also attenuates the 
release of proMMP-1 and proMMP-3 (precursor of MMP) induced by IL-1 J3 while 
augmenting the production of tissue inhibitor of MMP (TIMP)-1 and -2 in synovial 
fibroblasts (Lin eta/., 2001 ). Taken together, these extracts from TwHf affect 
production of various inflammatory mediators by immune cells including 
lymphocytes, macrophages, and fibroblasts. In so doing, they are able, through 
various mechanisms, to regulate the function of these cells, which are all involved 
in different capacities in the inflammatory process. This may be able to explain the 
observed high efficacy of the plant in ameliorating inflammatory conditions like 
arthritis. 
With the support of 2000 years of clinical use in China, TwHf has rapidly 
gained attention within the scientific community in North America during the past 
30 years. However, only relatively recently have the components been purified and 
chemically identified. 
6.1.3 Chemical constituents of TwHf compounds used in the present 
investigation 
Terpenoid compounds are the simplest naturally occurring isoprenoid 
compounds found widely in nature, especially in plants. All isoprenoid compounds 
have repeating five carbon atom units (isoprenes) in their carbon skeletons, with 
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terpanes containing two of these isoprene units joined together in a cyclic 
arrangement. Hence, a diterpene will have four and a triterpene will have six of 
these isoprene units. Using the same nomenclature, a terpenoid compound has 
multiples of the five carbon isoprene units. 
6.1.4 Inhibitory effects of TwHf compounds on LPS-lnduced NO 
production by monocytic cells 
Previously in Dr. Richardson's laboratory, seventeen TwHf compounds 
(provided by Dr. James Kutney), which were either natural or synthetic derivatives, 
were screened for their effects on: (1) cell toxicity and (2) the production of LPS-
mediated NO by murine monocytic cells (Barrett, 1998). These natural compounds 
included: (1) diterpenes and triterpenes triptophenolide, (2) triptoquinone, (3) 
celastrol, (4) triptolide, (5) tripdiolide, and (6) tingenone, while the synthetic 
derivatives of TwHf included JPK-1 09 and JPK-1 01. The results from this work 
have shown that these compounds varied in toxicity and their ability to inhibit NO 
production by murine monocytic cells from J77 4A.1. The in vitro therapeutic index 
(TI) for NO (TCsofiC50 with the TC50 being the dose where 50% of the cells die and 
the IC50 being the concentration at which NO synthesis is suppressed by 50%) was 
2. 7 for triptophenolide, 5.1 for celastrol, 9.4 for JPK-1 09, and 4.4 for triptolide. It 
should be noted that although celastrol and triptolide demonstrated high potency, 
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they also conferred a cytotoxic effect on the cells tested. Thus, these three 
compounds may have potential as novel anti-inflammatory agents providing that the 
observed level of cytotoxicity could be appropriately addressed. In contrast, 
suppression of LPS-mediated NO synthesis by tripdiolide and tingenone was due 
to their toxicity on the murine monocytic cells, and not due to direct 
inhibition/suppression of the expression of NOS II enzyme. An important 
observation made from the study by Barrett (1998) was that the compounds 
themselves did not induce NOS II expression or NO production in these cells. 
6.1.5 Aims 
The work succinctly summarized above (Barrett, 1998) has provided 
important information on toxicity and the ability to suppress NO production by 
murine macrophages. However, it was not known from these studies as to whether 
the drugs caused inactivation of the NOS II enzyme or whether they played a role 
in the suppression of NOS II expression. It is with this in mind that follow-up 
experiments were done and a summary of the results are presented in this chapter. 
In addition, it was also of interest to explore potential effects of these compounds 
on two other important macrophage functions thought to be essential in the 
development and maintenance of the inflammatory process: synthesis of TN F-a 
and MMP. In these experiments three compounds, namely JPK-1 01, JPK-1 09, and 
JPK-113 were studied. JPK-1 01 and JPK-1 09 are synthetic diterpenes, while JPK-
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113 ( celastrol) is a quinone methide triterpene purified from the plant. 
A manuscript containing the data reported in this chapter is in preparation 
for submission to a peer-reviewed journal. 
6.2. MATERIALS AND METHOD 
6.2.1. Materials 
Stocks of JPK-101 and JPK-109 were dissolved in 20% reagent grade 
absolute ethanol, while that of JPK-113 was prepared in 5% DMSO. In all three 
cases, the solutions were used within 45 min following preparation. 
6.2.2 Cell treatment with natural and synthetic derivatives of TwHf 
Monocytic cells were treated with appropriate doses of the drug (dissolved 
in either reagent ethanol or 0.5% DMSO/PBS). After 45 min, unless stated 
otherwise, LPS was added (usually 1 ~g/mL, unless specified to the contrary in 
figure legends), and the cells were cultured for 24 h or 48 h depending on the 
experiment. Cell-free supernatants or cells were prepared and analyzed, as 
appropriate. 
In certain experiments where mechanism of action for a TwHf compound 
(JPK-1 09) was desired, a fixed concentration (3 ~g/mL), earlier established to give 
maximum inhibition, of the drug was added to MM6 cells at various time points 
148 
before or after LPS addition. After 18 h, the cells were analyzed for NO and NOS 
II, as appropriate (see below). 
6.2.3 Assessment of the effects of TwHf on the induction of NO, TN F-a, and 
MMP 
After cells were treated as described above, they were harvested for 
extraction of totallysates, which were subjected to NOS II investigation by western 
blotting. Corresponding cell-free cultures were analyzed for: (1) nitrite by the 
Griess assay (Section 2.2.12.1 ), (2) TN F-a by the cytotoxicity bioassay with L929 
(Section 2.2.13), and (3) MMP activity by zymography (Section 2.2.14). Samples 
of untreated cells or cells treated with LPS alone served as negative and positive 
controls, respectively. 
6.2.4 Data analysis 
Magnitude of the inhibitory effects of the TwHf compounds on NOS II and 
MMP were quantified by densitometry image analysis. A baseline (value from 
untreated cells) was subtracted in the analysis. In the case of NOS II, NO, and 
TN F-a, the background-subtracted value was normalized against a positive control 
(cells treated with LPS alone). 
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6.3 RESULTS 
6.3.1 Toxicity studies 
In any experiment that involves assessing the effect(s) of a novel compound 
on a particular cell function, it is essential to perform preliminary studies to 
determine its toxic doses on the cells being investigated. This piece of information 
is extremely important and unfortunately often ignored in many studies. Such 
practice can lead to inaccurate determination of the true effects of the drug. With 
this in mind, we investigated toxicity of the three TwHf compounds on human and 
murine monocytic cells from the cell lines MM6 and J77 4A.1, respectively by the 
MTT assay. As shown in Figure 6.1, in both J77 4A.1 (Fig. 6.1 A) and MM6 (Fig. 6.1 
B), the toxic effect of JPK-1 01 started becoming obvious between 4-8 IJg/ml. The 
TC50 values were determined to be 6.1 ± 2.31Jg/ml for J77 4A.1 and 7.2 ± 0.81Jg/ml 
for MM6. Similarly with JPK-1 09, 50% of cell death was seen at 6.1 ± 1.2 IJg/mL 
in J77 4A.1 (Fig. 6.1 C) and 5.1 ± 0.8 IJg/mL (Fig. 6.1 D) in MM6. JPK-113 on the 
other hand appeared to be much more toxic in the two cell lines than JPK-101 and 
JPK-109 in that the TC50 was 170 ± 35 ng/ml for murine J774A.1 (Fig. 6.1 E) and 
150 ± 26 ng/ml (Fig. 6.1 F) for human MM6. Generally speaking, although the TC50 
values were different among the three compounds, the drugs appeared to exert 
similar toxicity on human and murine monocytic cells. 
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Figure 6.1: Effects of TwHf compounds on cell viability as determined by 
the MTT assay 
J77 4A.1 (A, C and E) or MM6 (B, D and F) cells were plated at density 2x1 05 per 
well in a 96-well plate. Drug solutions containing appropriate concentrations of 
JPK-101 (A and B), JPK-109 (C and D), or JPK-113 (E and F), were then added. 
After 45 min, the cells were supplemented with 1 lJg/mL LPS, and left incubated for 
another 24 h. The MTT assay was then carried out, as described (Section 2.2.5.2). 
Untreated cells served as a negative control, and assumed to remain viable after 
the 24-h incubation period, while those that were treated with 2.5% DMSO were 
assumed to have been all killed at the same time point. The optical density values 
obtained from these two samples were used as the reference points for 
normalization of test samples. Data analysis was done using Graph Pad Prism 
software. In most cases, the expressed values were mean ± SO of three different 
experiments done in triplicate. 
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6.3.2 Effects of TwHf compounds on NO production by murine monocytic 
cells: A reassessment 
Murine monocytic cells from the J77 4A.1 cell line were treated with 
increasing concentrations of the drugs for 45 min prior to being stimulated with LPS 
(1 ~g/ml). Cell-free supernatants collected 24 h later were measured for NO by the 
Griess assay. As shown in Figure 6.2 A, the synthetic derivative JPK-1 01 inhibited 
LPS-induced NO production in a dose dependent manner. At 2 ~g/mL, nearly 20% 
of NO production in murine J77 4A.1 was suppressed and the inhibition was steadily 
decreased at higher concentrations of NO. The IC50 was determined to be 2.2 ± 0.4 
~g/ml. A similar pattern of NO suppression was also seen in LPS-activated 
J774A.1 cells exposed to JPK-109 (Fig. 6.2 B). In this instance, JPK-109appeared 
to be more effective than JPK-101 in that as little as 500 ng/mL of the compound 
was sufficient to reduce the NO synthesis by 30%. A complete inhibition was 
observed at 6 ~g/mL of JPK-1 09. The IC50 for this compound was approximately 
1.05 ± 0.2 ~g/ml. Similar screening for NO suppression of the natural TwHf 
celastrol (JPK-113) revealed that although the pattern was similar to that of the 
other compounds in terms of dose response, JPK-113 was less effective than the 
other two at inhibiting NO production (IC50:75 ± 26 ng/mL). At the lowest dose 
tested (25 ng/mL), JPK-113 was found to mediate nearly 10% reduction in NO 
leading to 80% suppression at 250 ng/ml. However, given that the TC50 for this 
compound in J77 4A.1 was previously determined to be 170 ng/ml (Fig. 6.1 E), the 
Figure 6.2: Effect of TwHf compounds on LPS-induced NO production 
by murine J774A.1 cells 
J77 4A.1 cells (2.5 x 1 06 per well) was seeded in a 60-mm petri dish, and cultured 
over night. Old medium was removed, and the cells were briefly washed with ice 
cold PBS. Fresh medium (2.5 mL) containing appropriate concentrations of the 
drug was added to the wells. The cells were stimulated with LPS (1 J,Jg/mL) 45 min 
later for 18 h. Cell-free supernatant was measured for NO by the Griess assay, as 
detailed (Section 2.2.12.1 ). The cells were saved for a parallel western analysis 
(Fig. 6.3). The data were normalized to the control (cells treated only with LPS) 
using Graph Pad Prism software. (A), JPK-101; (B), JPK-109; and (C), JPK-113. 
Results were expressed as mean ± SO of four experiments done in triplicate. 
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dramatic inhibition at 250 ng/ml is not likely to have any biological significance as 
the results would probably be due to the presence of fewer NO producing cells (i.e., 
an indirect consequence of cell death). 
6.3.3 Effects of TwHf compounds on NOS II expression by murine monocytic 
cells 
In an effort to decipher the mechanism whereby these three TwHf 
compounds suppressed NO production in J77 4A.1 cells, total cell extracts from the 
LPS-stimulated cells were analyzed by western blotting for NOS II display. The 
level of induction was normalized against that of LPS-activated J77 4A.1 cells, which 
were not treated with the drug. As illustrated in Figure 6.3 (A and B), at 1 ~g/ml 
JPK-1 01 did not appear to have any suppressing effects on NOS II induction by 
J77 4A.1 cells. However, at higher concentrations, the synthetic compound began 
to show its inhibitory activity in that starting at 2 ~g/ml, it gave rise to a gradual but 
steady decrease in NOS II expression at increasing JPK-1 01 doses. Suppression 
of close to 90% was observed at 12 ~g/ml, the maximum concentration tested. 
Similarly, JPK-1 09 also caused significant attenuation of the NOS II enzyme 
in LPS-treated J774A.1 cells (Fig. 6.3 C and D). In accord with the NO data 
presented earlier (Fig. 6.2 B), NOS II induction was suppressed by nearly 40% that 
of the control (LPS-stimulated cells in the absence of JPK-1 09) at 500 ng/ml, the 
lowest concentration tested. As also shown with JPK-1 01, the response was dose 
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dependent with NOS II expression decreasing as the drug dosage increased. Less 
than 18% of the NOS II expression remained at 6 I.Jg/ml, the highest concentration 
used. 
When JPK-113 was screened for its effects on the induction of NOS II by 
LPS in J77 4A.1 cells, a gradual decrease in NOS II expression was observed with 
approximately 1 0% of the inhibition seen at 25 ng/mL. It was clear from our studies 
that the decrease in NOS II synthesis became more pronounced with higher 
concentrations of JPK-113 leading to 50% inhibition at approximately 100 ng/mL 
(Fig. 6.3 E and F). 
6.3.3.1 Mechanism of action of JPK-109 
The data obtained have revealed the suppressive effects of all three TwHf 
compounds on both NOS II expression and NO production in monocytic cells. In 
the next step, we wanted to explore further how one of these compounds JPK-1 09 
works. There are several possible mechanisms by which the compounds may be 
acting: (1) blocking of the LPS receptor; (2) interfering with receptor signalling; {3) 
preventing gene transcription; (4) inhibiting translation of NOS II mRNA, and (5) 
blocking synthesis or interfering with function of NOS II and/or co-factors required 
by the enzyme. In an effort to gain some insight as to which of these mechanism{ s) 
are likely to be involved in the observed inhibitory effect of JPK-1 09 on NOS II 
expression and NO production, we exposed the cells to the drug at various time 
Figure 6.3: Effects of TwHf compounds on NOS II induction by LPS-
stlmulated J77 4A.1 
The cells, obtained from the experiment described in legends to Figure 6.2, were 
harvested and extracted for total proteins. The lysates were subjected to western 
blotting analysis with a rabbit polyclonal anti-NOS II antibody, as detailed (Section 
2.9.2). Levels of NOS II display were then quantified by densitometry, and 
normalized against that of the control (J774A.1 treated with only LPS) by Graph 
Pad Prism software. (A) and (B), JPK-1 01; (C) and (D), JPK-1 09; and (E) and (F), 
JPK-113. The results are expressed as mean ± SD of three independent 
experiments. 
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points before, and where appropriate, after LPS stimulation. Then, we assessed its 
ability to suppress NOS II expression and NO production in these cells at each of 
the time points. The objective of the experiment was to delineate the time line when 
JPK-109 was active. This information may provide a clue as to which of the 
mechanism(s) mentioned above contributes. As evident in Figure 6.4 A, JPK-109 
was very effective at inhibiting NO synthesis, suppressing near complete NO 
production when given 15 min before or after LPS stimulation. When the cells were 
treated with JPK-1 09 1 h after being activated with LPS, their capability to release 
NO was suppressed by 80-90%. With regards to NOS II expression, the profile was 
relatively similar to that of NO in that when the drug was added to the cells 15 min 
after their activation with LPS, it inhibited NOS II induction by almost 100% (Fig. 6.4 
B). The presence of the drug at 1 h after LPS stimulation was still able to abrogate 
the level of NOS II by 80%. The data, although inconclusive at this point, suggests 
that the drug may exert its action by interfering with the activation of various 
transcription factors involved in signal transduction of NOS II, which may include, 
but are not yet proved, AP-1, NF-IL6 and/or NF-KB. 
6.3.4 Effects of TwHf compounds on TNF-a production by monocytic 
cells 
In addition to examining the modulatory effect of the TwHf compounds on 
Figure 6.4: A time course study of LPS-induced NO and NOS II 
Inhibition In J774A.1 cells by JPK-109 
Murine J77 4A.1 (2.5 x 106 per well) cell was plated in a 6-well plate, and incubated 
overnight. After which time, medium was removed, and the cells were 
supplemented with fresh medium containing 1 J.Jg/ml LPS. JPK-1 09 (3 J.Jg/ml) was 
added to the cells at different time intervals before or after LPS addition. After an 
18-h incubation, cell-free supernatant (1 00 J,JL) was measured for NO by the Griess 
assay while total cell extracts were subjected to western blotting analysis, as 
described (Section 2.2.11 ). Levels of NOS II display were quantified by 
densitometry, and normalized against that ofthe control (J774A.1 treated with LPS 
only) by Graph Pad Prism software. (A), Inhibition of NO production determined by 
the Griess assay. (B), Inhibition of NOS II expression assessed by western 
analysis. The results are expressed as mean ± SO of three quadruplicate (for NO 
measurement), or three single sample experiments (for NOS II investigation). 
A 
c 
0 ;; 
u 
:::s , 
.5 
~ 
.... 
0 
"#. 
B 
r:::: 
0 
~ 
u 
:::s 
"C 
.5 
-U) 
0 
z 
.... 
0 
~ 0 
1 
+ 
+ 
+ 
+ 
-15 0 
+ + 
+ + 
-15 0 
+ 
+ 
+ + + 
+ + + 
5 15 60 240 
+ + + + 
+ + + + 
5 15 60 240 
JPK-109 
+ LPS (1 JJ.g/ml) 
Time (min) 
JPK-109 
+ LPS (1 1-19/ml) 
Time (min) 
158 
both NOS II induction and NO production by macrophages, we wished to investigate 
if these three drugs also had any effects on TN F-a release by monocytic cells. To 
do this, human MM6 and murine J77 4A.1 monocytic cells were exposed to the 
compounds and then to LPS, as described above. Cell-free supernatants were 
evaluated for TN F-a levels by the bioassay with L929 fibroblast cells. 
When JPK-1 01 was screened for its effects on TN F-a production by murine 
J77 4A.1 cells, there was a gradual but steady decrease in cytokine release at 
increasing concentrations of the compound with slight inhibition seen at the lowest 
dose studied (11Jg/ml). Approximately 50% ofTNF-a production was suppressed 
at approximately 4.0 IJg/ml of JPK-1 01 (Fig. 6.5 A). Although an even more drastic 
reduction in cytokine release was observed at higher JPK-1 01 concentrations (at 
81Jg/ml and above), the finding may not have much significance physiologically as 
the TC50 for JPK-101 in J774A.1 cells was about 7.2 IJg/ml (Fig. 6.1 A). The 
inhibitory effect of JPK-1 01 on TN F-a production was also extended to human MM6 
cells, albeit less strongly (Fig. 6.4 B). Similar assessment of JPK-1 09 in the two cell 
lines showed that in both cases 50% of the inhibition was between 4-5 IJg/ml (Fig. 
6.5 C and D). JPK-113 (Fig. 6.5 E and F) was not as effective as the others in 
suppressing TN F-a production in that 50% reduction was not observed in either cell 
line at doses below the TC50 (see Fig. 6.1 E and F). 
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Figure 6.5: Effects of TwHf compounds on LPS-mediated TN F-a production 
by monocytic cells 
(A), (C), and (E), human MM6 and (B), (D), and (F), murine J77 4A.1 cells (2.5 x 106 
per well) were seeded in a 6-well plate and incubated overnight. The next morning, 
old media was removed, and cells supplemented with new media containing 
appropriate TwHf compounds. 45 min later, LPS (1 j.Jg/ml) was added, and cells 
cultured for 24 h. Cell-free supernatants (50 IJL) were measured for TN F-a by the 
L929 fibroblast cytotoxicity bioassay (Section 2.2.13). Untreated or LPS (only)-
treated cells served as negative and positive controls, respectively. TNF-a 
production in cells treated with the TwHf compound was normalized against that 
produced by cells treated with LPS alone. Inhibition of LPS-induced TNF-a 
production by MM6 and J77 4A.1 cells exposed to (A) and (B), JPK-1 01; (C) and 
(D), JPK-1 09; and (E) and (F), JPK-113. The results were analyzed by Graph pad 
Prism, and expressed as mean ± SD of three quadruplicate experiments. 
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6.3.5 Investigation of effect of JPK-101 on MMP production by LPS-
stimulated MM6 cells 
Although inhibitory effects of TwHf extracts on MMP production by 
chondrocytes have been demonstrated (Sylvester eta/., 2001), their effects 
on the synthesis of MMP by monocytic cells were unknown prior to this study. 
To look into this possibility, we studied the effects of JPK-101 on MMP in human 
MM6 cells before and after LPS activation. As with previous experiments, MM6 
cells were treated with various concentrations of JPK-1 01 for 45 min and then with 
LPS. After 24 h, total cell lysates were analyzed for expression of MMP by 
zymography (Section 2.2.18). As illustrated in Figure 6.6, JPK-1 01 did not appear 
to significantly cause any changes in the induction of MMP-2 and MMP-9 by MM6 
cells before or following their exposure to LPS. 
6.4 SUMMARY AND DISCUSSIONS 
In the present investigation, we evaluated effects of one natural (JPK-113) 
and two synthetic (JPK-101 and JPK-109) TwHf compounds on macrophage 
functions by assessing their ability to either stimulate or suppress NOS II 
expression/NO production, TNF-a release, and MMP induction. Preliminary 
experiments were also carried out to elucidate mechanism(s) of actions for the 
compounds. 
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Figure 6.6: Effect of JPK-1 01 on MMP production by LPS-stlmulated 
monocytic cells 
MM6 cells (1 06 per well) were treated with varying concentrations of JPK-1 01 for 45 
min and then with LPS (1 00 ng/mL) for 24 h. Total cell extracts were prepared, and 
the proteins were subjected to zymography analysis, as detailed (Section 2.2.8). 
Levels of enzyme expression was subsequently quantified by densitometry (Section 
2.2.21 ). (A), A zymogram of MMP-2 and MMP-9 gelatinases. Lane 1, untreated 
MM6 cells; Jane 2, 3 tJg/ml JPK-1 01; Jane 3, 6 tJg/ml JPK-1 01; Jane 4, 12 tJg/ml 
JPK-101; Jane 5, LPS; Jane 6, LPS + 31Jg/ml JPK-101; Jane 7, LPS + 61Jg/ml JPK-
1 01; lane 8, LPS + 12tJg/ml JPK-1 01. (B), MMP-2, and (C), MMP-9 expression was 
quantified by a Chemi Imager (Section 2.2.21 ). 
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With respect to induction of NOS II and production of NO, we found that the three 
compounds were all effective in attenuating both NOS II display and NO release in 
a dose-dependent manner, albeit at different dosage. The Tl value, a measure for 
therapeutic efficacy, for NO is 3.32 for JPK-1 01, 5.82 for JPK-1 09, and 2.26 for 
JPK-113 suggesting that all three are potentially useful in the development of 
therapeutic approaches. It should be noted that the Tl values for NO for these 
compounds in murine J77 4A.1 cells are lower than those previously found in our 
laboratory (Barrett, 1998) because of the higher TC50 value. A possible explanation 
for the discrepancy is probably due to differences in the cells used in this current 
work, which made them more susceptible to the drug. Such differences may also 
lead to possible alteration in function ofthe succinate-tetrazolium reductase system 
of the mitochondrial respiratory chain, the key component of the MTT assay 
(Section 2.2. 7), which in turn would lead to differences in the MTT reading. 
With regards to the mechanism of action (s) of these compounds, a time-
course study was conducted for JPK-1 09, and the data showed that this compound 
exhibited near complete suppression of NOS II/NO 15 min after cell activation with 
LPS and approximately 80% inhibition of NOS II induction 1 h after LPS stimulation. 
In addition, the compound remained effective even added 4 h after the cells had 
been treated with LPS. Taken together, the results suggest that JPK-109 inhibits 
NO production not by interfering with the LPS receptor binding and early signalling 
events from the receptor, which usually occurs, respectively, at approximately 5 min 
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and 15-20 min. Rather, JPK-1 09 perhaps targets signalling molecules further 
downstream to prevent activation of various transcription factors (e.g., AP-1 and 
NF-KB) involved in the signalling pathway leading to NOS II induction (Sylvester et 
a/., 2001 ). Obviously, some of these transcription factors are shared by many 
different genes including those for chemokines such as RANTES/CCLS and 
inflammatory cytokines such as IL-1. However, at this point we can only offer these 
possibilities as we do not have any concrete evidence to eliminate one or another. 
Further experimentation is needed: (1) to fully understand the precise mechanism 
of JPK-1 09 action, and (2) to determine which might be the target(s) for this 
chemical compound. Such understanding may also provide important insights into 
the mode of action for JPK-1 01 and JPK-113. 
In addition to suppressing NO synthesis and NOS II induction, our studies 
have also shown that all three compounds could inhibit the release of the pro-
inflammatory cytokine TN F-a by both human and murine monocytic cells following 
their activation with LPS. This effect of the three TwHf compounds is in agreement 
with their use in traditional medicine as anti-inflammatory mediators. Taken 
together, the data obtained from our experiments have provided important insights 
on monocyte functions. First, these TwHf compounds have no "default" effect on 
naive cells but can significantly suppress induction of LPS-induced NOS II as well 
as production of NO and TNF-a reflecting their known anti-inflammatory activity. 
In contrast, JPK-1 09 was not found to have any inhibitory effect on MMP expression 
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in human LPS-activated monocytic cells suggesting that the LPS-triggered 
signalling pathways leading to MMP expression and to production of NO and TN F-
a are distinct. It will be of great interest to investigate other immunoregulatory 
activities of these compounds and possibly piece together the puzzle of how the 
extracts from TwHf has such broad activity against many different inflammatory 
diseases (Section 6.1.2). 
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CHAPTER SEVEN 
INVESTIGATION OF THE EXPRESSION OF INDUCIBLE NITRIC 
OXIDE SYNTHASE AND PKC-ETA EXPRESSION IN MONOCYTE-
DERIVED MACROPHAGES FROM PATIENTS WITH 
INFLAMMATORY DISEASES 
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7.1 INTRODUCTION 
As discussed in Chapter 3 (Section 3.1.1 ), NOS II expression is only induced 
by LPS or cytokines such as TNF-a and INF-y as a result of infection or 
inflammatory diseases. When the presence of NO is no longer needed, the 
expression of NOS II enzyme will be shut off, or NOS 11-expressing cells eliminated 
by apoptosis. Failure to do so can result in tissue damage to the host via 
mechanisms discussed earlier (Section 3.1.3). In fact, it has been shown in a 
number of studies that NO is associated with pathogenesis of a number of 
inflammatory conditions, including lOOM (Suarez-Pinzon et a/., 2001), AIDS-
associated dementia (Adamson eta/., 1999; Vincent eta/., 1999), and RA (St. Clair 
eta/., 1996; Mapp eta/., 2001 ). 
Peroxynitrite, formed from the combination of NO and superoxide, has been 
shown to be in great abundance in islet beta cells of non-obese diabetic mice 
(NOD) (Suarez-Pinzon et a/., 2001 ). However, in mice treated with 
guanidineoethyl-disulphide, a selective NOS II inhibitor, the proportion ofthe beta-
islet cells that were positive for peroxynitrite became significantly decreased after 
the treatment (Suarez-Pinzon eta/., 2001 ). In other studies, cultures of isolated 
beta-islets revealed resident macrophages to be a major source of IL-1, which lead 
to upregulation of NOS II expression and NO production. A consequence of this 
was an increase in beta cell death by apoptosis (Hirasawa eta/., 1997; Reddy and 
Young, 2002). 
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Our investigation of PKC expression in monocytic cells (Chapter 5) revealed 
that PKC-11 was completely deficient in the human cells and that NOS II could not 
be induced in human mononuclear phagocytes following exposure to LPS. 
Subsequent transfection studies of human monocytic MM6 cells with PKC-11 
resulted in NOS II expression and NO production following endotoxin stimulation 
(Chapter 5). Therefore, these data suggested that PKC-11 expression may be 
required prior to the induction of the NOS II gene in human monocytic cells. In light 
of these findings, we set out to further test this hypothesis to determine whether we 
could establish a correlation between PKC-11 and NOS II in clinical situations. We 
chose to conduct the investigation in AIDS/HIV-infected patients. The choice 
stemmed from earlier findings connecting elevated NO levels and the inflammatory 
response seen in patients with this disease (Torre eta/., 1996). It was shown that 
elevation in NO was evident, especially in AIDS/HIV-infected patients succumbed 
to opportunistic infections (Torre eta/., 1996). Although we subsequently found an 
increase in plasma NO from AIDS/HIV-infected patients (Section 7.2.1 below), the 
work could not be continued due to great limitation in obtaining a sufficient number 
of peripheral blood monocytes from these patients. Therefore, we pursued further 
investigation with samples from arthritis patients. This model was plausible 
because of findings from several studies demonstrating upregulation of NO 
production in inflammatory arthritis patients (Mapp et a/., 2001; St-Ciare et a/., 
1995). For example, St-Ciare eta/. (1995) reported elevation of NOS II expression 
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in PBMC in RA patients. Mapp eta/. (2001) showed that 3-nitrotyrosine, a footprint 
marker of peroxynitrite, along with other NO-derived intermediates, was found in 
macrophages in the inflamed synovium. Also, elevated NO levels have been 
associated with an increase in apoptosis of the cells lining the synovial layer and 
articular cartilage (van't Hof eta/., 2000). Our decision to study this disease was 
strengthened by findings from studies in animal models which supported an 
association between NO and joint swelling/destruction in arthritis. In these 
investigations, the NOS inhibitor HNG-monomethyl L-arginine monoacetate was 
shown to lead to amelioration of adjuvant-induced (Stefanovic-Racic eta/., 1995) 
and virus-induced (McCartney-Francis eta/., 2001) arthritis. 
RA is one of the most common human autoimmune diseases characterized 
by inflammation of the joints (prevalence of 1 %). The principal pathological 
features of joint inflammation include invasion of leukocytes, their proliferation in the 
synovium and accumulation of peripheral mononuclear cells in the synovial fluids. 
It is thought that infiltration of these cells results in overproduction of TN F-a and 
IL-1, as well as other inflammatory mediators including NO, MMP, and PGE2 
(Abramson et a/., 2001 ). Dysregulation of these molecules eventually leads to 
damage to the joints. In some cases, extra articular disease may be manifested, 
and survival impaired. 
The spondyloarthropathies (SpA) are a group of inflammatory joint diseases 
characterized by an involvement of both synovium and entheses leading to spinal 
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and peripheral arthritis (Keat and Arnett, 2001 ). Although they were once 
considered as "variants" of RA, SpA are now known to be entities distinct from RA 
for three major reasons. First, SpA primarily involve axial inflammation and to a 
lesser extent, articular and extra-articular manifestations. Second, SpA patients are 
generally serologically negative for the rheumatoid factor (RF). Third, in most 
cases there is a strong association with MHC class I, HLA-827. Ankylosing 
spondylitis (AS), psoriatic arthritis (PsA), Crohn's, and Reiters are the principal 
clinical entities of SpA. AS is an inflammatory arthropathy that preferentially targets 
the axial skeleton, and has a male prevalence of 3: 1. Systemic manifestations of 
this disease occur in one third of the patients. It is estimated that nearly 30% of 
patients with psoriasis, with the disease itself having a prevalence of 1-3% adults, 
eventually develop PsA (Smiley, 1995). 
Majority of the data presented and discussed in this chapter have been 
published in the Journal of Rheumatology (Pham eta/., 2003b). 
7.2 PATIENTS 
Blood samples were obtained after written consent had been given, and the 
project was approved by the Human Investigation Committee (Memorial University). 
Laboratory investigators were blind to the diagnosis until completion of all analyses. 
170 
7.2.1 AIDS and HIV-infected 
Serum samples from thirteen patients with AIDS or infected with HIV were 
used in the evaluation of NO levels, and compared with values from a control group 
(see below). 
7 .2.2 Inflammatory arthritides (lA) 
Twenty patients (12 females and 8 males, aged 24-76), who fulfilled the 
American College of Rheumatology Criteria (Arnett eta/., 1988) were recruited for 
this study. Fourteen of these individuals (aged 36 to 76) had RA, while the other 
six had SpA (peripheral synovitis, aged 24 to 63). The SpA group was made up of 
three patients with AS and three with PsA. Based on clinical assessments of the 
number of swollen/tender joints at the time of study, patients with RA (RF-positive) 
and PsA (RF- negative) were further categorized as having severe (>10 active 
joints) (active disease), or mild inflammation(< 5 active joints). The patients with 
AS were classified as being either clinically quiescent or having inflammation. 
One patient in the inflammatory arthritic group did not receive any treatment 
(5%). 70% of the patients received Methotrexate (MTX), and 55% were on steroids 
(Table 7.1 ). 
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7 .2.3 Control groups 
For the evaluation of plasma NO in patients afflicted with AIDS or HIV 
infection, plasma samples from 14 healthy volunteers were obtained, and analyzed 
in the same way as the patient samples. For the study with lA patients, nine healthy 
volunteers (9 females, aged 22-48) and thirteen patients (8 females and 5 males, 
aged 47 to 81) with osteoarthritis (OA), who fulfilled the American College of 
Rheumatology Criteria for OA, were recruited. Most, if not all OA patients, received 
only non-steroidal anti-inflammatory drugs (NSAIDS, e.g., rofecoxib). 
7.3 RESULTS 
7.3.1 Assessment of NO in the plasma of HIV-infected patients 
In light of findings suggesting apparent involvement of NO in the 
inflammatory process associated with AIDS and its related disorders (Adamson et 
a/., 1999; Vincent et a/., 1999), we evaluated the levels of NO in serum samples 
from thirteen AIDS or HIV-infected patients by Griess assay. As shown in Figure 
7.1, AIDS patients or those infected with HIV, as a group, had elevated NO levels 
(70.1 ± 21. 71JM) in the circulation compared to the healthy control group (53.4 ± 6.2 
IJM). However, it should be noted that there is a weak difference in NO levels 
among the patients, as depicted by the high standard deviation value (21. 7 IJM). 
Many of these patients had circulating NO within the normal range, but four of them 
Figure 7.1: Assessment of plasma NO in patients with 
AIDS/HIV -Infection 
NO was measured in 50 J,JL of plasma from healthy volunteers (n = 14) or patients 
with AIDS/HIV-infection (n = 13). Nitrate was first reduced by nitrate reductase to 
nitrite, which was then measured by the Griess assay (Section 2.2.12.2). Statistical 
analysis with unpaired Student's t-tests showed a significant elevated plasma NO 
in the patients (70.2 ± 21.7 J,JM) when compared to that in the healthy subjects 
(53.42 ± 6.3 J,JM). The p from the analysis was 0.0165. 
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had a much higher NO value. 
7.3.21nvestigation of plasma NO in lA patients 
NO levels in plasma from patients with lA (RA, n = 14 and SpA, n = 6), OA 
(n = 13), and healthy individuals (n = 9) (Fig. 7.2) were assessed by measurement 
of its stable products nitrite and nitrate using the Griess assay. As evident, all ten 
lA patients (8 RA and 1 SpA) with severe inflammation/active disease (Fig. 7 .2, 
severe SpA and RA) had highly elevated NO (237.8 ± 34.41JM) relative to that seen 
in the 13 patients with OA (126.9 ±40.91JM) (Fig. 7.2, OA), or in healthy individuals 
(131 ± 18.91JM) (Fig. 7.2, healthy). Similarly, ten lA patients (6 RA and 4 SpA) with 
mild inflammation (<5 swollen joints) had slightly higher plasma NO (145.7 ± 20.2 
IJM) as that in the two control groups (OA and healthy). This elevation was not 
statistically significant by unpaired two-tailed Student's t-tests (p=0.11 and p= 0.53, 
respectively). It is clear from the data that the levels of NO in the circulation are 
strongly correlated with the degree of joint inflammation, as the severely inflamed 
had higher plasma NO than the mildly inflamed, who in turn had higher levels than 
osteoarthritis. It should be noted that the plasma NO previously observed in the 
healthy control individuals tested in parallel with the HIV-infected/AIDS patients 
(Fig. 7.1) was lower than that for the healthy group used as a control group in the 
study of lA patients. The discrepancy is likely due to different experimental 
conditions. During the course of the investigation (from HIV-infected/AIDS to lA 
Figure 7.2: Elevated plasma NO In lA patients 
NO was measured from 50 IJL of plasma from healthy volunteers (n = 9), RA (n = 
14), SpA (n = 6), and OA (n = 13). Nitrate was first reduced to nitrite by nitrate 
reductase and the total nitrite was then quantified by the Griess assay. SpA 
patients are inflammatory arthritides, who are serologically RF-negative of "severe" 
(minimum of 5 swollen joints) or "mild" (< 5 swollen joints) inflammation. Each dot 
represents a patient and the mean(± SO) indicated. 
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Figure 7.3: NOS II expression In MOM from lA patients with severe 
inflammation 
MOM from healthy individuals and arthritis patients were isolated, cultured and 
assessed for NOS II expression by RT -PCR using gene specific primers. GAPDH 
amplified from the same samples was used to control for sample loading. PCR 
products (91JL) were separated on a 1% EtBr-containing agarose gel, visualized 
by a UV light source, and the bands digitally photographed. 0.5 IJg of 100 bp DNA 
ladder was loaded as molecular markers. Lane 1 , recombinant NOS II fragment 
(excised from pBABE) served as a positive control; lane 2, case 42 (PsA, severe); 
lane 3, case 39 (AS, inflammation); lane 4, case 38 (AS, clinically quiescent); lane 
5, case 37 (AS, clinically quiescent); lane 6, case 29 (RA, severe); lane 7, case 28 
(RA, severe); lane 8, case 26 (RA, mild); lane 9, case 24 (RA, mild); lane 10, case 
23 (RA, severe); lane 11, case 22 (OA, no inflammation); lane 12, case 18 (OA, no 
inflammation); lane 13, case 14 (OA, no inflammation); lane 14, case 11 (OA, no 
inflammation); lane 15, case 4 (healthy); lane 16, case 2 (heathy}, and lane 17, 
case 1 (healthy). 
1 2 3 4 5 6 7 8 9 10 11 1213 14 15 16 17 
• NOS II 
""-- -- -' 
... 264bp 
GAPDH 
_____ .. _________ _ 
... 400bp 
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patients), the assay was modified in a hope to achieve the optimal conditions for the 
conversion of nitrate to nitrite by nitrate reductase. In the end, parameters such as 
longer incubation time and higher enzyme concentrations were adopted. 
7.3.3 Association between plasma NO, NOS II, and PKC-11 in peripheral blood 
monocyte-derived macrophages 
In Chapter 5, we showed that only after human monocytic MM6 cells were 
transfected with PKC-11 were they capable of expressing NOS II and releasing NO 
in the culture media following LPS stimulation. From these data we proposed that 
PKC-11 expression had to precede/or accompany NOS II expression in human 
monocytic cells, at least in the cell line model we studied. Therefore in this chapter, 
we wished to test this hypothesis to see if this could also be applicable to in vivo 
situations. 
In Figure 7.2, we showed that plasma NO levels were significantly elevated 
in RA patients with active disease, and that the absolute levels were correlated with 
progression of the conditions. Subsequently in Figure 7. 3, we showed that RA and 
SpA patients with active disease (cases 23, 28, 29, and 42; Table 7.1) strongly 
expressed NOS II mRNA, but healthy individuals (cases 1, 2, and 4) or those with 
OA (cases 11, 14, 18, and 22; Table 7.1) did not. Also, MOM cells from lA patients 
with normal circulating NO did not express NOS II (cases 24, 26, and 38; Table 7.1 ). 
The findings, thus, suggest that the elevation of plasma NO was associated with 
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NOS II expression in MOM from these patients. Therefore, in the next step, we 
wanted to determine if there was any correlation in expression between NOS II and 
PKC-11 in MOM from these patients. To do this, we screened for the presence of 
PKC-11 in MOM by RT -PCR. Figure 7.4 represents data from one such experiment. 
PKC-11 was found to be highly expressed in RA patients with active disease (cases 
23, 28, 29, and 42; Table 7.1 ). In sharp contrast, healthy volunteers (cases 2 and 
4) and OA patients (cases 14, 18 and 22), who lacked NOS II, were also negative 
for PKC-11. Also, as seen in the cases of NOS II, lA patients who did not have 
active disease, and who had normal circulating NO did not express PKC-11 (cases 
26, 37, and 38). Taken together, only in lA patients with severely active disease did 
we observe: (1) a statistically significant (p < 0.0021) up-regulation of NO in plasma 
compared to that seen in the control healthy individuals, and patients with OA, or 
with mildly inflammatory RA (Fig. 7.2) and (2) a constitutive co-expression of PKC-11 
and NOS II in MOM from severely affected lA patients. These data were fully 
summarized in Table 7.1. 
Interestingly, one anomaly to our hypothesis was observed in Patient 23 
(Table 7.1 ). Clinical assessments of the number of tender and swollen joints had 
shown that this particular individual had severe inflammation with more than 10 
active joints. Plasma NO level in this patient (227 IJM) was notably elevated when 
compared to that of the control individuals. In accord with this finding, RT -PCR 
analysis showed the expression of NOS II in MOM. However, PKC-11 appeared to 
Figure 7.4: Display of PKC-11 mRNA In MOM from lA patients with 
severe inflammation 
MOM from healthy individuals and arthritis patients were isolated, cultured and 
assessed for PKC-11 expression by RT -PCR using gene specific primers. GAPDH 
amplified from the same was used as a loading control. PCR products (9 IJL) 
were separated on a 1% EtBr-containing agarose gel, visualized by a UV light 
source, and digitally photographed. 100 bp DNA ladder (0.5 IJg) was loaded as 
molecular markers. Lane 1, no-template PCR (negative control); lane 2, case 42 
(PSA, severe); lane 3, case 39 (AS, inflammation); lane 4, case 38 (AS, clinically 
quiescent); lane 5, case 37 (AS, clinically quiescent); lane 6, case 29 (RA, severe); 
lane 7, case 28 (RA, severe); lane 8, case 26 (RA, mild); lane 9, case 25 (RA, 
severe); lane 10, case 24 (RA, mild); lane 11, case 23 (RA, severe); lane 12, 
recombinant PKC-11 fragment (excised from pks1. PKC-11 plasmid); lane 13, case 
22 (OA, no inflammation); lane 14, case 18 (OA, no inflammation); lane 15, case 
14 (OA, no inflammation); lane 16, case 4 (healthy), and lane 17, case 2 (healthy). 
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Table 7.1: mRNA co-expression of NOS II and PKC-r) is correlated 
with elevated plasma NO in lA patients 
F, female; M, male; N/A, not applicable; DMARD, disease modifying anti-rheumatic 
drug; N, no; Y, yes; N/0, not determined; OA, osteoarthritis; RA, rheumatoid 
arthritis; MTX, methotrexate; SpA, peripheral spondyloarthropathies; AS, 
ankylosing spondylitis; PsA, psoriatic arthritis. 
Subject (ID #) 
1 (001) 
2 (002) 
3(046) 
4(047) 
5(048) 
6 (057) 
7(058) 
8(061) 
9 (062) 
10(006) 
11 (007) 
12 (009) 
13(020) 
14(025) 
15(027) 
16(028) 
17(029) 
18 (032) 
19(034) 
20 (035) 
21 (037) 
22 (038) 
23 (004) 
24 (005) 
25(017) 
26 (019) 
27(021) 
28 (023) 
29 (030) 
30 (031) 
31 (053) 
32 (054) 
33 (055) 
34 (056) 
35 (059) 
36 (060) 
37(011) 
38(012) 
39 (013) 
40(018) 
41 (022) 
42 (026) 
Table 7.1 : Transcriptional co-expression of NOS II and PKC- TJ with elevated 
plasma NO in patients with inflammatory arthritis 
AGE SEX 
26 F 
42 F 
22 F 
25 F 
32 F 
40 F 
44 F 
48 F 
43 F 
54 F 
76 M 
58 F 
81 F 
49 F 
56 M 
60 M 
61 F 
47 F 
48 F 
55 F 
50 M 
63 M 
57 F 
39 F 
36 M 
44 M 
76 F 
54 M 
46 F 
51 F 
50 F 
54 F 
60 M 
52 F 
59 F 
75 F 
60 M 
24 M 
36 M 
37 M 
33 F 
63 F 
Healthy 
Healthy 
Healthy 
Healthy 
Healthy 
Healthy 
Healthy 
Healthy 
Healthy 
OA 
OA 
OA 
OA 
OA 
OA 
OA 
OA 
OA 
OA 
OA 
OA 
OA 
RA 
RA 
RA 
RA 
RA 
RA 
RA 
RA 
RA 
RA 
RA 
RA 
RA 
RA 
SpA(AS) 
SpA(AS) 
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SpA(PsA) 
SpA (PsA) 
SpA (PsA) 
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N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
N/A 
Not inflamed 
Not inflamed 
Not inflamed 
Not inflamed 
Not inflamed 
Not inflamed 
Not inflamed 
Not inflamed 
Not inflamed 
Not inflamed 
Not inflamed 
Not inflamed 
Not inflamed 
Severe 
Mild 
Severe 
Mild 
Severe 
Severe 
Severe 
Mild 
Severe 
Severe 
Mild 
Severe 
Mild 
Mild 
Clinically quiet 
Clinically quiet 
Inflamed 
Mild 
Mild 
Severe 
Steroids 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
Prednisone 
Prednisone 
N 
N 
Prednisone 
N 
N 
Prednisone 
N 
Prednisone 
N 
Prednisone 
Prednisone 
Prednisone 
Prednisone 
N 
Prednisone 
N 
N 
Prednisone 
DMARD 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
N 
MTX 
MTX 
MTX 
N 
MTX 
N 
MTX 
MTX 
MTX 
MTX 
N 
MTX 
MTX 
MTX 
MTX 
N 
MTX 
N 
MTX 
MTX 
N 
NO(!!M) 
143.2 
150.4 
153.0 
149.8 
122.4 
119.6 
125.6 
100.5 
115.0 
146.8 
168.0 
168.0 
192.4 
97.6 
83.6 
164.0 
97.6 
122.8 
87.6 
128.4 
92.4 
100.4 
227.2 
154.0 
289.2 
143.2 
172.2 
248.4 
226.2 
136.6 
265.7 
241.3 
115.0 
224.7 
145.0 
128.6 
148.4 
148.4 
205.6 
164.0 
179.3 
200.0 
PKC·11 
N 
N 
N/D 
N 
N/D 
N 
N 
N 
N 
N 
N 
N 
N/D 
N 
N 
N/D 
N 
N 
N 
N 
N 
N 
N 
N 
y 
N 
N/D 
y 
y 
N/D 
y 
y 
N 
y 
N 
N 
N 
N 
y 
N/D 
N/D 
y 
N/A, not applicable; N/D, not done. 
NOS II 
N 
N 
N/D 
N 
N/D 
N 
N 
N 
N 
N 
N 
N 
N/D 
N 
N 
N/D 
N 
N 
N 
N 
N 
N 
y 
N 
y 
N 
N/D 
y 
y 
N/D 
y 
y 
N 
y 
N 
N 
N 
N 
y 
N/D 
N/D 
y 
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be completely absent from these cells. Subsequently, we repeated the experiments 
for this particular case and the results remained the same as that we had originally 
obtained. At the present time, we have no clear-cut explanation as to why this was 
the case. However, there is some evidence in the literature suggesting that in some 
patients with inflammatory diseases who receive a very high dose of steroids, 
especially prednisone, in combination with disease-modifying antirheumatic drugs 
such as methotrexate, there is an increased total PKC activity relative to those not 
receiving this kind of combination treatment. This would, therefore, imply that the 
increased in total activity of the kinase would lead to a higher turn-over of total PKC 
expression. This observation may offer a plausible explanation for the absence of 
PKC-11 in macrophages from this particular patient. Having said that, it is prudent 
to investigate more patients with similar treatment to determine whether this is 
indeed the case. 
7.4 SUMMARY AND DISCUSSIONS 
Here, we have shown that on average, HIV-infected/AIDS patients have 
elevated circulating NO compared to that of healthy controls, with some patients 
displaying significantly higher levels of NO than normal. However, because of the 
large standard deviations in the NO values between the different patients relative 
to that seen in the healthy group, it is rather difficult to evaluate any significance of 
the elevation of NO with respect to its pathophysiology in rheumatic diseases. 
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Unfortunately, it was not possible for us to continue with this work due to the 
unavailability of the material. 
The elevation of NO was very pronounced in the circulation of lA patients with 
severe disease. Specifically, the data showed that the severely affected individuals 
had significantly elevated serum NO compared to OA patients. The latter, in turn, 
had comparable NO levels to healthy individuals (Fig. 7 .2). These elevations in NO 
levels appeared to correlate with circulating monocyte expression of the NOS II 
gene as its mRNA accumulation was also increased in these same patients (Fig. 
7.3 and Table 7.1 ). Although up-regulation of NO in plasma of individuals with RA 
has been reported previously (Ueki eta/., 1996), our findings are novel from two 
aspects. First, we were able to show that the elevated NO levels were only 
observed in patients with active disease, which is defined by a tender joint score of 
ten or greater. lA patients, with mild inflammation, had comparable levels of NO to 
those found in healthy people or in OA patients. Second, to the best of our 
knowledge, this is the first time that a positive correlation between PKC-11 and NOS 
II expression by MOM has been reported in arthritic patients. Specifically, the two 
genes were either both expressed or not expressed at all. Our hypothesis 
proposing that PKC-11 expression is required prior to or at the same time as NOS 
II was supported by the findings of all but one cases studied. The results from case 
23 contradicted our hypothesis in that this individual with severely active RA 
showed elevation in plasma NO and NOS II expression in peripheral MOM. 
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However, in contrast to the other patients in the same category, who also had 
similar active disease and were double positive for the two genes, this patient did 
not appear to express PKC-11 in MOM. 
Although TNF-a and ll-1 have long been considered as attractive targets 
for pharmacologic intervention and gene therapy for inflammatory diseases like 
arthritis, NOS II has also begun to gain attention as yet another candidate for the 
development of novel treatments for the disorders. In recent years, many 
compounds designed by different groups have been used to study their effects on 
the expression of NOS II. Some of these include: (1) L-arginine derivatives (e.g., 
HNG-monomethyl L-arginine monoacetate [L-NMMA]) that compete at the active site 
(Weinberg eta/., 1994; Amin eta/., 1999), (2) metabolic inhibitors (e.g., citrulline 
analogues, aminoguanidine) (Salerno et a/., 1995), and (3) inhibitors of 
dimerization, as NOS monomer is inactive (Xie eta/., 1996; Ohtsuka eta/., 2002). 
In some of these studies, the NOS inhibitors were shown to have direct anti-
inflammatory effects leading to amelioration of adjuvant or virus-induced arthritis. 
However, as NO does have other physiological roles (endothelium-relaxing factor 
and neurotransmitter) besides that of an inflammatory mediator, therapeutic 
approaches with these compounds may have severe side effects as these 
compounds are likely to suppress the effects of all three NOS. Obviously, the 
ultimate goal would be to suppress the over-production of NO in arthritis-affected 
joints and peripheral blood cells without compromising other important functions of 
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NO. 
In light of the fact that PKC plays an essential role in the signal transduction 
of various cellular processes including gene expression, several reports have 
surfaced in the literature proposing a role of PKC inhibitors (benzylidene derivative 
and staurosporine) as a possible anti-rheumatic agent in that they led to attenuation 
of IL-1a or PMA-induced IL-1(3 production by synovial cells from RA patients 
(Watanabe eta/., 1993). In addition, PKC inhibitor gold sodium thiomalate (GSTM) 
employed as a therapeutic agent for RA for many years has been shown by 
Hashimoto and colleagues (Hashimoto eta/., 1994) to suppress mitogen-induced 
T cell proliferation suggesting a role of PKC in modulation of the adaptive immune 
response in arthritis. Similarly, in an experimental model of adjuvant-induced 
arthritis, PKC inhibitors debromo-hymenialdisine (a catalytic site inhibitor) 
(DiMartino eta/., 1995) and Ro 32-0432 (Birchall eta/., 1994) have been shown to 
alleviate rat paw swelling via suppression of the proliferation of autoreactive 
lymphocytes. However, whether these PKC inhibitors have any effects on 
mononuclear phagocytes was not known as they were not investigated in these 
studies. 
In this chapter, we have shown that MOM from all but one patient with active 
inflammatory arthritis (RA and SpA) expressed both NOS II and PKC-1"). The cells 
are indicative of the inflammatory state of these patients, and their presence in the 
circulation adds to the systemic burden of this disease and should not be left 
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untreated. Therapeutic treatments, conventional or otherwise, appear to be 
uneffective in preventing/controlling the activation of these cells. These findings 
may pave the way for future investigation of PKC-11 as a potentially therapeutic 
target for the treatment of inflammatory conditions such as RA, where 
overproduction of NO and/or persistent expression of NOS II by peripheral blood 
monocytic cells have been shown to contribute to disease pathogenesis (Cawston, 
2000; Perkins eta/., 1998). 
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CHAPTER EIGHT 
INVESTIGATION OF THE CORRELATION OF PLASMA NITRIC 
OXIDE/ MONOCYTE NITRIC OXIDE SYNTHASE II AND CLINICAL 
SYMPTOMS IN INFLAMMATORY ARTHRITIS PATIENTS 
RECEIVING CYTOKINE-TARGETED THERAPIES 
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8.1 INTRODUCTION 
It is believed that the chronic inflammatory reaction in the joint synovium 
associated with conditions like RA and PsA is attributed to over-production of pro-
inflammatory cytokines such as TNF-a, IL-1, chemokines, MMP, and free radicals 
like NO. These molecules, especially TNF-a, play an important role in initiating 
and perpetuating inflammatory and destructive processes within the rheumatoid 
joint. 
In vivo, TN F-a is the most rapidly produced pro-inflammatory cytokine, with 
serum levels detectable in mice as early as 30 min following induction by mitogenic 
stimuli (Tracey eta/., 1986). Perhaps the initial surge of TNF-a comes from 
cleavage of membrane bound TNF-a on activated macrophages, T cells and 
neutrophils by TNF converting enzyme TACE/ADAM17 (Black et a/., 1997). 
Subsequent de novo synthesis by these cells ensures steady levels of the cytokine. 
Because of its early release, TN F-a is though to regulate expression of other late 
cytokines/chemokines, including IL-1, IL-6, RANTES, and IL-8. This notion is 
supported by studies where addition of anti-TNF antibodies to in vitro cultures of a 
representative population of cells derived from diseased joints led to inhibition of 
the aforementioned cytokines/chemokines (Brennan eta/., 1989; Feldmann eta/., 
1996). In addition, the apparent link between TNF-a and disease pathogenesis 
stemmed from its ability to up-regulate intercellular adhesion molecule-1 (ICAM-1) 
and vascular cell adhesion molecule-1 (VCAM-1 ), both of which are involved in 
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lymphocyte trafficking to inflammatory lesions (Wakefield et a/., 1991 ). Studies 
such as these, together with the observation of upregulation of TNFJTNFR on 
synovial tissues from patient with rheumatic disease ( Chu eta/., 1991 ) lend support 
to a pathogenic role of TN F-a in RA; hence, its promise as a therapeutic target 
candidate for the disease. Since then, various agents targeting either TN F-a (e.g., 
Remicade™ [infliximab]) or TNF receptor (e.g., Enbrel™ [etanercept]) have been 
adopted as novel treatments for RA. Currently, etanercept and infliximab, which 
are to be administered in conjunction with MTX, one of the most commonly used 
DMARD, have been approved for the treatment of RA. In earlier studies, both 
drugs were shown to be effective in patients with other rheumatic diseases 
including AS and PsA (Brandt eta/., 2000; Van den Bosch eta/., 2001 ). lnfliximab 
is a chimeric (mouse Fv1, human lgG1) monoclonal antibody which binds to both 
soluble and membrane forms of TN F-a with high affinity (Ka = 1 o-10 M) (Knight et 
a/., 1993). The medication is believed to help by reducing the progression of 
structural damage and improving physical function .. 
In addition to TNF-a, IL-1 is also thought to play an important role in 
pathophysiology of RA by causing cartilage destruction through inducing the loss 
of proteolgycan and stimulating bone resorption (Patwari eta/., 2003; Abramson 
and Amin, 2002). Results from randomized clinical trial studies have shown that 
arthritic patients receiving an IL-1 blocker show improvement in daily physical 
activities and reduction of symptoms including joint inflammation and stiffness when 
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compared to those receiving only the placebo (Garces, 2001 ). As a result, anakinra 
(Kineret™) has been recently added to the list of medications for the management 
of RA. Anakinra is a recombinant and non-glycosylated form of the IL-1 Ra that 
directly interferes with the binding of IL-1 to the receptor. Both anakinra and 
infliximab are often prescribed when the patient has had little or no response to one 
or more prescribed DMARD. 
In rheumatic diseases, several clinical and laboratory parameters are used 
to assess efficacy of a therapy in patients. Of note, a count of swollen and tender 
joints and a value of the erythrocyte sedimentation rate (ESR) are usually included 
in routine assessment of a patient's response to a particular treatment. ESR is a 
measure of the distance red blood cells (RBC) travel to settle at the bottom of a 
tube of blood during one hour (Wollheim, 1996). Factors that affect the ESR of 
RBC include: (1) size of cells; (2) viscosity of plasma, and (3) repellent forces 
between negatively charged red cell surfaces. The normal range for ESR is 0-15 
mm/h in male and 0-20 mm/h in female. The presence of asymmetric proteins, 
especially fibrinogen and gamma globulins, allows for the formation of rouleaux 
(cells moving closer together) that cause the cells to settle more rapidly, hence, 
giving rise to an increased ESR value. Clinically, the ESR is often used as an 
indirect marker of inflammation, as it is often elevated in inflammatory diseases 
such as RA. In certain cases, elevation in ESR has been observed in patients with 
neoplastic diseases (e.g., Hodgkin's, infertvos) (Cawston, 2000). 
189 
During the course of our initial investigation for a correlation between plasma 
NO, PKC-11, and NOS II in lA patients with active disease, we made a novel 
observation in case 43. Despite experiencing only mild inflammation in the joints, 
this RA patient still had highly elevated circulating NO (289.2 IJM), and expressed 
both NOS II and PKC-11 in MOM. Retroactive consultation with the collaborative 
rheumatologist led to the discovery that this patient was on infliximab (see above) 
therapy, which targeted TNF-a function. Therefore, we screened seven more 
patients to determine if the initial finding with case 43 (see below) was a 
consequence of a random observation, or may reflect a real trend. This second 
screening eventually led to another evaluation of NO in plasma and NOS II and 
PKC-11 in MOM from a different group of lA patients. This approach stemmed from 
the fact that one of the seven patients (case 50, see below) was receiving anakinra 
instead of infliximab, and the findings from this particular case, warranted further 
experimentation. 
A manuscript containing the data presented in this chapter is to be submitted 
to a peer-reviewed journal for possible publication. 
8.2 PATIENTS 
A total of fifteen lA patients were studied. Seven ofthem received infliximab, 
while the other eight anakinra. Clinical assessments of these patients after the 
therapy revealed that all of these individuals experienced only mild inflammation, 
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as determined by the swollen joint count of five or fewer. In addition, in response 
to the therapy the patients also exhibited reduction in the ESR value. 
Plasma and MOM were obtained prepared from each case, as described 
(Section 2.2.3). Plasma samples was used in assessment of circulating NO levels. 
8.3 RESULTS 
8.3.1 Disease activity following therapy with lnflixlmab 
Before and after therapy, the patients were assessed for the number of 
swollen and tender joints as well as the ESR. Figure 8.1 shows that in all eight 
patients there is a significant reduction in the ESR value after the therapy relative 
to that before the therapy. It should, however, be noted while the ESR in many of 
the cases studied did return to normal, that of cases 45 and 49 were still relatively 
high compared to the normal values (see above). In addition, clinical assessment 
of the number of swollen and tender (effused) joints from these patients after the 
therapy and at the time of sample collection showed a significant decrease in the 
number of effused joint count. As a results, these patients were classified as having 
mild inflammation with no active clinical disease and were considered excellent 
responders to the treatment. 
Figure 8.1: Improvement of ESR value In lA patients receiving 
infliximab 
Eight patients with inflammatory arthritis were measured for ESR before and after 
the therapy. In healthy individuals, the ESR value is 0-15 mm/h in male and 0-20 
mm/h in female. ESR is an indirect indicator of inflammation, and is often used as 
a measure of treatment efficacy in RA patients 
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8.3.2 Effect of infliximab on plasma NO, NOS II, and PKC-11 expression 
in MOM from lA patients 
In light of the unexpected results obtained for case 43, we performed 
similar experiments in seven more patients (cases 44-50) with lA (5 RA and 2 SpA), 
who were thought to have been receiving the same therapy. As before, we 
evaluated levels of NO in the plasma samples. As seen in case 43, despite showing 
improvement in the inflammatory status (e.g., ESR) after the therapy, all seven 
patients still had elevated serum NO levels (256.2 ± 41.3 IJM) (Fig. 8.2), and these 
were significantly higher than those seen in OA patients (Fig. 7.1) or healthy 
individuals (143.8 ± 12.5 IJM). In certain cases where we had enough MOM 
generated for the experiments, we evaluated the presence of NOS II expression to 
see if the elevation of NO in the circulation might be attributed to the monocyte NOS 
II gene being transcriptionally active. As shown in Figure 8.3 A, cases 46 and 49, 
but not 48, were positive for NOS II similar to what we had observed previously with 
case 43. In subsequent screening of PKC-11 in MOM from these patients (Fig. 8.3 
B), we found that all three cases 46, 48 and 49 were positive for PKC-11. This means 
that in a total of five cases that we tested (cases 43, 46, 48, 49 and 50. The data 
from case 50 are to be documented separately below), MOM from three of them 
expressed both PKC-11 and NOS II, and this was consistent with the elevated 
plasma NO levels we had observed (Table 8.1 ). Incidently, the level of expression 
Figure 8.2: Plasma NO levels In lA patients receiving lnfllxlmab 
NO was measured by assessments of nitrite and nitrate from 50 ~ L of fresh plasma 
from healthy or patient volunteers on infliximab therapy. Plasma nitrate was first 
reduced by nitrate reductase to nitrite, which was then measured by the Griess 
assay. Each dot represents a case and the mean ± SD is indicated. Statistical 
analyses were done using unpaired Student's t-tests (p = 0.016). 
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Figure 8.3: Expression of NOS II and PKC-r, in MOM from patients 
receiving infllximab 
RNA was extracted from MOM , and 2 I.Jg of total RNA was used in amplification by 
RT -PCR with gene-specific primers. A sample of water (W) in place of test eDNA 
was used as a negative control, while that of a recombinant NOS II or PKC-1") gene 
fragments served as positive control (PS). PCR products (9 IJL) were 
electrophoresed on a 1% EtBr-containing agarose gel, and the bands visualized 
were digitally photographed. The positive signals showed bands of the expected 
sizes for (A), NOS II (264 bp) and (8), PKC-1") (259 bp). 
A 
W 43 46 48 49 PS 
NOS II ~264bp 
B 
W 43 46 48 49 PS 
PKC-11 ~259bp 
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was shown to be comparable between the patients. Interestingly, an anomaly was 
also observed in this group. Despite showing moderately high NO levels in the 
plasma (226.2 IJM), MOM from case 50 was completely negative for both NOS II 
and PKC-11 gene. Subsequently, it was revealed that this individual was not 
receiving infliximab but anakinra instead. As discussed previously, anakinra 
targets IL-1 function. This finding lead us to examining seven more patients 
receiving this same therapy to ascertain if the data reflects a change in cell function 
as a result of IL-1 blocking. 
8.3.3 Disease activity following therapy with anakinra 
As was the case with the infliximab-treated patients, the individuals receiving 
anakinra also demonstrated improvement in both swollen joint count and the ESR 
value (Fig. 8.4). Prior to the therapy, all had significantly high ESR value ranging 
from 30 to 85. However, in response to the treatment all showed a dramatic drop 
in the ESR. Except in cases 54, 56, and 57, the post-therapy value was 
comparable to that in healthy adults. In addition, clinical assessments for evidence 
of joint inflammation at the time sample collection allowed for the determination by 
the attending rheumatologist that the patients were doing well clinically relative to 
how they were before the therapy. 
Figure 8.4: Improvement of ESR values In lA patients receiving 
anakinra 
Eight patients with inflammatory arthritis were measured for ESR before and after 
the therapy with anakinra. The normal ESR value is 0-15 mm/h for adult male and 
0-20 mm/h for adult female. 
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Figure 8.5: Plasma NO levels in arthritis patients receiving anaklnra 
NO was measured by indirect assessments of nitrite and nitrate from 50 1J L of fresh 
plasma from healthy or patients receiving anakinra. Plasma nitrate was first 
reduced by nitrate reductase to nitrite, which was then measured by the Griess 
assay, as described. Each dot represents a case and the mean ± SD is indicated. 
Statistical analyses were done using unpaired Student's t-tests (p = 0.62). 
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Figure 8.6: Effect of anakinra on NOS II and PKC-11 expression In 
MOM from patients with inflammatory arthritis 
MOM from healthy individuals and arthritic patients were isolated, cultured and 
assessed for (A), NOS II and (B), PKC-11 expression by RT-PCR using gene-
specific primers. A mock sample (W) (water in place of test eDNA) was used for 
contamination control and a sample of recombinant NOS II or PKC-11 fragment 
served as positive controls (PS). PCR products (91JL) were electrophoresed on 
a 1% EtBr-containing agarose gel, and the bands visualized digitally photographed. 
The positive signals showed the expected bands of 264 bp (for NOS II) and 259 bp 
(for PKC-11). 
A 
W 50 51 52 53 54 55 56 57 PS 
NOS II ~ 264bp 
B 
W 50 51 52 53 54 55 56 57 PS 
PKC-11 ~ 259bp 
Table 8.1: Evaluation of plasma NO and co-expression of NOS II and PCK-11 in MOM from 
arthritis patients receiving infliximab and anakinra 
Subject (ID#) Age Sex Dx Activity Steroids DMARD 1\1~ l~~J J5R~-Tt NOS II 
lnfliximab-treated 
43(016) 72 F RA Mild N N 289.2 y y 
44(039) 41 M SpA(AS) Clinically quiet N N 208.4 NID NID 
45(040) 72 F RA Mild N MTX 305.7 N/D N/D 
46(042) 39 F RA Mild y MTX 281.2 y y 
47(043) 43 F SpA (PsA) Mild N MTX 196.1 NID N/D 
48(044) 58 F RA Mild Prednisone MTX 255.2 y N 
49(045) 78 F RA Mild N MTX 287.8 y y 
Anakinra-treated 
50(041) 36 F RA Mild N MTX 226.2 N N 
51(046) 36 M RA Mild Prednisone MTX 141.4 y N 
52(047) 64 F SpA(AS) Clinically quiet Prednisone MTX 141.4 y N 
53(048) 57 F RA Mild Prednisone MTX 143.8 y N 
54(049) 36 F RA Mild Prednisone MTX 161.5 y N 
55(050) 39 F RA Mild Prednisone MTX 210.5 y N 
56(051) 43 F SpA (PsA) Mild N MTX 146.2 y N 
57(052) 42 F RA Mild Prednisone N 117.3 y N 
N/D,notdone 
200 
8.3.4 Effect of anakinra on plasma NO, NOS II and PKC-r] expression in MOM 
from lA patients 
As in the case of patients treated with infliximab, we evaluated the levels of 
circulating NO and studied expression of NOS II and PKC-r] in MOM from these lA 
patients. As shown in Figure 8.5, NO levels in the circulation of these patients 
(145.2 ± 32.5 IJM) were within the same range as healthy people (143.8 ± 32.5 
IJM), and significantly lower than those seen in infliximab receiving individuals 
(256.2 ± 41.31JM). When MOM from these cases were screened for the presence 
of NOS II, we found no evidence to support the expression (Fig. 8.6 A). Validity of 
the experiment was ensured by the inclusion of a positive control, a recombinant 
NOS II fragment; and a negative control, a mock sample in which test eDNA was 
replaced by water. Surprisingly, unlike what had been observed in case 50, MOM 
from all of these seven patients were tested positive for PKC-r] (Fig. 8.6 B). The 
data reported in this chapter are summarized in Table 8.1. 
8.4 SUMMARY AND DISCUSSIONS 
Our data presented here show the different effects of infliximab and anakinra 
on circulating NO and NOS II expression in MOM from lA patients. All four tested 
patients, who were treated with the TNF-a blocker, showed persistent elevated 
levels of NO and expressed PKC-r] in MOM. Three of the four individuals were also 
positive for NOS II mRNA in these cells. In contrast, NO levels in those patients, 
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who were treated with the IL-1 Ra, were comparable to those seen in healthy 
controls or in patients with OA. In accordance with the NO data, there was no 
evidence for NOS II gene transcription in MOM from any of these individuals. 
Surprisingly, seven of the eight patients tested were reactive for PKC-11. 
The observation in the infliximab-treated group was unexpected since the 
individuals had shown good response to the therapy and were doing well clinically 
(as evident from the low score of inflamed joints as well as a substantial decrease 
in the ESR value). Despite the surprising observation in regard to the NO levels 
in the infliximab-treated patients, this investigation of the two groups of patients 
patients has supported our hypothesis that PKC-11 appeared to be required for the 
development of human monocytic cells into a phenotype capable of expressing 
NOS II upon activation with endotoxin. Simply put, one can infer that when NOS 
II is expressed in monocytic cells, PKC-11 is also present in the same cell type. At 
this point, we don't have any concrete explanation for the expression of PKC-11 in 
human MOM, and further experimentation needs to be carried out before one can 
appreciate its significance. We can only speculate that some signals, which are 
activated during the course of the anakinra therapy, may influence directly, or 
otherwise, the expression of PKC-11 in these patients. As for the two cases where 
the co-expression of PKC-11 and NOS II was not found, it is impossible to draw any 
useful conclusions from the data, as the sample number was so small. However, 
it is feasible to offer some scenarios. First, the elevation of NO could be attributed 
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to other sources, such as the vascular endothelium or inflammatory joints 
themselves. Second, it is also possible that the genetic makeup of these two 
patients is such that NOS II is degraded more quickly than the turn-over of NO. 
Although the pathways leading to the induction of TN F-a and IL-1 J3 in monocytic 
cells are related, they are distinct in that some essential transcription factors are 
unique and not shared by the two pathways. It is conceivable that IL-1 J3 and TN F-
a might have different effects on how PKC-r) is regulated in monocytic cells. 
It has been documented that expression of NOS II in macrophages is 
upregulated in patients with inflammatory conditions like RA suggesting that 
potential overproduction of NO as a result of the upregulation may contribute to 
tissue destruction manifested in advanced stages of the disease (Abramson eta/., 
2001 ). Therefore, suppression of NOS II expression would offer therapeutic 
opportunity to the treatment of RA. The work by Perkins eta/. (1998) suggested 
that RA patients receiving cA2, which is also a monoclonal antibody to TNF-a, 
showed a decrease in NOS II enzymatic activity in PBMC, as measured by the 
levels of L-citrulline accumulated. Therefore, the authors hypothesized that TN F-a 
would also be involved in the regulation of the NOS II gene. However, our data 
presented here appear to suggest that suppression of TN F-a with infliximab may 
not play a role in pre-transcriptional regulation of NOS II, as shown by persistent 
accumulation of NOS II mRNA and NO in sera of inflammatory arthritis patients 
receiving infliximab. At the first glance, it seems as if the results from the two 
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studies contradict each other but there are several possible explanations for the 
discrepancy. First, the difference could be due to the fact that although patients in 
the two studies were receiving the same therapy, the drugs themselves were 
different (infliximab and cA2). It is, therefore, possible that they may have different 
effects on different patients. Second, while Weinberg's group (Perkins eta/., 1998) 
used PBMC in their study we opted for monocytic cells. We chose to study 
peripheral blood monocytes for two reasons. First, monocytic cells are the principal 
cells in the mononuclear fraction containing the NOS II antigen. Second, our in 
vitro data from a previous study suggested that PKC-r, may be required for the 
induction of NOS II and production of NO by LPS in human monocytic cells. We, 
therefore, wished to test this hypothesis further in MOM from inflammatory arthritic 
patients in an aim to establish an association between NOS II and PKC-r, co-
expression in vivo. Third, there has been increasing evidence that NOS II, 
especially in disease processes, can also be produced by 8 and T lymphocytes 
(Roman eta/., 2002; Schweyer eta/., 2000). The fact that Perkins and colleagues 
used PBMC instead of monocytes raises a strong possibility that the source of NOS 
II they measured may not be from monocytic cells entirely. In this case, it is 
possible that NOS II expression may be regulated differently in different cell types, 
and with that we speculate that a true effect of TN F-a on the regulation of NOS II 
in monocytes may be masked by that of TN F-a on lymphocytes. 
It has been previously proposed that in rheumatoid arthritis, IL-1 primarily 
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exerts its function locally, within the joint, while TN F-a has a more systemic effect 
(Oayer, 2002). However, from the perspective of NO release and NOS II 
expression, our data reported seem to support the reverse. Obviously, further 
experimentation needs to be performed before the phenomenon can be 
understood. One approach would be to test sequential samples (from both plasma 
and MOM) for NOS II in MOM and circulating NO from arthritis patients before and 
after anakinra therapy. If NO goes back to the normal level and this is 
accompanied by simultaneous disappearance of NOS II in MOM, the hypothesis of 
IL-1 being involved in the regulation of NOS II and it having a systemic effect in RA 
would be greatly strengthened. 
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CHAPTER NINE 
PERSPECTIVES AND FUTURE DIRECTIONS 
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9.1 PERSPECTIVES 
In this project, we investigated the comparative expression of the entire PKC 
family in both human and murine monocytic cells, and found complete absence of 
PKC-n in the human cells (Fig. 5.1 and Table 5.1 ). Subsequent transfection of this 
gene into human monocytic MM6 cells resulted in NOS II expression by these cells, 
following their activation with LPS (Fig. 5.6). This finding was not seen in 
untransfected cells or those transfected with the empty vector. Therefore, the data 
suggest that in an LPS-triggered signalling pathway, PKC-n is in some way 
involved in the regulation of NOS II expression in human monocytic cells. This 
finding may offer important insights into the long standing observation that in normal 
conditions human monocytic cells can not be induced by LPS readily in vitro to 
express NOS II and release NO. The results obtained from the transfection 
experiments prompted us to ask if the findings would bear any clinical relevance. 
To answer this question, we carried out similar investigations in plasma and MOM 
samples from lA patients. We, subsequently, found that NO levels in plasma from 
patients with severe disease were significantly elevated (Fig. 7.2). Also, in the 
same patients whose plasma NO was among the highest, there was evidence for 
the presence of NOS II mRNA in MOM (Fig. 7.3) suggesting that the transcripts 
were active. This status of the NOS II transcripts indicates that the source of NO 
elevation was likely to be from NOS II expressed in MOM. In addition to the 
presence of NOS II mRNA, we also found transcripts for PKC-f") in MOM from the 
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same patients (Fig. 7.4). It is important to point out that in majority of the cases, 
when MOM were negative for PKC-11, they were also negative for NOS II mRNA. 
Indeed, such correlation in expression between NOS II and PKC-11 was observed 
in more than 90% of cases tested. In short, the data from this clinical study 
confirmed our earlier in vitro data and strengthened our hypothesis that PKC-11 may 
be required before human monocytic cells can express NOS II (following their 
activation with LPS). 
Taken together, we propose the following sequential phenotypic changes of 
human monocytic cells from being double negative for PKC-11 and NOS II to being 
double positive for the two genes. This process is likely to occur in severely 
affected lA patients (Fig. 9.1 ). First, we have shown (Fig. 5.1 and Table 5.1) that 
circulating monocytes from healthy individuals do not express PKC-11 (stage 1 ). 
Second, signals (not yet identified), which are produced either spontaneously 
during certain disease processes or as a result of medical intervention, may 
stimulate transcription of PKC-11 in the monocytic cells (stage 2). This is supported 
by our findings that PKC-11 was present in MOM isolated from the three diabetic 
patients (data not shown) as well as from seven out of eight lA patients, who 
received the IL-1 Ra anakinra (Fig. 8.5). Upon activation with appropriate stimuli, 
these PKC-11 positive monocytic cells express NOS II (stage 3) and, subsequently, 
release NO locally or into the circulation. 
The normalization of NO levels observed in the plasma of the patients 
Figure 9.1: Possible mechanism for the development of PKC-11 positive phenotype 
in human monocytes of lA patients with active disease 
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receiving anakinra allows us to propose the following scenario for a role of IL-1 in 
the aforementioned phenotypic changes of human monocytic cells. On one hand, 
IL-1 may have an direct role in the transition from stage 2 to stage 3. This would 
involve IL-1 binding to the receptor, which is present only on PKC-fl-positive cells, 
and triggers a signalling cascade leading to NOS II gene expression. In fact, the 
notion of IL-1 promoting NOS II expression (see below) was recently illustrated in 
a study with cartilage isolated from OA and RA patients; attenuation of NO 
production was found in cartilage cultures previously treated with an IL-1 Ra 
(Vuolteenaho eta/., 2003). In addition, it is also feasible to vision an indirect 
involvement of IL-1 in the phenotypic change of human monocytic cells from stage 
2 to stage 3. Binding of IL-1 to its receptor on cells other than monocytes/ 
macrophages may induce a release offactors which, by binding to their appropriate 
ligands on PKC-fl-positive monocytic cells, can initiate progression to stage 3 from 
stage 2. 
Extracts from the TwHf plant, which is found naturally in China, have been 
used as traditional medication for thousands of years for a number of autoimmune 
diseases including inflammatory arthritis. Over the years, substantial effort has 
been devoted to the purification and characterization of the individual components 
of the extracts. In this project, two TwHf synthetic derivatives (JPK-1 01 and JPK-
109) and one natural compound (JPK-113) isolated from the root extract were 
investigated for their effects on the release of inflammatory mediators NO and 
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TNF-a, as well as NOS II synthesis by monocytic cells. Such investigation was 
important because elevated levels of these molecules are often associated with the 
inflammatory response seen in a number of diseases (Abramson eta/., 2001; 
Bingham, 2002; Brantdt eta/., 2000). The data have now provided us with several 
important insights on how these TwHf compounds function. First, the drugs, by 
themselves have no effect on the cells in terms of mediating default NOS II 
expression and NO production. Rather, they lead to down-regulation, albeit at 
varying extent, of the induction of NOS II enzyme as well as that of TNF-a and 
other cytokines, thereby further strengthening the observed anti-inflammatory 
characteristic of these agents. More importantly, the fact that the suppressive 
effects were mainly seen at doses well below the toxic concentration indicates that 
the findings were not an artefact and could not be attributed to a bystander effect 
of cell death. Third, although the effects of JPK-1 09 and JPK-113 on the induction 
of MMP by LPS in monocytic cells were not investigated in these studies, JPK-1 01 
was not found to have any inhibitory effect on MMP-2 and -9 activity in human LPS-
activated monocytic cells. This suggests that the LPS-triggered signalling pathway 
leading to induction of these two MMP and those giving rise to NO and TNF-a 
production are distinct from one another. 
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9.2 FUTURE DIRECTIONS 
9.2.1 Mechanism of action for PKC-11 and its involvement in the signalling 
pathway leading to NOS II expression 
Although findings from both experimental and clinical studies presented in 
this thesis have revealed an apparent involvement of PKC-11 in the regulation of 
NOS II expression in monocytic cells, it would be prudent to carry out further 
experimentation to delineate exactly where it is along the NOS II pathway that 
PKC-11 most likely to carry out its function. Determination of its substrate(s) by 
phosphorylation studies would also shed light on what molecules might be possible 
targets for the kinase. 
9.2.2 Possible connection between PKC-11 and IL-1: a role for IL-1 in the 
regulation of NOS II expression in monocytic cells 
The expression of NOS II and PKC-11 in MOM from patients receiving the 
monoclonal anti-TNF-a antibody, infliximab, was markedly different from that in 
those receiving anakinra, which targets IL-1 function. With the continuing 
advancement of technology, it would be feasible to perform gene expression profile 
using microarray analysis to ascertain which set of genes might be expressed in 
each case. This might offer important clues as to what might be involved in turning 
on the expression of PKC-11 in the anakinra receiving group. With respect to the 
proposed role of IL-1 in the development of stage 3 phenotype, the following 
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studies could be carried out in severely affected lA patients to test the hypothesis. 
First, expression of the IL-1 receptor (IL-1 R) on the MOM cell surface from PKC-rt 
expressing cells can be assessed by flow cytometry. If, the presence of IL-1 R is 
only found on PKC-rt expressing cells, this would suggest a direct involvement of 
IL-1 in cell differentiation from stage 2 to stage 3 in that the binding of IL-1 to IL-1 R 
mediates initiation of a signalling cascade leading to expression of NOS II enzyme. 
The other possibility from the IL-1 R screening experiment would be the absence of 
IL-1 R on monocytic cells which express PKC-rJ. In this instance, the data 
generated from the current work will likely suggest that the proposed IL-1 
involvement is indirect. That is, binding of IL-1 to its receptor on another cell type 
may induce production of other factor(s), which themselves bind to their receptors 
present on the PKC-rt expressing cells, and initiate a necessary cascade leading 
to NOS II expression. 
In regard to a possible relationship between IL-1 and NOS II, the findings 
from our study with the anakinra receiving patients offer a possibility that IL-1 is a 
positive regulator of NOS II expression in human monocytic cells. Indeed, previous 
findings have shown that NOS II enzyme could be induced in human chondrocytes 
following IL-1 stimulation (Charles eta/., 1993) and that in vitro NO production by 
cartilage explants from arthritic patients was attenuated in the presence of IL-1 
receptor antagonist (Vuolteenaho eta/., 2003). Whether these observations also 
hold true in monocytic cells remains to be determined. Thus, evaluation of 
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sequential samples (serum and MOM) from lA patients before and after therapy 
might help support or refute this hypothesis. Specifically, if co-expression of NOS 
II and PKC-11 in MOM (and elevated NO levels) seen in severely affected patients 
before the therapy is no longer the case in the same patients after the therapy, this 
would support a positive involvement of IL-1 in the LPS-mediated pathway leading 
to NOS II induction. 
Our findings with three diabetics (data not shown) and with the anakinra-
treated lA patients (Chapter 8) show the presence of PKC-11 gene transcription in 
MOM. This offer an in vivo model for further assessment of correlation in 
expression between PKC-11 and NOS II. If exposure of these PKC-11-positive cells 
to LPS leads to induction of NOS II expression and subsequently, to NO production, 
this would add significant strength to the proposed hypothesis that PKC-11 protein 
has to be present before LPS activated human monocytic cells could express NOS 
II. 
9.2.3 Future work with TwHf compounds 
It would be useful to conduct a time course study to ascertain the time 
point(s) at which these two compounds are most active. This piece of information 
would certainly provide important insights into the target molecules that are 
involved in the NOS II and TNF-a signalling pathways. Now that we have 
established that the three TwHf compounds significantly attenuate NOS II 
214 
expression in LPS-activated monocytes, and that PKC-r, appears to be required for 
the development of NOS 11-positive phenotype, it would be very useful to investigate 
a possibility of the TwHf compounds to inhibiUattenuate NOS II expression and NO 
production in LPS-activated human monocytes. A positive finding from such a 
study would greatly strengthen the notion that PKC-r, was involved in the regulation 
of NOS II expression in human monocytic cells. 
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